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Abstract
Five membered heterocyclic compounds and their derivatives have gained much
attraction of synthetic chemists due to their valuable biological activities. Especially
1,3,4-oxadiazole have shown remarkable broad spectrum biological activities which
prompted us to synthesize its different 2,5-disubstituted-1,3,4-oxadiazole derivatives.
Benzodioxole moiety has also shown numerous biological activities. It was assumed
that 2,5-disubstituted-1,3,4-oxadiazole ring along with the potential benzodioxole
moiety might boost up the pharmacological activities of the synthesized
molecules.Sulfamoyl derivatives werealso preparedto evaluate them for their various
biological activities. Many incurable fatal diseases can be made curable to much
extent by the help of latest and advanced research. So the presented research work
comprises of the synthesis of some novel multifunctional compounds followed by the
characterization of these compounds and biological evaluation including antibacterial
studies as well as enzyme inhibition studies. The selection of these moieties was made
on the basis of their known remarkable pharmacological activities.
The compounds presented in this particular work were synthesized according to the
protocol available in the literature and has been mentioned in respective schemes in
detail. In Scheme-1, twenty four(24) various 5-substituted-1,3,4-oxadiazole-2-thiol
4a-x were synthesized, starting from different carboxylic acids through formation of
correspondingesters converted intohydrazides and ultimately 5-substituted
oxadiazoles were obtained through an intermolecular cyclization
mechanism.Moreover, the reaction of different 5-substituted-1,3,4-Oxadiazol-2-
thiols4a-xScheme-2, 3 & 4,with electrophiles, 6-chloro-3,4-
methylenedioxybenzylchloride 5, 6-bromo-3,4-methylenedioxybenzylbromide7and 2-
bromo-N-(3,4-methylenedioxybenzyl)acetamide11,yielded twenty four(24)5-
(aryl/aralkyl)-2-((6-chloro-3,4-methylenedioxybenzyl)thio)-1,3,4-Oxadiazoles 6a-
x,twenty four(24)5-(aryl/aralkyl)-2-((6-bromo-3,4-methylenedioxybenzyl)thio)-1,3,4-
Oxadiazole8a-x,and  twenty (20)N-[3,4-methylenedioxybenzyl]-2-[(5-substituted-
1,3,4-oxadiazol-2-yl)thio]acetamide12a-t,respectively in the presence of N,N-
dimethylformamide and sodium hydride. According to the Scheme-5, twenty
(20)different electrophiles, N-substituted-2-bromoacetamides14a-t,were synthesized
in aquous basic conditions on simple shaking. Twenty(20)N-substituted-2-{(5-(3,4-
methylenedioxy)phenyl-1,3,4-Oxadiazol-2-yl) sulfanyl}acetamide derivatives15a-
XIV
t,were also produced by the reaction of twenty presynthesised electrophiles, 14a-t
with 5-(3,4-methylenedioxyphenyl)-1,3,4-Oxadiazol-2-thiol4a in N,N-
dimethylformamide and sodium hydrideScheme-6. In Scheme-7, twenty one(21)
different 2-alkyl/aralkylthio-5-(3,4-methylenedioxyphenyl)-1,3,4-Oxadiazole
derivatives17a-uwere synthesized on treating 5-(3,4-methylenedioxyphenyl)-1,3,4-
Oxadiazol-2-thiol 4awith twenty one aryl/aralkyl halides(16a-u).Scheme-8 comprises
of the synthesis of fourteen(14)sulfonamide derivatives of paroxetine20a-k,m-o by
the usual method of stirring in basic aquous medium with fourteen different sulfonyl
chlorides19a-k,m-o.Twelve(12)3,4-methylenedioxyphenylsulfonohydrazide
derivatives 21a-l, were prepared by the reaction of3,4-
methylenedioxybenzohydrazide3awith different sulfonyl chlorides19a-lby the
continuous stirring in basic aquous conditions using sodium carbonate solution.
All the synthesized compounds were characterized by using different spectroscopic
techniques i.e. IR, 1H-NMR and mass spectral data. 13C-NMR technique was also
used in some cases to elucidate and to support the structural analysis. A proposed
mass fragmentation pattern of some of the compounds is also given. Some of the 1H-
NMR, 13C-NMR and EIMS spectra of synthesized compounds are presented. The
synthesized compounds were also evaluated for antibacterial and enzyme inhibition
activities. All the nine schemes were put for antibacterial assay. Overall the
synthesized compounds showed significant results. In Scheme-2, the compound 5-
(Pyridin-3-yl)-2-((6-chloro-3,4-methylenedioxybenzyl)thio)-1,3,4-Oxadiazole 6i
showed overall maximum activity against E.coli (-), and Bacillissubtilis (+)among the
compounds. The compound remained at the top with %age inhibition value,
76.17±5.00 for E.coli, and 70.12±3.65 forBacillissubtilis (+),compared to the
reference standard,Ciprofloxacin with the %age inhibition value 92.02±1.97. In
Scheme-3, the compound, 8xexpressed the highest %age inhibition value 79.19±1.10
against Escherichia coli (-) relative to the reference standard, Ciprofloxacin with
%age inhibition value 90.44±1.23. In Scheme-4, the compound,N-[3,4-
methylenedioxybenzyl]-2-[(5-(4-chlorophenoxy)methyl)-1,3,4-Oxadiazol-2-
yl)thio]acetamide12mrevealed the maximum activity against Pseudomonas
aeruginosa with the %age inhibition value 76.45±0.70 relative to the reference
standard, ciprofloxacine with the %age inhibition value 93.45±0.42.In Scheme-6the
compounds which seem as highly active within the series are 15r, 15a, 15m and
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15bamong which N-[2,3-dimethylphenyl]-2-[(5-(3,4-methylenedioxyphenyl)-1,3,4-
oxadiazol-2-yl)thio]acetamide15a is the most active one with %age inhibition value
68.75±0.68 againstE.coli relative to the reference value92.79±0.83. In Scheme-7, the
compound, 2-(2-Phenylethyl)thio-5-(3,4-methylenedioxyphenyl)-1,3,4-
Oxadiazole17j,surprisingly, showed maximum excellent activity against all the
bacterial strains used under analysis. Its %age inhibition values are 80.50±2.64,
88.11±0.33, 87.20±1.65, 83.86±1.75, 84.25±0.58 and 87.46±0.69 relative to the
reference standard, ciprofloxacine whose inhibitory values are 90.85±1.53,
92.04±1.07, 91.83±2.77, 89.59±2.00, 89.25±1.92 and 88.15±1.23 against the bacterial
strains S. Typhi,E. Coli,K. Pneumonae andP. aeroginosa, B. Subtilis, S. Aerus
respectively. In the Scheme-8, lipoxygenaseenzyme inhibition assay,was carried out.
The excellent inhibition in LOX assay was shown by the compoundN-(4-
chlorobenzenesulfonyl)paroxetine(20m)with %age inhibition value98.01±0.01
compared with the reference standard baicalienvalue 93.79±1.27.The Scheme-9, was
tested for antibacterial activity and it was found that all the compounds were quite
active against E.coli. The results are very close to the reference standard value.
Amongst the compounds, 2-(1,3-Benzodioxol-5-ylcarbonyl)-3,5-dichloro-2-
hydroxybenzenesulfonohydrazide(21l), was found to be the most active against all
bacterial strains. Its % inhibition values are 70.35±3.06, 87.38±1.75, 89.33±1.42,
72.60±2.20 and 85.35±1.65compared with reference values; 91.19±2.10, 90.44±1.23,
92.00±2.76, 89.98±2.07 and 92.21±1.59 against S. typhi (-),E. coli (-),P. aeroginosa (-
),B. subtilis (+) and S. aureus (+)respectively.Overall it was observed that the
compounds having electron donating substitutions within their structures exhibited
good to excellent antibacterial results. Biological activity data in comparison with the
reference standard drugs is presented in biological activity section.
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1.0. Introduction
The resistivity of microorganisms towards the prevailing drugs arouse the impetus of
innovating new antibacterial drugs by incorporating critical pharmacophoric moieties to
the already existing drugs in order to enhance unique activity and functional diversity.
Organic and medicinal chemists have a key objective, one of many others, to formulate
and hence synthesize such molecules which have therapeutic worth [1,2]. There is a great
advancement in this regard. So naturally occurring and chemically synthesized active
agents came to the frontline.
1.1. Heteroaromatics
Those aromatic compounds which contain heteroatoms (N, O, S) in their structure are
called Heteroaromatics. They have shown astonishing biological properties which make
them the most salient and emerging class of drugs in medicinal chemistry. Among many
heterocycles following are of the most importance:
 Methylene Dioxy Core
 Oxadiazoles
 Pyrazoles
 Thiazoles
Literature studies have shown that although these moieties display diverse biological
activities solely but their union often ameliorates the responses many times with respect
to their biological activities depending upon the type and the position of attachment of the
substituent [3].
1.2. Methylene dioxy core
Methylene dioxy core is a hetero-aromatic core in which methylene group (-CH2-) is
sandwiched between two oxygen atoms. As far as methylene dioxy core is concerned, it
has, no doubt, occupied a significant place in medicinal chemistry and pharmaceutical
research as this structural scaffold is observed in various drugs and in natural products as
well [3,4].
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1.2.1. Occurance of methylene dioxy core
Methylene dioxy core is present in nature and synthetically as follows:
 In piperine, an alkaloid extracted from Piper nigrum which is the main
component of commonly used black pepper and is used as an insecticide [5].
O
OO
N
piperine
 In safrole (1,3-benzodoxale -5-yl), which is extracted from Sassafras albidum and
considered to be a weak hepatocarcinogen, its epoxy structure is endowed with
significant physiological activities [6]. Safrol oxide, a recently synthesized
compound induces apoptosis (cell-killing process). Safrol has shown anti-
angiogenesis besides the apoptosis activity during in vitro tumour therapy [7, 8].
O
O
safrol
 In “Berberine” which is an alkaloid extracted from a plant Berberis vulgaris. It
acts as an anticancer and antibiotic drug [9].
N+
O
O
OCH3
H3CO
berberine
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 In stiripentol drug and its analogues. It is used as anticonvulsant drug [10].
O
O
OH
CH3
CH3
CH3
stiripentol
 In Protopine and Egonol that are benzyl isoquinoline alkaloids present in opium
poppy. They are anti-allergic and inhibit platelet aggregation, also used as
analgesic [11].
O
ON
O
O
O O
O
O
HO
OCH3
egonolprotopine
 In the literature a comparative study between the simple chalcone (anticancer
drug) and its 1,3-benzodioxole incorporated analogue against carcinoma cells
revealed the enhanced cytotoxic activity for the incorporated analogue rather than
the simple chalcone [6].
 In epipodophyllotoxins and podophylotoxins [12] which are naturally occurring
anticancer agents include etoposide and teniposide [13].
O
O
O
O
O
O
O
OH
CH3
CH3
H3C
podophylotoxin
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 In Polygamain, a plant derived, microtubule disrupting agent, structurally similar
to podophylotoxin, has shown excellent utility in the skin cancer treatment [14].
O
O
O
O
O
O
polygamain
 In Paroxetine, an antidepressant drug, methylene dioxy ring system is also
present. It is the most prevailing antidepressant drug now-a-days [15].
1.3. Paroxetine
Paroxetine or (3S,4R)-3-[(2H-1,3-benzodioxol-5-yloxy)methyl]-4-(4-flouro phenyl)
piperidine is an orally administered antidepressant drug and  a disubstituted derivative
of piperidine. It is hydrochloride salt of phenyl piperidine which exists enantiomerically
in trans form [16, 17]. It is a selective serotonin reuptake inhibitor [18-21].
O
O
O
N
H
F
H
H
Paroxetine
Paroxetine is synthesized from (L)-pyroglutmaic acid through several catalytic steps [22].
N OHOOC
H
O
O
O
N
H
F
H
H
(L)-pyroglutamic acid
(_)-paroxetine
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An important metabolite, amongst some other metabolites, of paroxetine was found in
human beings and animals during a research experiment and was thought as a significant
intermediate regarding paroxetine synthesis. The experiment was carried out using [14C]-
labelled paroxtine. The metabolite is (3S,4R)-trans-4-(4-fluorophenyl)-3-hydroxy methyl
piperidine [23]. Its marketing began in 1991 and has been licensed in many European
countries. Other related antidepressant drugs are fluoxetine, sertraline and and
imipramine etc but the superiority of paroxetine over the other antidepressants is its mild
side effects [24-28].
F
HN
HO
4-(4-fluorophenyl)-3-hydroxy
methyl piperidine
1.3.1. Trade names of paroxetine
 Paxil
 Seroxat
 Aropax
 Sereupin [22].
1.3.2. Mode of Action
Brain communicates with itself through certain chemicals called neurotransmitters. These
neurotransmitters carry messages in the form of signals from one nerve to another. Any
abnormality in the neurotransmitters affects the behavioral change. Paroxetine is a
selective serotonine reuptake inhibitor (SSRI). SSRI are called selective because they
affect only serotonin significantly rather than other neurotransmitters (dopamine,
norepinephron, etc). It is the antagonistic phenomenon of paroxetine with the serotonin
transporter to inhibit neuronal serotonin reuptake. It inhibits the active transport process
across the membrane for the reuptake of serotonin hence stabilizing the appropriate
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concentration of serotonin in the brain. Literature revealed that it is the flexible structure
of paroxetine that permits conformational heterogeneity in order to adopt such
conformation which is favourable for serotonin (5-HTT) [29].
1.3.3. Half life of paroxetine
Half life of paroxetine is 21 hours [30].
1.3.4. Hydration behaviour of paroxetine
Two solid states of paroxetine has been reported in the literature i.e
 From-I (Hemihydrate)
 From-II (Anhydrate)
From-I is thermodynamically more stable while From-II is considered to be the more
desirable form pharmaceutically due to its fair solubility at all temperatures [23].
Experimental data, provided in the literature, suggests that anhydrate Form-II is not
anhydrous but it contains high level of water contents (3.8% w/w, 0.8 mol of water/mol
of drug). Moreover, the research showed that the water is slightly strongly bonded to the
crystal. Some other structural features of the crystal clearly show the tendency of Form-II
to convert to the more stable Form-I [31].
1.3.5. Applications of paroxetine
 Depression
 Obsessive compulsive disorders
 Painic disorders
 Social phobia
 Anxiety
 Prychiatric disorders.
 Post traumatic stress disorders [32]
 Obessive compulsive disorder [33]
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1.3.6. Adverse effects of paroxetine
 Nausea [34] Somnolence
 Asthenia Constipation
 Headache Sweating
 Tremor Dizziness
 Decreased appetite [35]
 Anxiety
 Gastrointestinal intolerance [36]
1.3.7. Preferance over other SSRIs
Paroxetine is proved to be the most potent inhibitor of (5-HT), serotonin amongst all
currently available antidepressants of the SSRI class. Factors which favour the first-line
treatment option of paroxetine over all other antidepressants are:
 Its highest ratio of inhibition of norepinephrine uptake to serotonin.
 Earlier onset of its action than any other SSRI [37].
 Low affinity for catecholaminergic, histaminergic and dopaminergic systems.
 Very low scale propensity to any adverse effect on central or autonomic nervous
system.
 Affinity to the muscarinic cholinergic receptor.
 Paroxetine is a highly protein binding drug compared with other SSRIs.
 It inhibits the production of an enzyme, nitric oxide synthase so reduced levels of
serum nitrate or nitrite.
 It behaves as a substrate and also as an inhibitor for cytochrome isoenzyme
P4502D6.
 It is orally absorbed very well.
 Its metabolites are quite inactive in vivo pharmacologically.
 In case of overdosing, adverse result are extremely very rare [30].
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1.3.8. Paroxetine in combination with another SSRI
The co-therapy of paroxetine, with another SSRI e.g., mirtazapine; effective in post-
traumatic stress disorder (PTSD), produce a more rapid response compared to the effect
of mirtazapine alone [38].
1.4. Oxadiazole
Oxadiazole is a five membered heterocyclic aromatic compound containing oxygen and
Nitrogen atoms in its ring [39]. Its molecular formula is C2H2N2O. It is an important
motif in vast number of biologically active compounds of various pharmacological
classes [40, 41].
O
NN
Oxadiazole
1.4.1. Chemistry of oxadiazoles
The presence of heteroatoms, nitrogen and oxygen, in oxadiazole makes it a very weak
base by their inductive effects. Moreover its aromaticity is highly affected by the
replacement of two (-CH=) groups in furan by two nitrogen atoms (-N=) [42].
Comparatively low electron density at carbon 2 & 5 and elevated electron density at
nitrogen at 3 & 4 positions in the ring allow mucleophilic reactions at carbon while
electrophilic attack at nitrogen. The ring becomes stable when its substitution is done by
one or more aryl groups. In the tautomeric form, oxadiazole react with an electrophile at
nitrogen atom at the heteroatom lying outside the ring or at both centers. Oxadiazole also
undergo thermal and photochemical relations [43].
1.4.2. Isomeric forms of oxadiazoles
Oxadiazoles exist as four possible isomers. These isomers are due to the different
positions of Nitrogen atoms within the ring [43].
 1,2,3-oxadiazole (diazo-oxides)
 1,2,4-oxadiazoles (azoximes)
 1,2,5-oxadiazoles (furazans)
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 1,3,4-oxadiazoles (biazo, oxybiazole)
O
N
NHC
HC
1,2,3-oxadiazole
(Diazo-oxides)
Furo (ab) diazole
aa'
bb'
O
N
CHN
HC
1,2,4-oxadiazole
(Azoximes)
Furo (ab') diazole
aa'
bb'
O
N
CHHC
N
1,2,5-oxadiazole
(Furazans)
Furon (aa') diazole
aa'
bb'
O
CH
NN
HC
1,3,4-oxadiazole
(Biazole, oxybiazole)
Furo (bb') diazole
aa'
bb'
1.4.3. 1,3,4-oxadiazole
Amongst all the four isomers, it is one which has been frequently exploited for its various
dramatic activities [42]. The two methine in furan (=CH-) are substituted with two
nitrogen atoms (_N=) to get oxadiazole. They have demonstrated broad spectrum
biological activities in pharmaceutical and agrochemical field as well [44]. 1,3,4-
oxadiazole  are proved to be the main building block in the synthetic route of new
bioactive molecular systems [1].
1,3,4-oxadiazole was synthesized as a liquid by Ainsworth in 1965 by the thermolytic
method. The precursor was ethyl formate formyl hydrazone [45].
O
NN
1,3,4-oxadiazole
H C
O
NH N CHOC2H5 C2H5OHHeat
1.4.4. Availability of oxadiazoles in the market
In the market, oxadiazoles derivatives are found as Tiodazosim, Furamizole, Nasapidil
[43], Ratragravir [42]. They are vastly used in dye manufacturing, scintillators and liquid
crystals [43].
Introduction
Department of Chemistry, GCU Lahore. Page 11
1.4.5. Physical properties
O
NN
1
2
34
5
a
b
cd
e A
B
C
D
E
Angles Bond angle (˚ ) Bonds Bond length (pm)
A 105 A 139
B 113 B 129
C 102 C 134
D 113 D 134
E 105 E 129
1.4.6. Spectral characterization
 The characteristic infrared spectral peaks for oxadiazoles are at 1640-1560 cm-1
for (C=N) and at 1030-1020 cm-1 for (C-O) [46-48].
 In mass spectrometry the graph usually shows the base peak for the molecular
ion.
1.4.7. Chemical properties of oxadiazole
 Oxadiazoles are synthesized from Diacyl-hydrazines on heating with thionyl
chloride.
O
NN
R C
O
NH NH Heat
C2H5OH
C
O
H
1,3,4-oxadiazole
Diacyl hydrazine
 1,3,4-oxadiazoles are prepared simply by the acidic or basic hydrolysis of 1,2,4
oxadiazoles.
 1,3,4-oxadiazoles can also be prepared by treating triazoles with acid chlorides.
O
NN
N
H
NN
Ph
PhCOCl
Ph Ph
1,3,4-oxadiazole
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1.4.8. Applications of oxadiazole
The show different biological activities and are used as
 Antimicrobial
 Antitubercular
 Antimalarial
 AntiHIV, Antiviral [49]
 Analgesic
 Anti inflammatory
 Anticancer [1, 2, 42]
 Fungicidal [50]
 Herbicidal and pesticidal
 Anti Parkinson
 Plant growth regulator activities [1,2, 42,51]
 Antiproliferate
 Antiedema
 Anticonvulsant [52]
 Antidiabetic [53]
 Hypoglycemic [54-56]
Oxadiazoles clubbed with other type of heterocyclic moieties including methylenedioxy
rings. Sulfonamide moieties and many others results in new biologically more active
compounds with less side effects [55].
1.4.9. Scifinder data base report for 1,3,4-oxadiazole
Due to the broad spectrum activities of 1,3,4-oxadiazoles, researchers kept their focus on
them and a lot of research work has been done on them for last two decades.  Scifinder’s
report clearly illustrates the work frequency on 1,3,4-oxadiazoles shows its importance
with the research point of view. The graph shows interesting facts about 1,3,4-oxadiazole
research. The graph shows the survey period from 2000 to 2012. The graph rises during
2000 to 2002 and inclined during 2003 and 2004. A prominent steady rise up is seen from
2005 to 2011but a fall in 2012 [57].
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Figure-A: Publications on 1,3,4-Oxadiazole till 2012
1.5. Sulfonamides
The compounds containing sulfamoyl group (NH2_SO2_) are called sulfonamides. It is a
very important pharmacophoric structural unit in medicinal chemistry [58].
S
O
O
NR1 R3
R2
1.5.1. Chemistry of sulfonamides
Sulfonamides are weak organic acids [58]. They are used as protecting groups of amines.
The proton attached to nitrogen behaves as acidic proton due to the presence of a strong
electron withdrawing sulfonyl group present in its neighborhood [59].
1.5.2. Mode of action
Para amino benzoic acid is necessary for folic acid synthesis which is ultimately the key
component in the bacterial DNA formation and hence multiplication. Sulfonamides
replace para amino benzoic acid molecules with themselves hence inhibiting the bacterial
multiplication.
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1.5.3. Applications of sulfonamides
Sulfonamides exhibit following diverse pharmacological activities:
 Antimicrobial [62, 63]
 Hypoglycemic [64]
 Antithyroid [65]
 Antitumor [66-69,70]
 Antiviral
 Antiparasitic [74-82, 83]
 Antiepileptic
 Diuretics [84,85]
 Antiinflamatotry [70]
 Anti-leishmanial and trypanosidal [86-96]
 Saluretics
 Insuline releasing agents [58].
1.5.4. Other applications
 Advance research show that sulfonamides play their role in diagnostic radiotracer
technology in cancer treatment. A progress has been made and C-11 labelled
naphthalein sulfonamides are in use for imaging human disease [97].
 N-acylated sulfonamides show diverse pharmacological activities; against
Alzheimer’s disease, acting as antibacterial inhibitor of t-RNA synthetase, for the
treatment of osteoporosis and act as antagonist for angiotensin II [98].
 Sulfonamides are also frequently used in veterinary medicines both for the
treatment of cattle for various infectious diseases and as feed additives to enhance
growth of animals [99].
 Metal complexes of sulfonamides have been used in the gravimetric analysis of
silver but recently they are being used as enzyme carbonic anhydrase inhibitors.
Some Zn (II) and Cu (II) complexes have shown very good in vitro inhibitory
activity. Moreover many aromatic/ heterocyclic sulfonamides have been designed
and synthesized as carbonic anhydrase inhibitors [100-108].
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 Sulfonamides also play significant role in polymer science. Polyamides and
polysulfonamides both are film-forming materials and are being used in
membrane technology [109].
1.5.5. Adverse effects of sulfonamides
 Crystallization of sulfonamides in kidney or urinary tract.
 Central nervous system problems
 Gastrointestinal disturbances
 Hypersensitivity
 Photosensitivity
 Blood dyscrasias
 Hepatitis
 Lyell’s syndrome
 Steven-Johnson syndrome [110]
Indeed, sulfonamides are continuously playing an important role in chemotherapy, both
as alone or as clubbed with other drugs.
1.6. Aim/Objectives of work
It has been observed in the previous section that benzodioxole moiety is emerging as a
central core for researchers owing its various biological activities, among which
anticancer activity is forefront. Natural extracts, from various plants, having
benzodioxole moiety have shown enhanced anticancer activity and they are being used in
antitumour therapy. Many synthetic formulations proved to be the better antitumour
species. However further research is the need of hour to explore its other hidden
activities. Oxadiazole ring is another motif and a major entity in the prevailing drugs,
serving the humanity for years. As far as the importance of oxadiazoles in other fields of
life is concerned, they are well known in dye manufacturing industry, scintillation and in
liquid crystal technology. Being a heterocycle, oxadiazole earned a significant position in
the field of research. Sulfonamides, a revolutionary candidate in the horizons of drugs
and without which medicinal chemistry is incomplete, is still under the research. Their
marvelous and undefeatable biological activities are still playing effective role in
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designing new drug candidates with better and enhanced therapeutic activities having
lesser side effects.
According to the whole scenario an attempt is made in order to synthesize such
biologically active species which are easy to synthesize as well as environmentally
friendly and which can play a little bit progressive role in the ongoing research fields.
The main focus of research was the effort to make such revolutionary drug candidates in
which oxadiazole bearing entities along with benzodioxole ring or in combination with
sulfonamides can prove themselves as the leading moieties in combination. It was kept in
consideration that perhaps these functionalities can play effective role solely or might
boost up their effectiveness when in different combinations.
The resistivity of microorganisms was still another challenging problem. In the
course of research work special care was carried about the selection of those starting
materials which might be helpful to lessen these problems. So the compounds with
various combinations having 2,5-disubstituted oxadiazole ring, benzodioxole moiety and
sulfonamide functionality, altogether are synthesized. Later on their biological activities
including antibacterial and enzyme inhibition assays were tested to reach our goal. Their
activity results are discussed in detail in the respective chapter.
1.7. Plan of work
The whole research work is designed on environment friendly, already established
methods. The details of the plan are giving as follows:
1. Various 5-substituted 1,3,4- oxadiazoles were prepared from different carboxylic
acids (1a-x), as starting materials and converting them to corresponding esters
(2a-x) which were subsequently converted to hydrazides (3a-x) and finally in the
last step, which is an intermolecular cyclization, different 5-alkyl/aralkyl
substituted oxadiazoles (4a-x) were obtained in the presence of carbon disulfide
and potassium hydroxide. (Scheme-1).
2. On treating all the synthesized oxadiazoles (4a-x) with two commercially
available electrophiles, 6-chloro-3,4-methylenedioxybenzylchloride (5) and 6-
bromo-3,4-methylenedioxybenzylbromide (7) and one synthesized electrophile, 2-
bromo-N-(3,4-methylenedioxybenzyl)acetamide (11) in N,N-dimethylformamide
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and sodium hydride, three series were obtained, 5-(aryl/aralkyl)-2-((6-chloro-3,4-
methylenedioxybenzyl)thio)-1,3,4-Oxadiazole (6a-x), 5-(aryl/aralkyl)-2-((6-
bromo-3,4-methylenedioxybenzyl)thio)-1,3,4-Oxadiazole (8a-x) and N-[3,4-
methylenedioxybenzyl]-2-[(5-substituted-1,3,4-oxadiazol-2-yl)thio]acetamide
(12a-t) respectively. (Scheme-2,3,4).
3. N-substituted-2-bromoacetamides (14a-t) were synthesized by the reaction of
different N-substituted amines (13a-t) with 2-bromoacetylbromide (10) in basic
aqueous medium and then on treating these acetamides one by one with 5-(3,4-
methylenedioxyphenyl)-1,3,4-Oxadiazol-2-thiol (4a) in N,N-dimethylformamide
and sodium hydride, a novel series of N-substituted-2-{(5-(3,4-
methylenedioxy)phenyl-1,3,4-Oxadiazol-2-yl) sulfanyl}acetamide (15a-t) was
obtained. (Scheme-5,6).
4. S-alkylation was processed in the presence of N,N-dimethylformamide and
sodium hydride, on treating 5-(3,4-methylenedioxyphenyl)-1,3,4-oxadiazol-2-
thiol (4a) with various alkyl/aralkyl halides (16a-u) and 2-Alkyl/aralkylthio-5-
(3,4-methylenedioxyphenyl)-1,3,4-Oxadiazoles (17a-u)were obtained. (Scheme-
7).
5. A novel series of sulfonamide derivatives of paroxetine (20a-k, m-o) was
obtained by the reaction of commercially available paroxetine (18) with different
sulfonyl chlorides (19a-k, m-o) in basic aqueous conditions. (Scheme-8).
6. The reaction of 3,4-methylenedioxybenzohydrazide (3a) with different sulfonyl
chlorides (19a-l) in basic aqueous conditions produced a series of 3,4-
methylenedioxyphenylsulfonohydrazide (21a-l). (Scheme-9).
1.8. Synthetic schemes
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N
O
N
SHR
O
OHR
O
OC2H5R
O
N
H
NH 2
R
I II III
Acid
1a-x
Ester
2a-x
Acid hydrazide
3a-x
5-substituted-1,3,4-oxa
diazol-2-thiol 4a-x
Scheme-1: Outline for the synthesis of different 5-Aryl/aralkyl-1,3,4-oxadiazol-2-thiols.
Reagents & conditions: (I) Ethanol, Conc. H2SO4, Reflux for 4-5 hrs. (II) Hydrazine hydrate,
Methanol, Reflux for 2-3 hrs. (III) CS2, KOH, Ethanol, Reflux for 6-7 hrs.
Table-I: Different 5-substituted aralkyl/aryl groups of 1,3,4-oxadiazol-2-thiol
compd R compd R compd R
4a
O
O
4i
N
4q
NO2
4b
Cl
4j
CH3
O2N
NO2
4r
O 2N
4c
Cl
4k
O
O
4s
Cl
O2N
NO2
4d
Cl
4l 4t
Cl
Cl
4e
O2N
4m
O
Cl
4u
HO
4f 4n 4v
O2N
NO2
4g
H3C
4o H3C O
4w
4h NS
O
O
4p
CH3
4x
H2N
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R
N
O
N
SH
+
I
5
6a-x
5-Substituted-1,3,4
-Oxadiazol-2-thiol
4a-x
5-Substituted-2-((6-chloro-3,4-methylene
dioxyphenyl)methylthio)-1,3,4-oxadiazole
6-chloro-3,4-methylene
dioxybenzylchloride
R
N
O
N
S
Cl O
O
Cl
Cl O
O
Scheme-2: Outline for the synthesis of different 5-Substituted-2-((6-chloro-3,4-
methylenedioxyphenyl)methylthio)-1,3,4-oxadiazole derivatives (6a-x). Reagents & conditions:
(I) DMF, LiH, Stirring for 3-4 hrs.
Table-II: Different 5-substituted alkyl/aryl groups
Compd R Compd R Compd R
6a
O
O
6i
N
6q
NO2
6b
Cl
6j
CH3
O2N
NO2
6r
O2N
6c
Cl
6k
O
O
6s
Cl
O2N
NO2
6d
Cl
6l 6t
Cl
Cl
6e
O2N
6m
O
Cl
6u
HO
6f 6n 6v
O2N
NO2
6g
H3C
6o H3C O
6w
6h NS
O
O
6p
CH3
6x
H2N
Introduction
Department of Chemistry, GCU Lahore. Page 20
R
N
O
N
SH
+
I
7
8a-x
5-Substituted-1,3,4
-Oxadiazol-2-thiol
4a-x
5-Substituted-2-((6-bromo-3,4-methylene
dioxyphenyl)methylthio)-1,3,4-oxadiazole
6-bromo-3,4-methylene
dioxybenzylbromide
R
N
O
N
S
Br O
O
Br
Br O
O
Scheme-3: Outline for the synthesis of different 5-Substituted-2-((6-bromo-3,4-
methylenedioxyphenyl)methylthio)-1,3,4-oxadiazole derivatives (8a-x). Reagents & conditions:
(I) DMF, LiH, Stirring for 3-4 hrs.
Table-III: Different 5-substituted aralkyl/aryl groups
Compd R Compd R Compd R
8a
O
O
8i
N
8q
NO2
8b
Cl
8j
CH3
O2N
NO2
8r
O2N
8c
Cl
8k
O
O
8s
Cl
O2N
NO2
8d
Cl
8l 8t
Cl
Cl
8e
O2N
8m
O
Cl
8u
HO
8f 8n 8v
O2N
NO2
8g
H3C
8o H3C O
8w
8h NS
O
O
8p
CH3
8x
H2N
Introduction
Department of Chemistry, GCU Lahore. Page 21
N
O
N
SHR
I
II
N-[3,4-methylenedioxybenzyl]-2-[(5-substituted-1,
3,4-oxadiazol-2-yl)thio]acetamide
3,4-methylenedioxy
benzylamine 9
11
12a-t
4a-t
5-substituted-1,3,4-o
xadiazol-2-thiol
O
ON
H
Br
O
O
OH2N
N
O
N
SR
H
N O
O
O
2-bromo-N-[3,4-methylene
dioxybenzyl]acetamide
Scheme-4: Outline for the synthesis of N-(3,4-Methylenedioxybenzyl)-2-((5-substituted-1,3,4-
oxadiazol-2-yl)thio)acetamides (12a-t). Reagents & conditions: (I) 2-Bromoacetyl bromide (10),
Aq. Na2CO3 soln., stir for ½ hr (II) DMF, NaH, stir for 4-5 hrs.
Table-IV: Different 5-substituted aralkyl/aryl groups
Compd R Compd R Compd R
12a
O
O
12h NS
O
O
12o H3C O
12b
Cl
12i
N
12p
CH3
12c
Cl
12j
CH3
O2N
NO2
12q
NO2
12d
Cl
12k
O
O
12r
O2N
12e
O2N
12l 12s
Cl
O2N
NO2
12f 12m
O
Cl
12t
Cl
Cl
12g
H3C
12n
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R1H2N
I Br
N
H
O
N-Substitued-2-bromoacetamideDifferent N-substituted amines
13a-t 14a-t
R1
Scheme-5: Outline for the synthesis of different N-Substituted-2-bromoacetamides (14a-t).
Reagents & conditions: (I) 2-Bromoacetyl bromide (10), H2O, 5% Na2CO3 soln, stirring for 1
hour.
Table-V: Different N-substituted alkyl/aryl/aralkyl groups.
Compd R1 Compd R1 Compd R1
14a
CH3
H3C 14h
H3C
14o
H3C
14b
H3C
CH3
14i
N
H3C
14p
O
CH3
14c
CH3
CH3
14j
OO
H3C
14q
O
CH3
14d
CH3
CH3
14k
Cl
O
H3C
14r
CH3
H3C
14e
H3C
CH3
14l
O
14s
CH3O
14f 14m 14t
CH3
HO
14g
CH3
14n
CH3
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N-Substituted-2-((5-(3,4-methylenedioxyphenyl)-
1,3,4-oxadizole-2-yl)thio)acetamide
Br
N
H
O
R1
15a-t
N-Substitued-2-bromoacetamide
14a-t
I
O
O
5-(3,4-methylenedioxyphenyl)-
1,3,4-oxadiazol-2-thiol 4a
N
O
N
SH
O
O
N
O
N
S
H
N
R1
O
Scheme-6: Outline for the synthesis of N-Substituted-2-((5-(3,4-methylenedioxyphenyl)-1,3,4-
Oxadiazol-2-yl)thio)acetamide derivatives (15a-t). Reagents & conditions: (I) DMF, NaH,
stirring for 3-4 hours.
Table-VI: Different N-substituted alkyl/aryl/aralkyl groups.
Compd R1 Compd R1 Compd R1
15a
CH3
H3C 15h
H3C
15o
H3C
15b
H3C
CH3
15i
N
H3C
15p
O
CH3
15c
CH3
CH3
15j
OO
H3C
15q
O
CH3
15d
CH3
CH3
15k
Cl
O
H3C
15r
CH3
H3C
15e
H3C
CH3
15l
O
15s
CH3O
15f 15m 15t
CH3
HO
15g
CH3
15n
CH3
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IO
O
5-(3,4-methylenedioxyphenyl)-
1,3,4-oxadiazol-2-thiol
4a
2-Alkyl/aralkylthio-5-(3,4-methylene
dioxyphenyl)-1,3,4-Oxadiazole
17a-u
N
O
N
SH O
O
N
O
N
S
R
Scheme-7: Outline for the synthesis of 2-Alkyl/aralkylthio-5-(3,4-methylenedioxyphenyl)-1,3,4-
oxadiazole derivatives (17a-u). Reagents & conditions: (I) Different alkyl/aryl halides (16a-u),
DMF, NaH, stirring for 3-5 hours.
Table-VII: Different 5-substituted alkyl/aryl groups
Compd R Compd R Compd R
17a 17i 17q
Cl
17b CH2 CH3 17j 17r
Cl
17c CH2
CH2
CH3
17k 17s
NO2
17d CH2
CH2
CH2
CH3 17l
CH3
17t
NO2
17e CH2
CH2
CH2
CH2
CH3
17m
Br
17u
F
17f CH2 CH2 Cl 17n
Br
17g CH2 CH2 Br 17o
Br
17h
CH2
C
OC2H5
O
17p
Cl
CH3
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I
R
S
Cl
O O
+
Alkyl/Aryl substituted
sulfonyl chloride
O
O
O
H
N
F
H
H
20a-k,m-o
19a-k,m-o
18
Paroxetine
N-(alkyl/aryl substituted
sulfonyl)paroxetine
O
O
O
N
S
F
H
H
O R
O
Scheme-8: Outline for the synthesis of sulfonamide derivatives of paroxetine (20a-k, m-o).
Reagents & conditions: (I) H2O, 5% Na2CO3 soln., stirring for 3-4 hours.
Table-VIII: Different substituted R groups.
Compd R Compd R Compd R
20a 20f H3C O
20k
20b
H3C
20g
N
H
H3C
O
20m
Cl
20c H3C
CH3
CH3
20h
Br
20n
20d
CH3
CH3H3C
20i
Cl
Cl 20o
20e H3C
O
20j
Cl
Cl
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I
3a
3,4-methylenedioxy
benzohydrazide
19a-l
21a-l
3,4-methylenedioxyphenyl
sulfonohydrazide
O
O
N
H
NH2
O
R
S
Cl
O O
O
O
N
H
S
H
N R
O
O O
Scheme-9: Outline for the synthesis of 3,4-Methylenedioxyphenylsulfonohydrazide derivatives
(21a-l). Reagents & conditions: (I) H2O, 5% Na2CO3 soln., stirring for 2-3 hours.
Table-IX: Different substituted R groups.
Compd R Compd R
21a 21g
N
H
H3C
O
21b
H3C
21h
Br
21c H3C
CH3
H3C
21i
Cl
Cl
21d
CH3
CH3H3C
21j
Cl
Cl
21e H3C
O
21k
21f H3C O
21l
OH
Cl
Cl
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CHAPTER-2
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2.0. Methods of synthesizing different molecules bearing benzodioxole
moiety
Ana Cristina and co-workers synthesized peptide like derivatives having methylene
dioxy moiety from Safrol and evaluate them for antitumor activity [6].
O
O NO2
O
O
COOH
NO2
O
O NO2
N
P
O
O R2
H
DMF,NH 2CH(R2)COP,
0OC
KMnO4, C6H6,
AcOH/NaHSO4
/H2SO4
Hai-Hong Wang, with his co-workers prepared some derivatives of thiazolylpyrazoline
which contain methylene dioxy ring and put them for anticancer activity. The results
were supported through docking studies. [3]
O
R1
+ O
(CH2)n
OOHC
O
(CH2)n
OR1
O
O
(CH2)n
OR1
N N
H2N
S
O
(CH2)n
OR1
N N
S
N
R2
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Yin Luo and co-workers designed novel pyrazole derivatives containing methylene
dioxy core and examined their anticancer activity. The reaction conditions are shown in
the scheme [4].
+
OHC OH
OH Br
(CH 2)n
Br
OHC
O
(CH2)n
O
O
R
O
(CH 2)n
O
O
RO
(CH 2)n
OR
N N
O
K2CO3/acetone/24h
EtOH/KOH/2h
Acetic acid,hydrazine
hydrate/2h
2.1. Methods of synthesizing different substituted paroxetine derivatives
Scott P. Runyon and co-workers designed and synthesized some novel tropane derived
paroxetine analogues in order to cheque the structural requirements for binding with
serotonin transporter and hence understanding their mechanism [15].
NH3C COOCH3
F
NH3C O
F
NH3C OH
F
S
O
O
CH3
O
O
O
F
HN
LiAlH4,
THF,0 oC
Methane sulfonyl
chloride,TEA,0oC
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Kiyoshi Sugi and co-workers successfully synthesized paroxetine with the help of a
piperidine derivative, one of the important metabolite in human andput the synthesized
crystals for characterization. The whole reaction is multistep which is represented in brief
as follows [23].
F
CHO
F
N
H
OH
O
O
O
N
H
F
H
H
(3S,
4R)-trans-4-(4-fluorophenyl
)-3-hydroxymethyl
piperidine
4-Florobenzaldehyde
HCl
Paroxetine
Janine Cossy and co-workers performed total synthesis of paroxetine by a ring
expansion method. Pyroglutamic acid is converted into aminoalcohol through seven step
reaction series which is finally transformed into proxetine. Each step is a catalytic step
[22].
O
O
O
N
H
F
H
H
HCl
N
H
HOOC O
(L ) _ pyroglutamic acid
F
N
OH
Ph
Amino alcohol Paroxetine
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2.2. Methods of synthesizing different oxadiazole ring containing
molecules
M.C Hosur synthesized 1,3,4-oxadiazoles from acid hydrazides. The reaction was
carried out in the presence of CS2 and KOH. Ethanol was used as solvent [111].
R C
O
NH NH2
NN
OR SH
CS2/KOH
M.A Elborai with his co-workers reported the synthesis of 1,3,4-oxadiazoles from 2-
thienyl hydrazide in the presence of cyanogen bromide. Methanol was used as a solvent
[112].
C
O
NH NH2
NN
O NH2
CNBr/CH3OH
S S
D.H Boschelli and co-workers synthesized substituted 1,3,4-oxadizolone by treating
carbonyl diimidazole  with triethylamine in THF as a solvent [113].
C
O
NH NH2
NHN
O OCDI/ETA
NH
R
THF NH
R
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Li and Dickson developed a very convenient method for the synthesis of oxadiazoles by
treating carboxylic acid with hydrazides using HATU and Burgess Reagent [114].
R OH
O
N
H
H2N
O NN
OR
HATU/DIEA
Burgess reagent+
Pouliot and co-workers prepared 1,3,4-oxadiazoles from 1,2-diacyl hydrazines with the
use of diethylaminodiflorosulfinium tetra flouroborate as cyclo dehydration agent [115].
R1 N
H
O NN
OR1
Xtalflour-E (1.5 eq)
AcOH (0 or 1.5 eq)
DCE (0.1M), 90oC, 12h
H
N R2
O
,
R2
Sharma and co-workers developed a new method for the synthesis of 1,3,4-oxadiazoles
from diacylhydrazines. ZrCl4 was used as a catalyst. The advantage of this reaction is that
it is a shorter time reaction yielding maximum product [116].
Ar N
H
O NN
OA
r
10 mol%, ZrCl4
CH2Cl2, rt, 2-3h, 71-88%
H
N Ar1
O
,
Ar1
Li and co-workers reported a method in which 1,3,4-oxadiazoles are prepared from 1,2-
diacyl hydrazines using solvent free envoirnment and under microwave irradiation.
Dichlorophosphate is used as a dehydration agent. Symmetrical and unsymmetrical 1,3,4-
oxadiazoles can be prepared by this method [117].
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Ar N
H
O NN
OArneat,MW,2 min,76-95%
H
N Ar1
O
,
Ar1
O2Si O RCl2
O
Amir and Kumar synthesized novel 1,3,4-oxadiazoles starting from ibuprofen drug.
Phosphorus oxy chloride (POCl3) was used as a dehydrating agent [118].
H3C
CH3
OH
O
CH3
H3C
CH3
O
O
CH3
EtOH
H2SO4
CH3
H3C
CH3
NHNH2
O
CH3
NH2NH2/EtOH
HO
R
O
+
POCl3/reflux
NN
OH3C
H3C
R
H3C
Dolman and co-workers synthesized 1,3,4-oxadiazoles from acylsemicarbazide and
acylthiosemicarbazide in the presence of tosyl chloride. The reaction gave 97-99% yield
[119].
N. Sikder and co-workers prepared long chain bis-1,3,4-oxadiazol by the cyclization of
N N’-dinitrobenzoyldihydrazide of malonic acid or adipic acid. POCl3 was used as a
dehydrating agent [120].
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CHAPTER-3
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3.0. General
The chemicals used in the whole research work were of analytical grade and purchased
from two well known suppliers, Sigma Aldrich and Alfa Aesar (Germany). After getting
the products, their physical analysis was done by recording their appearance, odour,
molecular weight and % yield. The common and usual, open capillary tube method was
applied to record the melting points of the synthesized compounds on Griffin and George
apparatus and were uncorrected. Reactions were monitored by thin layer chromatography
(TLC) untill completion and purity of synthesized compounds was also ensured by using
TLCin a combination of n-hexane (non polar) and ethyl acetate (polar) as mobile phase at
254 nm. Different spectral techniques were used for further confirmation and for
structure elucidation. Major functional groups were assigned by using KBr disc method
in IR spectroscopy. Bands were recorded in the form of spectra on Jasco-320-A
spectrophotometer. 1H-NMR spectra were gained at 300, 400, 500& 600 MHz in CDCl3.
Moreover 13C-NMR spectra at 75 & 100 MHz in CDCl3by using Bruker
spectrophotometers, were recorded. JMS-HX-110 spectrometer was used to get different
peaks in EIMS spectrophotometer.
3.1. Synthesis of 5-aryl/aralkyl-1,3,4-Oxadiazol-2-thiol(4a-x)
3.1.1. General procedure for the synthesis of different aryl/aralkyl carboxylate
esters (2a-x)
Mixture of different aryl/aralkyl carboxylic acids (0.2 mol, 1a-x), absolute ethanol (50-60
mL) used as solvent and Conc. H2SO4 (5-7 mL) used as a catalyst, was taken in a round
round bottom flask. The reaction mixture was refluxed for 4-5 hrs. Reaction progress was
monitored by TLC, using n-hexane and EtOAc as mobile phase. After the maximum
reaction completion, it was transferred to a separating funnel. The unreacted acids were
neutralized by adding solution of Na2CO3. The oily esters were recovered by using
appropriate organic solvents which, on evaporating, gave pure products,2a-x.
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3.1.2. General procedure for the synthesis of different aryl/aralkyl carbohydrazides
(3a-x)
The recovered esters(0.1 mol, 2a-x) were taken in 250 mL round bottom flask.
Hydrazine hydrate (15-20 mL) and methanol (25-40 mL) in excess were added to it and
the mixture was allowed to reflux for 2-3 hrs. Reaction progress was checked by
Thinlayer chromatography (TLC). Excess methanol was distilled off after the reaction
completion. Ice cold distilled water was added to get the solid aryl/aralkyl
carbohydrazides (3a-x) which were filtered, washed with distilled water and dried.
3.1.3. General procedure for the synthesis of different 5-aryl/aralkyl-1,3,4-
Oxadiazol-2-thiol (4a-x)
To get the final required products, the carbohydrazides (0.05 mol, 3a-x) were dissolved in
excess ethanol and KOH pallets (0.1 mol) were added to it to make the pH basic. The
whole reaction mixture was introduced to a 250 mL reaction flask. Carbon disulfide (CS2,
0.05 mol) was slowly added to reaction flask. Reaction contents were refluxed for 9-10
hrs. The production of H2S gas as a side product clearly indicates the reaction progress.
After the reaction completion, monitored and checked by TLC, ice cold distilled water
was added to the reaction mixture with vigorous shaking. Mineral acid, HCl, was added
dropwise to establish a pH of 3-4 to get pure product as well as to neutralize the
unreacted base present in the reaction mixture. After the filtration, precipitates of the
required compounds, 5-Aryl/aralkyl-1,3,4-oxadiazol-2-thiol (4a-x)were washed with
water and dried.
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3.2. General procedure for the synthesis of different 5-(aryl/aralkyl)-2-
((6-chloro-3,4-methylenedioxybenzyl)thio)-1,3,4-Oxadiazole (6a-x)
In the first step, 5-aryl/aralkyl-1,3,4-Oxadiazol-2-thiol (0.002 mol, 4a-x) were taken in a
100 mL round bottom flask. To it, DMF (5-10 mL), used as polar aprotic solvent and
catalytic amount of solid NaH (0.002 mol), acting as a base, were added. The whole
reaction mixture was stirred at room temperature for about thirty minutes. The
electrophile, 6-chloro-3,4-methylenedioxybenzylchloride (5)was added to the reaction
mixture in equimolar ratio. After 3-4 hrs stirring, different 5-(aryl/aralkyl)-2-((6-chloro-
3,4-methylenedioxybenzyl)thio)-1,3,4-oxadiazoles(6a-x) were obtained in a good yield
on adding ice cold distilled water to the reaction contents. The products were obtained
either in the form of solid precipitates or as oily liquid. The solid products were filtered,
washed and dried while oily products were extracted with organic solvent by solvent
extraction method. The solvent, after evaporation, gave pure liquid product. The mobile
phase used was n-hexane and ethyl acetate in a ratio of (4:1).
3.2.1. 5-(3,4-Methylenedioxyphenyl)-2-((6-chloro-3,4-methylenedioxybenzyl) thio)-
1,3,4-Oxadiazole (6a)
White amorphous solid; Yield: 95%; M.P. 199oC; Mol. formula: C17H11ClN2O5S; Mol.
Wt: 390 gmol-1; IR (KBr, cm-1) vmax: 3053 (Ar-H stretching), 1550 (Ar C=C stretching),
1125 (C-O stretching), 708 (C-Cl stretching), 617 (C-S stretching).
1H-NMR (400 MHz, CDCl3, ppm):See Table 1
13C-NMR (100 MHz, CDCl3, ppm):165.9 (C-2), 165.1 (C-5), 154.3 (C-3ꞌꞌ), 150.2 (C-4ꞌꞌ),
149.8 (C-4ꞌ), 148.2 (C-3ꞌ), 129.9 (C-1ꞌ), 125.9 (C-6ꞌ), 121.6 (C-1ꞌꞌ), 116.5 (C-6ꞌꞌ), 111.0
(C-5ꞌ), 110.3 (C-2ꞌ), 109.5 (C-5ꞌꞌ), 108.8 (C-2ꞌꞌ), 101.7 (C-7ꞌ), 101.0 (C-7ꞌꞌ), 32.1 (C-8ꞌ).
EIMS m/z: 392 [M+2]+ (0.3%), 390 [M]+ (1%), 355 (100%), 222 (23%),  200 (9%), 189
(16%), 169 (86%), 163 (2%), 149 (4%), 147 (3%), 139 (4%), 134 (3%), 121 (3%), 104
(9%), 91 (39%).
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3.2.2. 5-(2-Chlorophenyl)-2-((6-chloro-3,4-methylenedioxybenzyl)thio)-1,3,4-
Oxadiazole (6b)
White amorphous solid; Yield: 98%; M.P. 160-162 oC,; Mol. formula: C16H10Cl2N2O3S;
Mol. Wt: 380 gmol-1; IR (KBr, cm-1) vmax: 3055 (Ar-H stretching), 1536 (Ar C=C
stretching), 1127 (C-O stretching), 713 (C-Cl stretching).
1H-NMR (400 MHz, CDCl3, ppm):See Table 1
13C-NMR (100 MHz, CDCl3, ppm):167.3 (C-5), 165.3 (C-2), 150.7 (C-4ꞌ), 149.9 (C-3ꞌ),
132.8 (C-4ꞌꞌ), 131.1 (C-2ꞌꞌ), 130.7 (C-1ꞌ), 128.4 (C-3ꞌꞌ), 126.7 (C-6ꞌꞌ), 125.7 (C-5ꞌꞌ), 124.3
(C-1ꞌꞌ), 123.5 (C-6ꞌ), 110.8 (C-5ꞌ), 110.4 (C-2ꞌ), 101.4 (C-7ꞌ), 31.9 (C-8ꞌ).
EIMS m/z: 384 [M+4]+ (0.3%), 382 [M+2]+ (0.7%), 380 [M]+ (1%), 345 (100%), 212
(3%), 200 (2%), 179 (16%), 169 (9%), 153 (85%), 139 (6%), 137 (5%), 134 (2%), 111
(8%), 104 (6%), 51 (3%).
3.2.3. 5-(3-Chlorophenyl)-2-((6-chloro-3,4-methylenedioxybenzyl)thio)-1,3,4-
Oxadiazole(6c)
White amorphous solid; Yield: 99 %; M.P. 152-154 oC;Mol. formula: C16H10Cl2N2O3S;
Mol. Wt: 380 gmol-1; IR (KBr, cm-1) vmax: 3057 (Ar-H stretching), 1551 (Ar C=C
stretching), 1129 (C-O stretching), 695 (C-Cl stretching).
1H-NMR (400 MHz, CDCl3, ppm):See Table 2
13C-NMR (100 MHz, CDCl3, ppm):166.1 (C-5), 165.4 (C-2), 149.6 (C-4ꞌ), 148.9 (C-3ꞌ),
135.8 (C-3ꞌꞌ), 133.1 (C-2ꞌꞌ), 131.4 (C-1ꞌꞌ), 130.7 (C-1ꞌ), 128.8 (C-4ꞌꞌ), 127.2 (C-6ꞌꞌ), 126.7
(C-5ꞌꞌ), 125.5 (C-6ꞌ), 110.8 (C-5ꞌ), 110.0 (C-2ꞌ), 101.6 (C-7ꞌ), 32.4 (C-8ꞌ).
EIMS m/z: 384 [M+4]+ (0.3%), 382 [M+2]+ (0.7%), 380 [M]+ (1%), 345 (100%), 212
(3%), 200 (2%), 179 (16%), 169 (9%), 153 (5%), 139 (6%), 137 (3%), 134 (2%), 111
(9%), 104 (6%), 76 (21%), 50 (3%).
3.2.4. 5-(4-Chlorophenyl)-2-((6-chloro-3,4-methylenedioxybenzyl)thio)-1,3,4-
Oxadiazole (6d)
White amorphous solid; Yield: 97 %; M.P. 164 oC; Mol. formula: C16H10Cl2N2O3S; Mol.
Wt: 380 gmol-1; IR (KBr, cm-1) vmax: 3059 (Ar-H stretching), 1555 (Ar C=C stretching),
1131 (C-O stretching), 697 (C-Cl stretching), 613 (C-S stretching).
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1H-NMR (400 MHz, CDCl3, ppm):See Table 2
13C-NMR (100 MHz, CDCl3, ppm):165.4 (C-5), 164.7 (C-2), 149.7 (C-4ꞌ), 149.0 (C-3ꞌ),
136.6 (C-4ꞌꞌ), 130.9 (C-1ꞌ), 129.1 (C-3ꞌꞌ & C-5ꞌꞌ), 128.7 (C-1ꞌꞌ), 128.2 (C-2ꞌꞌ & C-6ꞌꞌ), 125.6
(C-6ꞌ), 110.7 (C-5ꞌ), 110.1 (C-2ꞌ), 101.7 (C-7ꞌ), 32.3 (C-8ꞌ).
EIMS m/z: 384 [M+4]+ (0.3%), 382 [M+2]+ (0.7%), 380 [M]+ (1%), 345 (100%), 212
(4%), 200 (3%), 179 (14%), 169 (7%), 153 (8%), 139 (5%), 137 (4%), 134 (2%), 111
(8%), 104 (5%), 76 (20%).
3.2.5. 5-(3-Nitrophenyl)-2-((6-chloro-3,4-methylenedioxybenzyl)thio)-1,3,4-
Oxadiazole (6e)
Creamy white amorphous solid; Yield: 99 %; M.P. 200-202 oC; Mol. formula:
C16H10ClN3O5S; Mol. Wt: 391 gmol-1; IR (KBr, cm-1) vmax: 3065 (Ar-H stretching), 1543
(Ar C=C stretching), 1253 (C-N stretching), 1134 (C-O stretching), 708 (C-Cl
stretching), 616 (C-S stretching).
1H-NMR (400 MHz, CDCl3, ppm):See Table 3
13C-NMR (100 MHz, CDCl3, ppm):165.4 (C-5), 164.6 (C-2), 150.7 (C-4ꞌ), 150.0 (C-3ꞌ),
149.2 (C-3ꞌꞌ), 136.3 (C-6ꞌꞌ), 132.5 (C-1ꞌꞌ), 131.2 (C-5ꞌꞌ), 129.8 (C-1ꞌ), 126.3 (C-6ꞌ), 125.1
(C-4ꞌꞌ), 122.6 (C-2ꞌꞌ), 110.8 (C-5ꞌ), 110.0 (C-2ꞌ), 101.1 (C-7ꞌ), 32.4 (C-8ꞌ) .
EIMS m/z: 393 [M+2]+ (0.3%), 391 [M]+ (1%), 356 (25%), 222 (100%), 200 (4%), 192
(7%), 190 (5%), 169 (9%), 164 (90%), 150 (2%), 148 (5%), 139 (2%), 134 (3%), 122
(7%), 104 (3%), 51 (3%).
3.2.6. 5-Benzyl-2-((6-chloro-3,4-methylenedioxybenzyl)thio)-1,3,4-Oxadiazole (6f)
White amorphous solid, Yield: 89 %; M.P. 148-150 oC;Mol. formula: C17H13ClN2O3S;
Mol. Wt: 360 gmol-1; IR (KBr, cm-1) vmax: 3046 (Ar-H stretching), 1547 (Ar C=C
stretching), 1119 (C-O stretching), 698 (C-Cl stretching).
1H-NMR (300 MHz, CDCl3, ppm):See Table 3
13C-NMR (75 MHz, CDCl3, ppm):165.6 (C-5), 164.2 (C-2), 150.2 (C-4ꞌ), 149.1 (C-3ꞌ),
133.5 (C-1ꞌꞌ), 130.6 (C-1ꞌ), 129.4 (C-3ꞌꞌ & 5ꞌꞌ), 128.9 (C-2ꞌꞌ & 6ꞌꞌ), 127.2 (C-4ꞌꞌ), 125.8 (C-
6ꞌ), 110.8 (C-5ꞌ), 110.3 (C-2ꞌ), 101.6 (C-7ꞌ), 34.7 (C-7ꞌꞌ), 32.8 (C-8ꞌ).
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EIMS m/z: 362 [M+2]+ (0.5%), 360 [M]+ (1.5%), 325 (100%), 200 (2%), 192 (5%), 169
(9%), 159 (2%), 139 (2%), 134 (2%), 133 (3%), 119 (4%), 117 (3%), 104 (3%), 91
(21%), 77 (6%), 65 (5%), 51 (3%).
3.2.7. 5-(4-Methylphenyl)-2-((6-chloro-3,4-methylenedioxybenzyl)thio)-1,3,4-
Oxadiazole (6g)
White amorphous solid; Yield: 96 %; M.P. 198-200 oC; Mol. formula: C17H13ClN2O3S;
Mol. Wt. 360 gmol-1; IR (KBr, cm-1) vmax: 3047 (Ar-H stretching), 1536 (Ar C=C
stretching), 1118 (C-O stretching), 705 (C-Cl stretching).
1H-NMR (400 MHz, CDCl3, ppm):See Table 4
13C-NMR (100 MHz, CDCl3, ppm):165.7 (C-5), 164.4 (C-2), 149.8 (C-4ꞌ), 149.2 (C-3ꞌ),
140.4 (C-4ꞌꞌ), 130.9 (C-1ꞌ), 130.2 (C-2ꞌꞌ & 6ꞌꞌ), 129.7 (C-1ꞌꞌ), 129.1 (C-3ꞌꞌ & 5ꞌꞌ), 125.6 (C-
6ꞌ), 110.5 (C-5ꞌ), 110.0 (C-2ꞌ), 101.6 (C-7ꞌ), 32.9 (C-8ꞌ), 20.9 (C-7ꞌꞌ).
EIMS m/z: 62 [M+2]+ (0.3%), 360 [M]+ (1%), 325 (100%), 200 (3%), 192       (4%), 169
(7%), 160 (3%), 139 (6%), 134 (4%), 133 (5%), 119 (6%), 117 (2%), 104 (7%), 91
(23%), 51 (6%).
3.2.8. 5-[1-(Phenylsulfonyl)piperidyl]-2-((6-chloro-3,4-methylenedioxybenzyl)thio)-
1,3,4-oxadiazole (6h)
White amorphous solid; Yield: 95 %; M.P. 130-132 oC; Mol. formula:
C21H20ClN3O5S2;Mol. Wt: 493 gmol-1; IR (KBr, cm-1) vmax: 3047 (Ar-H stretching), 1529
(Ar C=C stretching), 1407 (S=O stretching), 1123 (C-O stretching), 712 (C-Cl
stretching), 615 (C-S stretching).
1H-NMR (400 MHz, CDCl3, ppm):See Table 4
13C-NMR (100 MHz, CDCl3, ppm):170.7 (C-5), 164.7 (C-2), 149.9 (C-4ꞌ), 148.3 (C-3ꞌ),
144.8 (C-1ꞌꞌꞌ), 133.5 (C-4ꞌꞌꞌ), 130.4 (C-1ꞌ), 129.3 (C-3ꞌꞌꞌ & 5ꞌꞌꞌ), 128.4 (C-2ꞌꞌꞌ & 6ꞌꞌꞌ), 125.7
(C-6ꞌ), 110.7 (C-5ꞌ), 110.0 (C-2ꞌ), 101.5 (C-7ꞌ), 41.5 (C-2ꞌꞌ & 6ꞌꞌ), 35.1 (C-4ꞌꞌ), 32.7 (C-8ꞌ),
29.6 (C-3ꞌꞌ & 5ꞌꞌ) .
EIMS m/z: 495 [M+2]+ (0.3%), 493 [M]+ (1%), 458 (100%), 394 (1%), 325 (2%), 224
(7%), 200 (3%), 183 (3%), 169 (4%), 141 (9%), 139 (2%), 134 (2%), 104 (8%).
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3.2.9. 5-(Pyridin-3-yl)-2-((6-chloro-3,4-methylenedioxybenzyl)thio)-1,3,4-
Oxadiazole (6i)
White amorphous solid; Yield: 96 %; M.P. 148-150 oC;Mol. formula: C15H10ClN3O3S;
Mol. Wt: 347 gmol-1; IR (KBr, cm-1) vmax: 3054 (Ar-H stretching), 1539 (Ar C=C
stretching), 1127 (C-O stretching), 699 (C-Cl stretching).
1H-NMR (400 MHz, CDCl3, ppm):See Table 5
13C-NMR (100 MHz, CDCl3, ppm):165.6 (C-5), 164.7 (C-2), 152.4 (C-6ꞌꞌ), 150.5 (C-2ꞌꞌ),
149.4 (C-4ꞌ), 148.7 (C-3ꞌ), 130.8 (C-1ꞌ), 129.3 (C-4ꞌꞌ), 126.8 (C-5ꞌꞌ), 125.4 (C-6ꞌ), 123.1
(C-3ꞌꞌ), 110.8 (C-5ꞌ), 110.3 (C-2ꞌ), 101.5 (C-7ꞌ), 32.4 (C-8ꞌ).
EIMS m/z: 349 [M+2]+ (0.3%), 347 [M]+ (1%), 312 (100%), 200 (2%), 179 (5%), 169
(9%), 146 (2%), 139 (2%), 134 (2%), 120 (3%), 106 (11%), 104 (3%), 78 (21%).
3.2.10. 5-(2-Methyl-3,5-dinitrophenyl)-2-((6-chloro-3,4-methylenedioxybenzyl) thio)-
1,3,4-Oxadiazole (6j)
Yellow amorphous solid; Yield: 98 %; M.P. 120 oC; Mol. formula: C17H11ClN4O7S; Mol.
Wt: 450 gmol-1; IR (KBr, cm-1) vmax: 3063 (Ar-H stretching), 1557 (Ar C=C stretching),
1121 (C-O stretching), 708 (C-Cl stretching), 611 (C-S stretching).
1H-NMR (400 MHz, CDCl3, ppm):See Table 5
13C-NMR (100 MHz, CDCl3, ppm):169.9 (C-5), 165.7 (C-2), 153.3 (C-3ꞌꞌ), 149.9 (C-4ꞌ),
149.1 (C-3ꞌ), 146.8 (C-5ꞌꞌ), 135.1 (C-1ꞌꞌ), 130.6 (C-1ꞌ), 125.7 (C-6ꞌ), 124.8 (C-6ꞌꞌ), 124.2
(C-2ꞌꞌ), 117.4 (C-4ꞌꞌ), 110.8 (C-5ꞌ), 110.3 (C-2ꞌ), 101.8 (C-7ꞌ), 32.5 (C-8ꞌ), 18.1 (C-7ꞌꞌ).
EIMS m/z: 452 [M+2]+ (0.3%), 450 [M]+ (1%), 415 (40%), 282 (6%), 249 (8%), 223
(100%), 209 (7%), 207 (5%), 200 (2%), 181 (15%), 169 (9%), 139 (4%), 134 (3%), 104
(9%), 74 (12%), 48 (2%).
3.2.11. 5-(2-(3,4-Methylenedioxyphenyl)ethenyl)-2-((6-chloro-3,4-methylene
dioxybenzyl)thio)-1,3,4-Oxadiazole (6k)
Grey amorphous solid; Yield: 98 %; M.P. 116-118 oC; Mol. formula: C19H13ClN2O5S;
Mol. Wt: 416 gmol-1; IR (KBr, cm-1) vmax: 3063 (Ar-H stretching), 1654 (C=C
stretching), 1543 (Ar C=C stretching), 1135 (C-O stretching).
1H-NMR (400 MHz, CDCl3, ppm):See Table 6
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13C-NMR (100 MHz, CDCl3, ppm):165.3 (C-2), 164.8 (C-5), 150.8 (C-4ꞌꞌ), 150.4 (C-4ꞌ),
149.3 (C-3ꞌ), 148.9 (C-3ꞌꞌ), 140.5 (C-8ꞌꞌ), 131.2 (C-1ꞌꞌ), 130.7 (C-1ꞌ), 125.1 (C-6ꞌ), 121.3
(C-6ꞌꞌ), 110.7 (C-5ꞌ), 110.3 (C-2ꞌ), 108.6 (C-9ꞌꞌ), 107.8 (C-5ꞌꞌ), 107.2 (C-2ꞌꞌ), 101.7 (C-7ꞌ),
101.3 (C-7ꞌꞌ), 32.4 (C-8ꞌ).
EIMS m/z: 418 [M+2]+ (0.3%), 416 [M]+ (1%), 381 (100%), 248 (8%), 215 (100%), 200
(7%), 189 (3%), 175 (2%), 173 (2%), 169 (7%), 147 (4%), 139 (4%), 134 (3%), 121
(7%), 104 (9%), 91 (13%).
3.2.12. 5-(Naphthalen-1-ylmethyl)-2-((6-chloro-3,4-methylenedioxybenzyl)thio)-
1,3,4-Oxadiazole (6l)
White amorphous solid; Yield: 99 %; M.P. 98-100 oC; Mol. formula: C21H15ClN2O3S;
Mol. Wt: 410 gmol-1; IR (KBr, cm-1) vmax: 3051 (Ar-H stretching), 1537 (Ar C=C
stretching), 1126 (C-O stretching), 703 (C-Cl stretching).
1H-NMR (400 MHz, CDCl3, ppm):See Table 6
13C-NMR (100 MHz, CDCl3, ppm):165.9 (C-5), 164.6 (C-2), 149.9 (C-4ꞌ), 148.4 (C-3ꞌ),
141.7 (C-1ꞌꞌ), 131.2 (C-5ꞌꞌ), 130.6 (C-1ꞌ), 130.1 (C-4ꞌꞌ), 129.7 (C-10ꞌꞌ), 128.1 (C-7ꞌꞌ), 127.4
(C-6ꞌꞌ), 126.8 (C-3ꞌꞌ), 125.3 (C-6ꞌ), 125.1 (C-2ꞌꞌ), 123.9 (C-8ꞌꞌ), 120.5 (C-9ꞌꞌ), 110.8 (C-5ꞌ),
110.1 (C-2ꞌ), 101.4 (C-7ꞌ), 34.2 (C-11ꞌꞌ), 32.7 (C-8ꞌ).
EIMS m/z: 412 [M+2]+ (0.3%), 410 [M]+ (1%), 375 (100%), 242 (4%), 209 (5%), 200
(2%), 183 (3%), 169 (9%), 167 (7%), 141 (4%), 139 (3%), 134 (1%), 127 (8%).
3.2.13. 5-(4-Chlorophenoxymethyl)-2-((6-chloro-3,4-methylenedioxybenzyl)thio)-
1,3,4-Oxadiazole (6m)
White amorphous solid; Yield: 98 %; M.P. 96-98 oC; Mol. formula: C17H12Cl2N2O4S;
Mol. Wt: 410 gmol-1; IR (KBr, cm-1) vmax: 3056 (Ar-H stretching), 1649 (C=C
stretching), 1540 (Ar C=C stretching), 1131 (C-O stretching), 705 (C-Cl stretching).
1H-NMR (400 MHz, CDCl3, ppm):See Table 7
13C-NMR (100 MHz, CDCl3, ppm):165.6 (C-2), 164.4 (C-5), 153.7 (C-1ꞌꞌ), 149.5 (C-4ꞌ),
148.1 (C-3ꞌ), 142.4 (C-4ꞌꞌ), 130.8 (C-1ꞌ), 127.6 (C -3ꞌꞌ & 5ꞌꞌ), 125.5 (C-6ꞌ), 113.6 (C-2ꞌꞌ &
6ꞌꞌ), 110.9 (C-5ꞌ), 110.3 (C-2ꞌ), 101.8 (C-7ꞌ), 65.7 (C-7ꞌꞌ), 32.4 (C-8ꞌ) .
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EIMS m/z: 414 [M+4]+ (0.5%), 412 [M+2]+ (1.2%), 410 [M]+ (1.5%), 375 (100%), 242
(1%), 209 (1%), 200 (2%), 183 (2%), 169 (9%), 167 (6%), 141 (2%), 139 (2%), 134
(2%), 111 (15%), 104 (5%), 76 (63%), 51 (3%).
3.2.14. 5-Phenyl-2-((6-chloro-3,4-methylenedioxybenzyl)thio)-1,3,4-Oxadiazole
(6n)
White amorphous solid; Yield; 98 %; M.P. 96-98 oC; Mol. formula: C17H12Cl2N2O4S;
Mol. Wt: 410 gmol-1; IR (KBr, cm-1) vmax: 3053 (Ar-H stretching), 1533 (Ar C=C
stretching), 1125 (C-O stretching), 711 (C-Cl stretching), 610 (C-S stretching).
1H-NMR (400 MHz, CDCl3, ppm):See Table 7
13C-NMR (100 MHz, CDCl3, ppm):165.4 (C-5), 164.6 (C-2), 150.3 (C-4ꞌ), 148.7 (C-3ꞌ),
135.2 (C-3ꞌꞌ & 5ꞌꞌ), 132.8 (C-2ꞌꞌ & 6ꞌꞌ), 130.4 (C-4ꞌꞌ), 129.8 (C-1ꞌꞌ), 129.5 (C-1ꞌ), 125.7 (C-
6ꞌ), 110.9 (C-5ꞌ), 110.2 (C-2ꞌ), 101.9 (C-7ꞌ), 32.7 (C-8ꞌ).
EIMS m/z: 348 [M+2]+ (0.3%), 346 [M]+ (1%), 311 (100%), 200 (2%), 178 (2%), 169
(8%), 145 (12%), 139 (4%), 134 (3%), 119 (7%), 105 (8%), 104 (4%), 103 (5%), 77
(9%), 51 (3%).
3.2.15. 5-(4-Methoxyphenyl)-2-((6-chloro-3,4-methylenedioxybenzyl)thio)-1,3,4-
Oxadiazole (6o)
White amorphous solid; Yield: 98 %; M.P. 150-152 oC; Mol. formula: C17H13ClN2O4S;
Mol. Wt: 376 gmol-1; IR (KBr, cm-1) vmax: 3047 (Ar-H stretching), 1536 (Ar C=C
stretching), 1139 (C-O stretching), 704 (C-Cl stretching).
1H-NMR (400 MHz, CDCl3, ppm):See Table 8
13C-NMR (100 MHz, CDCl3, ppm):164.6 (C-5), 163.8 (C-2), 158.2 (C-4ꞌꞌ), 150.3 (C-4ꞌ),
149.7 (C-3ꞌ), 130.3 (C-1ꞌ), 125.7 (C-6ꞌ), 124.1 (C-1ꞌꞌ), 117.4 (C-2ꞌꞌ & 6ꞌꞌ), 116.7 (C-3ꞌꞌ &
5ꞌꞌ), 110.8 (C-5ꞌ), 110.2 (C-2ꞌ), 101.6 (C-7ꞌ), 58.2 (C-7ꞌꞌ), 32.4 (C-8ꞌ) .
EIMS m/z: 378 [M+2]+ (0.3%), 376 [M]+ (1%), 341 (100%), 208 (16%), 200 (2%), 175
(7%), 169 (9%), 149 (2%), 139 (4%), 133 (6%), 134 (3%), 135 (4%), 107 (3%), 104
(9%), 51 (2%).
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3.2.16. 5-(2-Methylphenyl)-2-((6-chloro-3,4-methylenedioxybenzyl)thio)-1,3,4-
Oxadiazole (6p)
White amorphous solid; Yield: 96 %; M.P.: 198-200 oC; Mol. formula: C17H13ClN2O3S;
Mol. Wt: 360 gmol-1; IR (KBr, cm-1) vmax: 3047 (Ar-H stretching), 1536 (Ar C=C
stretching), 1118 (C-O stretching), 705 (C-Cl stretching).
1H-NMR (400 MHz, CDCl3, ppm):See Table 8
13C-NMR (100 MHz, CDCl3, ppm):164.8 (C-5), 164.1 (C-2), 150.1 (C-4ꞌ), 149.4 (C-3ꞌ),
134.3 (C-2ꞌꞌ), 131.6 (C-1ꞌ), 130.9 (C-4ꞌꞌ), 128.8 (C-3ꞌꞌ), 128.1 (C-1ꞌꞌ), 127.6 (C-5ꞌꞌ), 126.8
(C-6ꞌ), 126.2 (C-6ꞌꞌ), 111.2 (C-5ꞌ), 110.6 (C-2ꞌ), 101.8 (C-7ꞌ), 32.5 (C-8ꞌ), 20.1 (C-7ꞌꞌ) .
EIMS m/z: 362 [M+2]+ (0.3%), 360 [M]+ (1%), 325 (100%), 200 (3%), 192 (4%), 169
(7%), 160 (3%), 139 (6%), 134 (4%), 133 (5%), 119 (6%), 104 (7%), 91 (23%).
3.2.17. 5-(2-Nitrophenyl)-2-((6-chloro-3,4-methylenedioxybenzyl)thio)-1,3,4-
Oxadiazole (6q)
White amorphous solid; Yield: 97 %; M.P. 125-127 oC; Mol. formula: C16H10ClN3O5S;
Mol. Wt: 391 gmol-1; IR (KBr, cm-1) vmax: 3061 (Ar-H stretching), 1542 (Ar C=C
stretching), 1258 (C-N stretching), 1133 (C-O stretching), 710 (C-Cl stretching), 619 (C-
S stretching).
1H-NMR (400 MHz, CDCl3, ppm):See Table 9
13C-NMR (100 MHz, CDCl3, ppm):165.1 (C-2), 164.2 (C-5), 150.4 (C-4ꞌ), 149.7 (C-3ꞌ),
146.2 (C-2ꞌꞌ), 132.5 (C-4ꞌꞌ), 130.8 (C-5ꞌꞌ), 130.1 (C-1ꞌ), 127.9 (C-3ꞌꞌ), 126.8 (C-6ꞌ), 126.2
(C-6ꞌꞌ), 124.7 (C-1ꞌꞌ), 110.9 (C-5ꞌ), 110.3 (C-2ꞌ), 101.5 (C-7ꞌ), 31.8 (C-8ꞌ) .
EIMS m/z: 393 [M+2]+ (0.3%), 391 [M]+ (1%), 356 (25%), 222 (100%), 200 (4%),
192 (7%), 190 (5%), 169 (9%), 164 (90%), 148 (5%), 122 (7%), 104 (3%),
3.2.18. 5-(4-Nitrophenyl)-2-((6-chloro-3,4-methylenedioxybenzyl)thio)-1,3,4-
Oxadiazole(6r)
Light brown amorphous solid; Yield: 98 %; M.P.  146-148 oC; Mol. formula:
C16H10ClN3O5S; Mol. Wt: 391 gmol-1; IR (KBr, cm-1) vmax: 3059 (Ar-H stretching), 1542
(Ar C=C stretching), 1126 (C-O stretching), 703 (C-Cl stretching).
1H-NMR (400 MHz, CDCl3, ppm):See Table 9
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13C-NMR (100 MHz, CDCl3, ppm):164.9 (C-5), 164.2 (C-2), 149.8 (C-4ꞌ), 149.1 (C-3ꞌ),
148.5 (C-4ꞌꞌ), 137.1 (C-1ꞌꞌ), 131.3 (C-1ꞌ), 128.5 (C-2ꞌꞌ & C-6ꞌꞌ), 125.8 (C-6ꞌ), 124.4 (C-3ꞌꞌ
& C-5ꞌꞌ), 110.9 (C-5ꞌ), 110.2 (C-2ꞌ), 101.6 (C-7ꞌ), 31.8 (C-8ꞌ).
EIMS m/z: 393 [M+2]+ (0.3%), 391 [M]+ (1%), 356 (25%), 223 (100%), 200 (4%), 190
(5%), 169 (9%), 164 (9%), 134 (3%), 122 (2%), 104 (3%), 76 (6%).
3.2.19. 5-(2-Chloro-3,5-dinitrophenyl)-2-((6-chloro-3,4-methylenedioxybenzyl)
thio)-1,3,4-Oxadiazole(6s)
Light yellow liquid; Yield: 95 %; Mol. formula: C16H8Cl2N4O7S; Mol. Wt: 470 gmol-1;
IR (KBr, cm-1) vmax: 3067 (Ar-H stretching), 1556 (Ar C=C stretching), 1135 (C-O
stretching), 703 (C-Cl stretching), 609 (C-S stretching).
1H-NMR (400 MHz, CDCl3, ppm):See Table 10
13C-NMR (100 MHz, CDCl3, ppm):171.7 (C-5), 164.6 (C-2), 152.5 (C-3ꞌꞌ), 149.8 (C-4ꞌ),
148.6 (C-3ꞌ), 145.2 (C-5ꞌꞌ), 135.5 (C-1ꞌꞌ), 131.8 (C-2ꞌꞌ), 130.4 (C-1ꞌ), 127.1 (C-6ꞌꞌ), 125.6
(C-6ꞌ), 123.2 (C-4ꞌꞌ), 110.9 (C-5ꞌ), 110.1 (C-2ꞌ), 101.7 (C-7ꞌ), 32.7 (C-8ꞌ).
EIMS m/z: 474 [M+4]+ (0.3%), 472 [M+2]+ (0.7%), 470 [M]+ (1%), 435 (22%), 302
(16%), 269 (17%), 243 (100%), 229 (4%), 169 (9%), 134 (5%), 104 (9%), 74 (14%).
3.2.20. 5-(2,4-Dichlorophenyl)-2-((6-chloro-3,4-methylenedioxybenzyl)thio)-1,3,4-
Oxadiazole(6t)
Brown amorphous solid; Yield: 98 %; M.P. 110-112 oC; Mol. formula: C16H9Cl3N2O3S;
Mol. Wt: 414 gmol-1; IR (KBr, cm-1) vmax: 3057 (Ar-H stretching), 1539 (Ar C=C
stretching), 1121 (C-O stretching), 701 (C-Cl stretching).
1H-NMR (400 MHz, CDCl3, ppm):See Table 10
13C-NMR (100 MHz, CDCl3, ppm):167.5 (C-5), 165.2 (C-2), 149.9 (C-4ꞌ), 148.7 (C-3ꞌ),
136.7 (C-4ꞌꞌ), 134.5 (C-2ꞌꞌ), 132.9 (C-6ꞌꞌ), 131.4 (C-3ꞌꞌ), 130.6 (C-1ꞌ), 128.4 (C-5ꞌꞌ), 126.1
(C-1ꞌꞌ), 125.8 (C-6ꞌ), 110.9 (C-5ꞌ), 110.3 (C-2ꞌ), 101.8 (C-7ꞌ), 32.7 (C-8ꞌ).
EIMS m/z: 420 [M+6]+ (0.3%), 418 [M+4]+ (0.6%), 416 [M+2]+ (0.7%), 414 [M]+ (1%),
379 (100%), 246 (6%), 213 (14%), 200 (2%), 187 (9%), 173 (7%), 171 (5%), 169 (9%),
145 (17%), 139 (4%), 134 (3%), 106 (9%), 75 (10%), 49 (4%).
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3.2.21. 5-(4-Hydroxyphenyl)-2-((6-chloro-3,4-methylenedioxybenzyl)thio)-1,3,4-
Oxadiazole (6u)
White amorphous solid; Yield: 98 %; M.P. 145-147 oC; Mol. formula: C16H11ClN2O4S;
Mol. Wt: 362 gmol-1; IR (KBr, cm-1) vmax: 3060 (Ar-H stretching), 1537 (Ar C=C
stretching), 1119 (C-O stretching), 703 (C-Cl stretching).
1H-NMR (400 MHz, CDCl3, ppm):See Table 11
13C-NMR (100 MHz, CDCl3, ppm):164.9 (C-5), 164.1 (C-2), 159.7 (C-4ꞌꞌ), 150.0 (C-4ꞌ),
148.6 (C-3ꞌ), 130.6 (C-1ꞌ), 125.3 (C-6ꞌ), 124.4 (C-1ꞌꞌ), 123.2 (C-2ꞌꞌ & 6ꞌꞌ), 119.1 (C-3ꞌꞌ &
5ꞌꞌ), 110.8 (C-5ꞌ), 110.1 (C-2ꞌ), 101.5 (C-7ꞌ), 32.7 (C-8ꞌ).
EIMS m/z: 364 [M+2]+ (0.3%), 362 [M]+ (1.5%), 327 (100%), 200 (2%), 194 (5%), 169
(9%), 161 (2%), 139 (4%), 135 (9%), 134 (20%), 121 (8%), 119 (6%), 104 (7%), 93
(15%), 51 (4%).
3.2.22. 5-(2-Methyl-3,5-dinitrophenyl)-2-((6-chloro-3,4-methylenedioxybenzyl)
thio)-1,3,4-Oxadiazole(6v)
Yellow amorphous solid; Yield: 98 %; M.P. 120-122 oC; Mol. formula: C17H11ClN4O7S;
Mol. Wt: 450 gmol-1; IR (KBr, cm-1) vmax: 3063 (Ar-H stretching), 1557 (Ar C=C
stretching), 1121 (C-O stretching), 708 (C-Cl str), 611 (C-S str).
1H-NMR (400 MHz, CDCl3, ppm):See Table 11
13C-NMR (100 MHz, CDCl3, ppm):169.6 (C-5), 165.4 (C-2), 149.6 (C-4ꞌ), 148.8 (C-3ꞌ),
147.2 (C-3ꞌꞌ & C-5ꞌꞌ), 134.3 (C-1ꞌꞌ), 130.5 (C-1ꞌ), 128.2 (C-2ꞌꞌ & C-6ꞌꞌ), 125.5 (C-6ꞌ), 116.3
(C-4ꞌꞌ), 111.0 (C-5ꞌ), 110.2 (C-2ꞌ), 101.6 (C-7ꞌ), 32.4 (C-8ꞌ).
EIMS m/z: 452 [M+2]+ (0.3%), 450 [M]+ (1%), 415 (40%), 282 (6%), 249 (8%), 223
(100%), 209 (7%), 207 (5%), 200 (2%), 181 (15%), 169 (9%), 139 (4%), 134 (3%), 104
(9%), 74 (12%), 48 (2%).
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3.2.23. 5-(2-Phenylethenyl)-2-((6-chloro-3,4-methylenedioxybenzyl)thio)-1,3,4-
Oxadiazole(6w)
Grey amorphous solid; Yield: 92 %; M.P. 126-128 oC; Mol. formula: C18H13ClN2O3S;
Mol. Wt: 372 gmol-1; IR (KBr, cm-1) vmax: 3052 (Ar-H stretching), 1567 (Ar C=C
stretching), 1129 (C-O stretching), 703 (C-Cl stretching).
1H-NMR (400 MHz, CDCl3, ppm):See Table 12
13C-NMR (100 MHz, CDCl3, ppm):164.4 (C-5), 162.9 (C-2), 149.5 (C-4ꞌ), 147.7 (C-3ꞌ),
143.8 (C-1ꞌꞌ), 140.3 (C-7ꞌꞌ), 129.7 (C-1ꞌ), 127.8 (C-4ꞌꞌ), 127.2 (C-3ꞌꞌ & 5ꞌꞌ), 126.3 (C-2ꞌꞌ &
6ꞌꞌ), 125.7 (C-6ꞌ), 122.1 (C-8ꞌꞌ), 110.9 (C-5ꞌ), 110.1 (C-2ꞌ), 101.3 (C-7ꞌ), 32 .4 (C-8ꞌ).
EIMS m/z: 374 [M+2]+ (0.3%), 372 [M]+ (1%), 337 (100%), 200 (2%), 204 (5%), 171
(2%), 169 (9%), 145 (3%), 139 (2%), 134 (2%), 131 (3%), 129 (4%), 104 (2%), 103
(3%), 91 (1%), 77 (14%), 65 (3%), 51 (7%).
3.2.24. 5-(4-Aminophenyl)-2-((6-chloro-3,4-methylenedioxybenzyl)thio)-1,3,4-
Oxadiazole(6x)
White amorphous solid; Yield: 97 %; M.P. 158-160 oC; Mol. formula: C16H12ClN3O3S;
Mol. Wt: 361 gmol-1; IR (KBr, cm-1) vmax: 3048 (Ar-H stretching), 1543 (Ar C=C
stretching), 1123 (C-O stretching), 708 (C-Cl str.), 612 (C-S str).
1H-NMR (500 MHz, CDCl3, ppm):See Table 12
13C-NMR (125 MHz, CDCl3, ppm):164.8 (C-5), 164.1 (C-2), 156.2 (C-4ꞌꞌ), 150.7 (C-4ꞌ),
149.9 (C-3ꞌ), 131.5 (C-1ꞌ), 125.6 (C-6ꞌ), 124.8 (C-2ꞌꞌ & C-6ꞌꞌ), 124.0 (C-1ꞌꞌ), 115.3 (C-3ꞌꞌ &
C-5ꞌꞌ), 110.8 (C-5ꞌ), 110.3 (C-2ꞌ), 101.8 (C-7ꞌ), 32.4 (C-8ꞌ).
EIMS m/z: 363 [M+2]+ (0.7%), 361 [M]+ (2%), 326 (100%), 200 (2%), 193 (4%), 169
(10%), 160 (5%), 139 (2%), 134 (2%), 120 (4%), 118 (3%), 104 (2%), 76 (7%).
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3.3. General procedure for the synthesis of 5-(aryl/aralkyl)-2-((6-bromo-
3,4-methylenedioxybenzyl)thio)-1,3,4-Oxadiazole (8a-x)
In the first step, 5-aryl/aralkyl-1,3,4-Oxadiazol-2-thiol (0.002 mol, 4a-x) were taken in a
100 mL round bottom flask. To it, DMF (5-10 mL), used as polar aprotic solvent and
catalytic amount of solid NaH (0.002 mol), acting as a base, were added. The whole
reaction mixture was stirred at room temperature for about thirty minutes. The
electrophile, 6-bromo-3,4-methylenedioxybenzylbromide 7was added to the reaction
mixture in equimolar ratio. After 4-5 hrs stirring, different 5-(aryl/aralkyl)-2-((6-bromo-
3,4-methylenedioxybenzyl)thio)-1,3,4-Oxadiazoles8a-x were obtained in a good yield on
adding ice cold distilled water to the reaction contents. The products were obtained either
in the form of solid precipitates or as oily liquid. The solid products were filtered, washed
and dried while oily products were extracted with organic solvent by solvent extraction
method. The solvent, after evaporation, gave pure liquid product. The mobile phase used
was n-hexane and ethyl acetate in a ratio of (4:1).
3.3.1. 5-(3,4-Methylenedioxyphenyl)-2-((6-bromo-3,4-methylenedioxybenzyl) thio)-
1,3,4-Oxadiazole (8a)
Grey amorphous solid; Yield: 96 %; M.P. 176-178 oC; Mol. formula: C17H11BrN2O5S;
Mol. Wt: 434 gmol-1; IR (KBr, cm-1) vmax: 3067 (Ar-H stretching), 1540 (Ar C=C
stretching), 1133 (C-O stretching), 610 (C-S stretching).
1H-NMR (300 MHz, CDCl3, ppm):See Table 13
13C-NMR (75 MHz, CDCl3, ppm):164.7 (C-2), 164.4 (C-5), 152.1 (C-4ꞌꞌ), 150.6 (C-4ꞌ),
148.9 (C-3ꞌꞌ), 148.1 (C-3ꞌ), 129.7 (C-1ꞌ), 122.4 (C-1ꞌꞌ), 116.5 (C-6ꞌ), 115.4 (C-6ꞌꞌ), 114.7
(C-5ꞌ), 110.4 (C-2ꞌ), 109.1 (C-5ꞌꞌ), 108.6 (C-2ꞌꞌ), 102.3 (C-7ꞌ), 101.8 (C-7ꞌꞌ), 32.5 (C-8ꞌ).
EIMS m/z: 436 [M+2]+ (1%), 434 [M]+ (1%), 355 (100%), 244 (2%), 222 (23%), 213
(86%), 189 (16%), 183 (4%), 163 (2%), 149 (2%), 147 (4%), 134 (3%), 121 (3%), 104
(9%), 91 (39%).
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3.3.2. 5-(2-Chlorophenyl)-2-((6-bromo-3,4-methylenedioxybenzyl)thio)-1,3,4-
Oxadiazole (8b)
White amorphous solid; Yield: 97 %; M.P. 148-150 oC; Mol. formula: C16H10BrClN2O3S;
Mol. Wt: 424 gmol-1; IR (KBr, cm-1) vmax: 3067 (Ar-H stretching), 1540 (Ar C=C
stretching), 1133 (C-O stretching), 610 (C-S stretching).
1H-NMR (500 MHz, CDCl3, ppm):See Table 13
13C-NMR (125 MHz, CDCl3, ppm):166.5 (C-5), 164.2 (C-2), 150.6 (C-4ꞌ), 146.1 (C-3ꞌ),
133.8 (C-4ꞌꞌ), 131.3 (C-2ꞌꞌ), 129.7 (C-1ꞌ), 128.9 (C-3ꞌꞌ), 128.2 (C-6ꞌꞌ), 127.6 (C-5ꞌꞌ), 126.1
(C-1ꞌꞌ), 115.5 (C-6ꞌ), 114.4 (C-5ꞌ), 110.6 (C-2ꞌ), 102.2 (C-7ꞌ), 32.8 (C-8ꞌ).
EIMS m/z: 428 [M+4]+ (0.3%), 426 [M+2]+ (1.3%), 424 [M]+ (1%), 345 (100%), 244
(2%), 213 (85%), 211 (3%), 183 (6%), 179 (16%), 153 (11%), 139 (4%), 137 (3%), 134
(2%), 104 (6%), 76 (4%), 51 (3%).
3.3.3. 5-(3-Chlorophenyl)-2-((6-bromo-3,4-methylenedioxybenzyl)thio)-1,3,4-
Oxadiazole (8c)
Golden amorphous solid; Yield: 98 %; M.P. 130-132 oC;Mol. formula:
C16H10BrClN2O3S; Mol. Wt: 424 gmol-1; IR (KBr, cm-1) vmax: 3067 (Ar-H stretching),
1543 (Ar C=C stretching), 1131 (C-O stretching), 702 (C-Cl stretching), 665 (C-Br
stretching), 616 (C-S stretching)
1H-NMR (400 MHz, CDCl3, ppm):See Table 14
13C-NMR (100 MHz, CDCl3, ppm):165.6 (C-5), 164.2 (C-2), 150.4 (C-4ꞌ), 148.7 (C-3ꞌ),
133.8 (C-3ꞌꞌ), 130.9 (C-2ꞌꞌ), 130.3 (C-1ꞌꞌ), 129.7 (C-1ꞌ), 128.8 (C-4ꞌꞌ), 127.5 (C-6ꞌꞌ), 126.8
(C-5ꞌꞌ), 116.4 (C-6ꞌ), 114.8 (C-5ꞌ), 110.3 (C-2ꞌ), 102.6 (C-7ꞌ), 32.3 (C-8ꞌ).
EIMS m/z: 428 [M+4]+ (1%), 426 [M+2]+ (1.3%), 424 [M]+ (1%), 389 (3%), 345 (100%),
244 (2%), 214 (86%), 213 (23%), 212 (13%), 183 (4%), 179 (19%), 153 (4%), 139 (3%),
137 (3%), 134 (3%), 111 (7%), 104 (9%), 85 (12%).
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3.3.4. 5-(4-Chlorophenyl)-2-((6-bromo-3,4-methylenedioxybenzyl)thio)-1,3,4-
Oxadiazole (8d)
Creamy white amorphous solid; Yield: 98 %; M.P. 156-158 oC;Mol. formula:
C16H10BrClN2O3S; Mol. Wt: 424 gmol-1; IR (KBr, cm-1) vmax: 3063 (Ar-H stretching),
1540 (Ar C=C stretching), 1129 (C-O stretching), 706 (C-Cl stretching), 667 (C-Br
stretching), 622 (C-S stretching).
1H-NMR (500 MHz, CDCl3, ppm):See Table 14
13C-NMR (125 MHz, CDCl3, ppm):165.1 (C-5), 164.6 (C-2), 150.8 (C-4ꞌ), 146.3 (C-3ꞌ),
134.7 (C-4ꞌꞌ), 130.4 (C-3ꞌꞌ & 5ꞌꞌ), 129.7 (C-1ꞌ), 128.8 (C-1ꞌꞌ), 128.2 (C-2ꞌꞌ & 6ꞌꞌ), 115.5 (C-
6ꞌ), 114.6 (C-5ꞌ), 110.3 (C-2ꞌ), 102.8 (C-7ꞌ), 32.2 (C-8ꞌ).
EIMS m/z: 428 [M+4]+ (0.3%), 426 [M+2]+ (1.3%), 424 [M]+ (1%), 345 (100%), 244
(3%), 213 (84%), 211 (2%), 183 (5%), 179 (15%), 153 (13%), 139 (3%), 137 (5%), 134
(3%), 104 (5%), 76 (3%), 51 (2%).
3.3.5. 5-(3-Nitrophenyl)-2-((6-bromo-3,4-methylenedioxybenzyl)thio)-1,3,4-
Oxadiazole (8e)
Golden amorphous solid; Yield: 98 %; M.P. 150-152 oC; Mol. formula: C16H10BrN3O5S;
Mol. Wt: 435 gmol-1; IR (KBr, cm-1) vmax: 3065 (Ar-H stretching), 1544 (Ar C=C
stretching), 1131 (C-O stretching), 622 (C-S stretching).
1H-NMR (400 MHz, CDCl3, ppm):See Table 15
13C-NMR (100 MHz, CDCl3, ppm):166.3 (C-5), 164.2 (C-2), 150.4 (C-4ꞌ), 148.7 (C-3ꞌꞌ),
146.6 (C-3ꞌ), 135.9 (C-6ꞌꞌ), 132.1 (C-1ꞌꞌ), 130.9 (C-5ꞌꞌ), 129.5 (C-1ꞌ), 125.2 (C-4ꞌꞌ), 120.6
(C-2ꞌꞌ), 115.3 (C-6ꞌ), 114.7 (C-5ꞌ), 110.9 (C-2ꞌ), 102.8 (C-7ꞌ), 32.3 (C-8ꞌ).
EIMS m/z: 437 [M+2]+ (1%), 435 [M]+ (1%), 356 (25%), 244 (2%), 222 (6%), 213
(100%), 190 (5%), 183 (2%), 164 (3%), 150 (4%), 148 (4%), 134 (3%), 122 (3%), 104
(3%), 76 (3%), 51 (2%).
Experimental Work
Department of Chemistry, GCU Lahore. Page 51
3.3.6. 5-Benzyl-2-((6-bromo-3,4-methylenedioxybenzyl)thio)-1,3,4-Oxadiazole (8f)
Light pink amorphous solid; Yield: 96 %; M.P.  97-98 oC; Mol. formula:
C17H13BrN2O3S; Mol. Wt: 404 gmol-1; IR (KBr, cm-1) vmax: 3058 (Ar-H stretching), 1539
(Ar C=C stretching), 657 (C-Br stretching), 609 (C-S stretching).
1H-NMR (300 MHz, CDCl3, ppm):See Table 15
13C-NMR (75 MHz, CDCl3, ppm):166.7 (C-5), 164.4 (C-2), 150.6 (C-4ꞌ), 148.3 (C-3ꞌ),
136.1 (C-1ꞌꞌ), 129.9 (C-1ꞌ), 128.2 (C-3ꞌꞌ & 5ꞌꞌ), 127.7 (C-2ꞌꞌ & 6ꞌꞌ), 125.3 (C-4ꞌꞌ), 116.2 (C-
6ꞌ), 114.5 (C-5ꞌ), 110.4 (C-2ꞌ), 102.8 (C-7ꞌ), 32.6 (C-8ꞌ), 31.1 (C-7ꞌꞌ).
EIMS m/z: 406 [M+2]+ (1%), 404 [M]+ (1%), 325 (100%), 244 (2%), 213 (86%), 192
(5%), 183 (2%), 159 (2%), 134 (2%), 133 (4%), 119 (2%), 117 (3%), 104 (3%), 91
(21%), 77 (3%), 65 (5%), 51 (3%).
3.3.7. 5-(4-Methylphenyl)-2-((6-bromo-3,4-methylenedioxybenzyl)thio)-1,3,4-
Oxadiazole (8g)
White amorphous solid; Yield: 96 %; M.P. 178-180oC; Mol. formula: C17H13BrN2O3S;
Mol. Wt: 404 gmol-1; IR (KBr, cm-1) vmax: 3048 (Ar-H stretching), 1537 (Ar C=C
stretching), 1112 (C-O stretching), 663 (C-Br stretching).
1H-NMR (400 MHz, CDCl3, ppm):See Table 16
13C-NMR (100 MHz, CDCl3, ppm):165.3 (C-5), 164.7 (C-2), 150.7 (C-4ꞌ), 146.4 (C-3ꞌ),
141.6 (C-4ꞌꞌ), 129.5 (C-1ꞌ), 128.9 (C-2ꞌꞌ & 6ꞌꞌ), 128.2 (C-1ꞌꞌ), 127.6 (C-3ꞌꞌ & 5ꞌꞌ), 115.8 (C-
6ꞌ), 114.3 (C-5ꞌ), 110.7 (C-2ꞌ), 102.3 (C-7ꞌ), 32.5 (C-8ꞌ), 21.6 (C-7ꞌꞌ).
EIMS m/z:406 [M+2]+ (1%), 404 [M]+ (1%), 325 (100%), 244 (2%), 213 (86%), 192
(5%), 183 (4%), 159 (2%), 134 (3%), 133 (7%), 119 (3%), 104 (9%), 76 (10%).
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3.3.8. 5-[1-(Phenylsulfonyl)piperidin-4-yl]-2-((6-bromo-3,4-methylene
dioxybenzyl)thio)-1,3,4-Oxadiazole (8h)
White amorphous solid; Yield: 95 %; M.P. 120-122oC; Mol. formula: C21H20BrN3O5S2;
Mol. Wt: 537 gmol-1; IR (KBr, cm-1) vmax: 3069 (Ar-H stretching), 1545 (Ar C=C
stretching), 1387 (S=O stretching), 1137 (C-O stretching).
1H-NMR (500 MHz, CDCl3, ppm):See Table 16
13C-NMR (125 MHz, CDCl3, ppm):171.3 (C-5), 164.8 (C-2), 150.6 (C-4ꞌ), 148.3 (C-3ꞌ),
144.9 (C-1ꞌꞌꞌ), 134.2 (C-4ꞌꞌꞌ), 129.5 (C-1ꞌ), 128.4 (C-3ꞌꞌꞌ & 5ꞌꞌꞌ), 127.1 (C-2ꞌꞌꞌ & 6ꞌꞌꞌ), 116.5
(C-6ꞌ), 114.3 (C-5ꞌ), 110.5 (C-2ꞌ), 102.2 (C-7ꞌ), 43.7 (C-2ꞌꞌ & 6ꞌꞌ), 32.3 (C-8ꞌ), 30.8 (C-4ꞌꞌ),
28.9 (C-3ꞌꞌ & 5ꞌꞌ) .
EIMS m/z: 539 [M+2]+ (1%), 537 [M]+ (1%), 458 (100%), 325 (2%), 213 (4%), 292
(1%), 266 (2%), 252 (3%), 250 (2%), 224 (5%), 183 (2%), 160 (4%), 141 (3%), 104
(8%), 77 (10%).
3.3.9. 5-(Pyridin-3-yl)-2-((6-bromo-3,4-methylenedioxybenzyl)thio)-1,3,4-
Oxadiazole (8i)
White amorphous solid; Yield: 93 %; M.P. 158-160oC; Mol. formula: C15H10BrN3O3S;
Mol. Wt: 391 gmol-1; IR (KBr, cm-1) vmax: 3061 (Ar-H stretching), 1540 (Ar C=C
stretching), 1132 (C-O stretching), 672 (C-Br stretching).
1H-NMR (400 MHz, CDCl3, ppm):See Table 17
13C-NMR (100 MHz, CDCl3, ppm):165.7 (C-5), 164.3 (C-2), 152.2 (C-6ꞌꞌ), 150.6 (C-4ꞌ),
149.1 (C-2ꞌꞌ), 146.7 (C-3ꞌ), 130.9 (C-4ꞌꞌ), 129.4 (C-1ꞌ), 127.8 (C-5ꞌꞌ), 124.3 (C-3ꞌꞌ), 115.7
(C-6ꞌ), 114.2 (C-5ꞌ), 110.5 (C-2ꞌ), 102.9 (C-7ꞌ), 32.2 (C-8ꞌ).
EIMS m/z: 393 [M+2]+ (0.5%), 391 [M]+ (0.5%), 312 (100%), 244 (2%), 213 (86%), 183
(2%), 179 (5%), 146 (2%), 134 (2%), 120 (4%), 106 (2%), 104 (3%), 78 (21%).
Experimental Work
Department of Chemistry, GCU Lahore. Page 53
3.3.10. 5-(2-Methyl-3,5-dinitrophenyl)-2-((6-bromo-3,4-methylenedioxybenzyl)
thio)-1,3,4-Oxadiazole (8j)
Creamy white amorphous solid; Yield: 97 %; M.P. 145-147oC; Mol. formula:
C17H11BrN4O7S; Mol. Wt: 494 gmol-1; IR (KBr, cm-1) vmax: 3054 (Ar-H stretching), 1532
(Ar C=C stretching), 1124 (C-O stretching), 651 (C-Br stretching).
1H-NMR (400 MHz, CDCl3, ppm):See Table 17
13C-NMR (100 MHz, CDCl3, ppm):170.3 (C-5), 164.7 (C-2), 150.8 (C-4ꞌ), 149.5 (C-3ꞌꞌ),
148.1 (C-3ꞌ), 147.6 (C-5ꞌꞌ), 136.3 (C-1ꞌꞌ), 129.7 (C-1ꞌ), 125.8 (C-6ꞌꞌ), 124.9 (C-2ꞌꞌ), 118.5
(C-4ꞌꞌ), 116.8 (C-6ꞌ), 114.4 (C-5ꞌ), 110.1 (C-2ꞌ), 102.6 (C-7ꞌ), 32.9 (C-8ꞌ), 19.2 (C-7ꞌꞌ).
EIMS m/z: 496 [M+2]+ (1%), 494 [M]+ (1%), 415 (35%), 282 (6%), 249 (8%), 244 (2%),
223 (9%), 213 (100%), 209 (15%), 207 (8%), 183 (4%), 134 (3%), 104 (9%).
3.3.11. 5-(2-(3,4-Methylenedioxyphenyl)ethenyl)-2-((6-bromo-3,4-methylene
dioxybenzyl)thio)-1,3,4-Oxadiazole (8k)
Grey amorphous solid; Yield: 90 %; M.P. 175-177oC; Mol. formula: C19H13BrN2O5S;
Mol. Wt: 460 gmol-1; IR (KBr, cm-1) vmax: 3067 (Ar-H stretching), 1545 (Ar C=C
stretching), 1134 (C-O stretching), 663 (C-Br stretching).
1H-NMR (400 MHz, CDCl3, ppm):See Table 18
13C-NMR (100 MHz, CDCl3, ppm):164.7 (C-5), 164.2 (C-2), 150.6 (C-4ꞌ), 149.4 (C-4ꞌꞌ),
148.9 (C-3ꞌꞌ), 148.3 (C-3ꞌ), 142.7 (C-8ꞌꞌ), 130.9 (C-1ꞌꞌ), 129.6 (C-1ꞌ), 122.3 (C-9ꞌꞌ), 120.1
(C-6ꞌꞌ), 116.6 (C-6ꞌ), 114.3 (C-5ꞌ), 110.8 (C-2ꞌ), 108.2 (C-5ꞌꞌ), 107.5 (C-2ꞌꞌ), 102.8 (C-7ꞌ),
101.2 (C-7ꞌꞌ), 32.7 (C-8ꞌ).
EIMS m/z: 462 [M+2]+ (1%), 460 [M]+ (1%), 381 (100%), 244 (7%), 215 (7%), 213
(95%), 189 (10%), 175 (3%), 147 (4%), 121 (7%), 104 (9%), 91 (13%).
3.3.12. 5-(1-Naphthylmethyl)-2-((6-bromo-3,4-methylenedioxybenzyl)thio)-1,3,4-
Oxadiazole (8l)
White amorphous solid; Yield: 99 %; M.P. 100-102oC; Mol. formula: C21H15BrN2O3S;
Mol. Wt: 454 gmol-1; IR (KBr, cm-1) vmax: 3049 (Ar-H stretching), 1527 (Ar C=C
stretching), 1118 (C-O stretching), 658 (C-Br stretching), 611 (C-S stretching).
1H-NMR (400 MHz, CDCl3, ppm):See Table 18
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13C-NMR (100 MHz, CDCl3, ppm):165.4 (C-5), 164.7 (C-2), 150.1 (C-4ꞌ), 147.9 (C-1ꞌꞌ),
146.5 (C-3ꞌ), 130.8 (C-5ꞌꞌ), 130.1 (C-4ꞌꞌ), 129.8 (C-1ꞌ), 128.7 (C-10ꞌꞌ), 127.4 (C-7ꞌꞌ), 126.8
(C-6ꞌꞌ), 126.1 (C-3ꞌꞌ), 125.4 (C-2ꞌꞌ), 124.7 (C-8ꞌꞌ), 115.3 (C-6ꞌ), 114.1 (C-5ꞌ), 110.6 (C-2ꞌ),
102.3 (C-7ꞌ), 32.6 (C-8ꞌ), 30.2 (C-7ꞌꞌ).
EIMS m/z: 456 [M+2]+ (1%), 454 [M]+ (1%), 375 (100%), 244 (2%), 241 (4%), 213
(87%), 209 (5%), 192 (6%), 183 (5%), 169 (3%), 167 (3%), 141 (8%), 134 (1%), 127
(8%), 120 (5%), 115 (7%), 104 (2%), 101 (2%).
3.3.13. 5-((4-Chlorophenoxy)methyl)-2-((6-bromo-3,4-methylenedioxybenzyl)thio)-
1,3,4-Oxadiazole (8m)
White amorphous solid; Yield: 95%; M.P.120-122oC; Mol. formula: C17H12BrClN2O4S;
Mol. Wt: 454 gmol-1; IR (KBr, cm-1) vmax: 3058 (Ar-H stretching), 1537 (Ar C=C
stretching), 1124 (C-O stretching), 704 (C-Cl stretching), 668 (C-Br stretching), 613 (C-S
stretching).
1H-NMR (300 MHz, CDCl3, ppm):See Table 19
13C-NMR (75 MHz, CDCl3, ppm):164.9 (C-2), 164.2 (C-5), 155.6 (C-1ꞌꞌ), 150.2 (C-4ꞌ),
146.7 (C-3ꞌ), 144.3 (C-4ꞌꞌ), 130.2 (C-1ꞌ), 128.5 (C-3ꞌꞌ & 5ꞌꞌ), 116.1 (C-2ꞌꞌ & 6ꞌꞌ), 115.6 (C-
6ꞌ), 114.3 (C-5ꞌ), 110.8 (C-2ꞌ), 102.1 (C-7ꞌ), 66.5 (C-7ꞌꞌ), 32.9 (C-8ꞌ).
EIMS m/z: 458 [M+4]+ (0.2%), 456 [M+2]+ (0.7%), 454 [M]+ (0.5%), 375 (100%), 244
(2%), 241 (4%), 213 (86%), 209 (3%), 192 (5%), 183 (5%), 169 (4%), 167 (2%), 141
(7%), 134 (2%), 120 (10%), 111 (15%), 104 (5%), 85 (13%), 76 (63%), 50 (3%).
3.3.14. 5-Phenyl-2-((6-bromo-3,4-methylenedioxybenzyl)thio)-1,3,4-Oxadiazole
(8n)
White amorphous solid; Yield: 97%; M.P. 153-155oC; Mol. formula: C16H11BrN2O3S;
Mol. Wt: 390 gmol-1; IR (KBr, cm-1) vmax: 3059 (Ar-H stretching), 1541 (Ar C=C
stretching), 1133 (C-O stretching), 675 (C-Br stretching).
1H-NMR (500 MHz, CDCl3, ppm):See Table 19
13C-NMR (125 MHz, CDCl3, ppm):165.2 (C-5), 164.7 (C-2), 150.8 (C-4ꞌ), 148.6 (C-3ꞌ),
134.1 (C-3ꞌꞌ & 5ꞌꞌ), 133.2 (C-2ꞌꞌ & 6ꞌꞌ), 132.7 (C-4ꞌꞌ), 131.2 (C-1ꞌꞌ), 129.6 (C-1ꞌ), 116.4 (C-
6ꞌ), 114.3 (C-5ꞌ), 110.8 (C-2ꞌ), 102.3 (C-7ꞌ), 32.5 (C-8ꞌ).
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EIMS m/z: 392 [M+2]+ (1%), 390 [M]+ (1%), 311 (100%), 244 (2%), 213 (89%), 183
(4%), 178 (2%), 145 (12%), 134 (3%), 119 (7%), 104 (8%), 103 (2%), 77 (4%).
3.3.15. 5-(4-Methoxyphenyl-2-((6-bromo-3,4-methylenedioxybenzyl)thio)-1,3,4-
Oxadiazole (8o)
White amorphous solid; Yield: 95%; M.P. 153-155oC; Mol. formula: C17H13BrN2O4S;
Mol. Wt: 420 gmol-1; IR (KBr, cm-1) vmax: 3071 (Ar-H stretching), 1547 (Ar C=C
stretching), 1138 (C-O stretching), 667 (C-Br stretching).
1H-NMR (300 MHz, CDCl3, ppm):See Table 20
13C-NMR (75 MHz, CDCl3, ppm):165.1 (C-5), 164.6 (C-2), 162.2 (C-4ꞌꞌ), 150.7 (C-4ꞌ),
148.3 (C-3ꞌ), 129.8 (C-1ꞌ), 124.6 (C-1ꞌꞌ), 117.1 (C-2ꞌꞌ & 6ꞌꞌ), 116.4 (C-3ꞌꞌ & 5ꞌꞌ), 115.8 (C-
6ꞌ), 114.4 (C-5ꞌ), 110.7 (C-2ꞌ), 102.8 (C-7ꞌ), 32.3 (C-8ꞌ), 54.6 (C-7ꞌꞌ).
EIMS m/z: 422 [M+2]+ (1%), 420 [M]+ (1%), 341 (100%), 244 (2%), 213 (86%), 208
(16%), 183 (4%), 175 (7%), 135 (7%), 134 (3%), 133 (4%), 104 (9%), 81 (40%).
3.3.16. 5-(2-Methylphenyl)-2-((6-bromo-3,4-methylenedioxybenzyl)thio)-1,3,4-
Oxadiazole (8p)
Yellow amorphous solid; Yield: 98%; M.P. 122-124oC;Mol. formula: C17H13BrN2O3S;
Mol. Wt: 404 gmol-1; IR (KBr, cm-1) vmax: 3055 (Ar-H stretching), 1534 (Ar C=C
stretching), 1124 (C-O stretching), 654 (C-Br stretching).
1H-NMR (400 MHz, CDCl3, ppm):See Table 20
13C-NMR (100 MHz, CDCl3, ppm):164.8 (C-2), 164.3 (C-5), 150.8 (C-4ꞌ), 148.2 (C-3ꞌ),
133.9 (C-2ꞌꞌ), 130.6 (C-4ꞌꞌ), 129.8 (C-1ꞌ), 128.7 (C-3ꞌꞌ), 127.2 (C-1ꞌꞌ), 126.5 (C-5ꞌꞌ), 125.8
(C-6ꞌꞌ), 116.7 (C-6ꞌ), 114.2 (C-5ꞌ), 110.7 (C-2ꞌ), 102.5 (C-7ꞌ), 32.8 (C-8ꞌ), 20.3 (C-7ꞌꞌ) .
EIMS m/z: 406 [M+2]+ (0.5%), 404 [M]+ (0.5%), 325 (100%), 244 (2%), 213 (76%),
192 (5%), 183 (8%), 160 (2%), 134 (3%), 133 (4%), 119 (2%), 117 (3%), 104 (9%), 91
(30%), 65 (10%), 51 (2%).
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3.3.17. 5-(2-Nitrophenyl)-2-((6-bromo-3,4-methylenedioxybenzyl)thio)-1,3,4-
Oxadiazole (8q)
Pale yellow amorphous solid; Yield: 96%; M.P. 140-142oC; Mol. formula:
C16H10BrN3O5S; Mol. Wt: 435 gmol-1; IR (KBr, cm-1) vmax: 3067 (Ar-H stretching), 1545
(Ar C=C stretching), 1132 (C-O stretching), 670 (C-Br stretching).
1H-NMR (300 MHz, CDCl3, ppm):See Table 21
13C-NMR (75MHz, CDCl3, ppm):164.6 (C-2), 163.2 (C-5), 150.5 (C-4ꞌ), 148.4 (C-2ꞌꞌ),
146.4 (C-3ꞌ), 132.1 (C-4ꞌꞌ), 130.7 (C-5ꞌꞌ), 129.6 (C-1ꞌ), 128.9 (C-3ꞌꞌ), 125.3 (C-6ꞌꞌ), 123.7
(C-1ꞌꞌ), 115.9 (C-6ꞌ), 114.3 (C-5ꞌ), 110.8 (C-2ꞌ), 102.3 (C-7ꞌ), 32.1 (C-8ꞌ).
EIMS m/z: 437 [M+2]+ (1%), 435 [M]+ (1%), 356 (25%), 244 (4%), 222 (7%), 213
(100%), 190 (5%), 183 (2%), 164 (2%), 150 (3%), 148 (5%), 134 (3%), 122 (2%), 104
(3%), 76 (6%), 51 (3%).
3.3.18. 5-(4-Nitrophenyl)-2-((6-bromo-3,4-methylenedioxybenzyl)thio)-1,3,4-
Oxadiazole (8r)
Pale yellow amorphous solid; Yield: 97%; M.P. 109-111oC; Mol. formula:
C16H10BrN3O5S; Mol. Wt: 435 gmol-1; IR (KBr, cm-1) vmax: 3063 (Ar-H stretching), 1547
(Ar C=C stretching), 1135 (C-O stretching), 678 (C-Br stretching).
1H-NMR (300 MHz, CDCl3, ppm):See Table 21
13C-NMR (75 MHz, CDCl3, ppm):165.3 (C-5), 164.8 (C-2), 150.6 (C-4ꞌ), 148.5 (C-4ꞌꞌ),
146.2 (C-3ꞌ), 137.1 (C-1ꞌꞌ), 129.6 (C-1ꞌ), 126.2 (C-2ꞌꞌ & 6ꞌꞌ), 124.9 (C-3ꞌꞌ & 5ꞌꞌ), 115.4 (C-
6ꞌ), 114.1 (C-5ꞌ), 110.4 (C-2ꞌ), 102.9 (C-7ꞌ), 32.3 (C-8ꞌ).
EIMS m/z: 437 [M+2]+ (1%), 435 [M]+ (1%), 356 (35%), 244 (2%), 222 (5%), 213
(100%), 190 (3%), 183 (2%), 164 (3%), 150 (2%), 148 (4%), 134 (3%), 122 (4%).
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3.3.19. 5-(2-Chloro-3,5-dinitrophenyl)-2-((6-bromo-3,4-methylenedioxybenzyl)
thio)-1,3,4-Oxadiazole (8s)
White amorphous solid; Yield: 93%; M.P. 184-186oC; Mol. formula: C16H8BrClN4O7S;
Mol. Wt: 514 gmol-1; IR (KBr, cm-1) vmax: 3069 (Ar-H stretching), 1551 (Ar C=C
stretching), 1137 (C-O stretching), 701 (C-Cl stretching), 669 (C-Br stretching), 617 (C-S
stretching).
1H-NMR (400 MHz, CDCl3, ppm):See Table 22
13C-NMR (100 MHz, CDCl3, ppm):171.7 (C-5), 164.3 (C-2), 152.1 (C-3ꞌꞌ), 150.6 (C-4ꞌ),
149.0 (C-5ꞌꞌ), 148.3 (C-3ꞌ), 137.1 (C-1ꞌꞌ), 132.7 (C-2ꞌꞌ), 129.5 (C-1ꞌ), 125.9 (C-6ꞌꞌ), 124.2
(C-4ꞌꞌ), 116.8 (C-6ꞌ), 114.4 (C-5ꞌ), 110.5 (C-2ꞌ), 102.2 (C-7ꞌ), 32.6 (C-8ꞌ).
EIMS m/z: 518 [M+4]+ (1%), 516 [M+2]+ (1.3%), 514 [M]+ (1%), 435 (22%), 302 (16%),
269 (17%), 244 (2%), 243 (9%), 229 (2%), 227 (2%), 213 (100%), 201 (3%), 183 (4%),
134 (5%), 104 (9%).
3.3.20. 5-(2,4-Dichlorophenyl)-2-((6-bromo-3,4-methylenedioxybenzyl)thio)-1,3,4-
Oxadiazole (8t)
Grey amorphous solid; Yield: 91%; M.P. 160oC;Mol. formula: C16H9BrCl2N2O3S;
Mol. Wt: 458 gmol-1; IR (KBr, cm-1) vmax: 3064 (Ar-H stretching), 1545 (Ar C=C
stretching), 1139 (C-O stretching), 705 (C-Cl stretching), 668 (C-Br stretching).
1H-NMR (400 MHz, CDCl3, ppm):See Table 22
13C-NMR (100 MHz, CDCl3, ppm):168.2 (C-5), 164.7 (C-2), 150.3 (C-4ꞌ), 148.6 (C-3ꞌ),
137.2 (C-4ꞌꞌ), 133.6 (C-2ꞌꞌ), 132.9 (C-6ꞌꞌ), 131.2 (C-3ꞌꞌ), 129.6 (C-1ꞌ), 128.3 (C-5ꞌꞌ), 127.1
(C-1ꞌꞌ), 116.4 (C-6ꞌ), 114.5 (C-5ꞌ), 110.2 (C-2ꞌ), 102.7 (C-7ꞌ), 32.5 (C-8ꞌ).
EIMS m/z: 464 [M+6]+ (1%), 462 [M+4]+ (1.6%), 460 [M+2]+ (1.3%), 458 [M]+ (1%),
380 (100%), 246 (3%), 244 (2%), 213 (84%), 187 (4%), 183 (4%), 173 (3%), 171 (6%),
145 (5%), 134 (3%), 119 (4%), 105 (9%), 85 (10%).
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3.3.21. 5-(4-Hydroxyphenyl)-2-((6-bromo-3,4-methylenedioxybenzyl)thio)-1,3,4-
Oxadiazole (8u)
Creamy white amorphous solid; Yield: 98%; M.P. 203-205oC;Mol. formula:
C16H11BrN2O4S; Mol. Wt: 406 gmol-1; IR (KBr, cm-1) vmax: 3069 (Ar-H stretching), 1544
(Ar C=C stretching), 1133 (C-O stretching), 662 (C-Br stretching).
1H-NMR (400 MHz, CDCl3, ppm):See Table 23
13C-NMR (100 MHz, CDCl3, ppm):165.7 (C-5), 164.2 (C-2), 162.6 (C-4ꞌꞌ), 150.1 (C-4ꞌ),
148.5 (C-3ꞌ), 129.8 (C-1ꞌ), 123.3 (C-1ꞌꞌ), 122.6 (C-2ꞌꞌ & 6ꞌꞌ), 119.2 (C-3ꞌꞌ & 5ꞌꞌ), 116.5 (C-
6ꞌ), 114.8 (C-5ꞌ), 110.4 (C-2ꞌ), 102.1 (C-7ꞌ), 32.7 (C-8ꞌ).
EIMS m/z: 408 [M+2]+ (0.5%), 406 [M]+ (0.5%), 327 (100%), 244 (2%), 213 (78%), 193
(5%), 183 (4%), 161 (2%), 135 (4%), 134 (20%), 121 (6%), 119 (4%), 104 (7%), 93
(15%), 67 (9%).
3.3.22. 5-(3,5-Dinitrophenyl)-2-((6-bromo-3,4-methylenedioxybenzyl)thio)-1,3,4-
Oxadiazole (8v)
Bright yellow amorphous solid; Yield: 98%; M.P. 190-192oC;Mol. formula:
C16H9BrN4O7S; Mol. Wt: 480 gmol-1; IR (KBr, cm-1) vmax: 3063 (Ar-H stretching), 1542
(Ar C=C stretching), 1126 (C-O stretching), 661 (C-Br stretching).
1H-NMR (400 MHz, CDCl3, ppm):See Table 23
13C-NMR (100 MHz, CDCl3, ppm):171.3 (C-5), 164.7 (C-5), 150.9 (C-4ꞌ), 149.2 (C-3ꞌꞌ &
C-5ꞌꞌ), 147.2 (C-3ꞌ), 135.3 (C-1ꞌꞌ), 129.7 (C-1ꞌ), 127.3 (C-3ꞌꞌ & C-6ꞌꞌ), 117.4 (C-4ꞌꞌ), 116.8
(C-6ꞌ), 114.1 (C-5ꞌ), 110.5 (C-2ꞌ), 102.9 (C-7ꞌ), 32.6 (C-8ꞌ).
EIMS m/z: 482 [M+2]+ (1%), 480 [M]+ (1%), 401 (40%), 268 (11%), 244 (2%), 235
(19%), 213 (100%), 209 (12%), 195 (10%), 193 (15%), 183 (8%), 167 (5%), 137 (4%),
134 (3%), 107 (6%), 104 (5%).
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3.3.23. 5-(2-Phenylethenyl)-2-((6-bromo-3,4-methylenedioxybenzyl)thio)-1,3,4-
Oxadiazole (8w)
Creamy white amorphous solid; Yield: 92%; M.P.: 136-138oC;Mol. formula:
C18H13BrN2O3S; Mol. Wt: 416 gmol-1; IR (KBr, cm-1) vmax: 3065 (Ar-H stretching), 1539
(Ar C=C stretching), 1120 (C-O stretching), 675 (C-Br stretching).
1H-NMR (300 MHz, CDCl3, ppm):See Table 24
13C-NMR (75 MHz, CDCl3, ppm):164.5 (C-5), 163.7 (C-2), 150.3 (C-4ꞌ), 146.8 (C-3ꞌ),
145.1 (C-1ꞌꞌ), 141.4 (C-7ꞌꞌ), 129.8 (C-1ꞌ), 129.2 (C-4ꞌꞌ), 128.7 (C-3ꞌꞌ & 5ꞌꞌ), 127.3 (C-2ꞌꞌ &
6ꞌꞌ), 122.6 (C-8ꞌꞌ), 115.8 (C-6ꞌ), 114.5 (C-5ꞌ), 110.6 (C-2ꞌ), 102.2 (C-7ꞌ), 32.7 (C-8ꞌ).
EIMS m/z: 418 [M+2]+ (2%), 416 [M]+ (2%), 337 (17%), 244 (2%), 213 (100%), 204
(8%), 183 (3%), 171 (5%), 145 (11%), 131 129 (9%), 120 (3%), 103 (6%), 77 (8%).
3.3.24. 5-(4-Aminophenyl)-2-((6-bromo-3,4-methylenedioxybenzyl)thio)-1,3,4-
Oxadiazole (8x)
Dark brown amorphous solid; Yield: 80%; M.P. 161-163oC;Mol. formula:
C16H12BrN3O3S; Mol. Wt: 405 gmol-1; IR (KBr, cm-1) vmax: 3068 (Ar-H stretching), 1535
(Ar C=C stretching), 1136 (C-O stretching), 614 (C-S stretching).
1H-NMR (500 MHz, CDCl3, ppm):See Table 24
13C-NMR (125 MHz, CDCl3, ppm):164.8 (C-5), 164.1 (C-2), 154.5 (C-4ꞌꞌ), 150.7 (C-4ꞌ),
146.9 (C-3ꞌ), 129.5 (C-1ꞌ), 125.7 (C-2ꞌꞌ & 6ꞌꞌ), 124.4 (C-1ꞌꞌ), 115.8 (C-6ꞌ), 114.3 (C-3ꞌꞌ &
5ꞌꞌ), 113.5 (C-5ꞌ), 110.2 (C-2ꞌ), 102.6 (C-7ꞌ), 32.5 (C-8ꞌ).
EIMS m/z: 407 [M+2]+ (2%), 405 [M]+ (2%), 326 (15%), 244 (2%), 213 (100%), 193
(4%), 183 (2%), 160 (5%), 134 (2%), 120 (3%), 118 (2%), 104 (2%), 92 (30%), 76 (7%),
50 (4%).
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3.4. General procedure for synthesisof N-[3,4-methylenedioxy benzyl]-2-
[(5-substituted-1,3,4-oxadiazol-2-yl)thio] acetamides (12a-t)
3.4.1. Procedure for the synthesis of 2-bromo-N-(3,4-methylenedioxy
benzyl)acetamide (11)
In an iodine flask, 3,4-methylenedioxybenzylamine (0.3 mol, 9) was taken which already
had 15-20 mL distilled water and 5 mL of Na2CO3 solution creating a basic reaction
envoirnment (pH of 10-11). An equimolar quantity of 2-bromoacetyl bromide (0.3 mol,
10) was introduced to the flask drop wise with constant handshaking. The inside pressure
was released by gradually loosing the flask stopper. Flask was put on stirring till reaction
completion. Using TLC, reaction progress and purity of the compound was monitored.
Precipitates of the synthesized compound,11, were filtered, washed with ice cold distilled
water and dried for further reactions. Recrystallization of the synthesized compound was
done by using absolute methanol as an organic solvent.
3.4.2. Procedure for synthesis of N-[3,4-methylenedioxybenzyl]-2-[(5-substituted-
1,3,4-oxadiazol-2-yl)thio]acetamides (12a-t)
Different 5-substituted-1,3,4-Oxadiazol-2-thiol (0.002 mol, 4a-t) were taken one by one
in a 50 mL round bottom flask. DMF (5-10 mL) was used as solvent to dissolve the
compound. Solid NaH (acting as base, 0.002 mol) was added to reaction contents. The
mixture was put on stirring for half an hour. The already synthesized electrophile, 2-
bromo-N-(3,4-methylenedioxy benzyl)acetamide11,was added to reaction mixture in
equimolar quantity in order to synthesize different N-[3,4-methylenedioxybenzyl]-2-[(5-
substituted-1,3,4-oxadiazol-2-yl)thio]acetamides (12a-t). The reaction mixture was
stirred for different timings varied from 4-5 hrs according to the need. Thin layer
chromatography (TLC) was used to monitor the reaction progression and completion.
The mobile phase used was n-hexane and ethyl acetate. At the end of the reaction, ice
cold distilled water was added in the reaction flask. The precipitates were obtained at
once which were filtered, washed with H2O and then dried for analysis.
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3.4.2.1.N-[3,4-methylenedioxybenzyl]-2-[(5-(3,4-methylenedioxyphenyl)-1,3,4-
oxadiazol-2-yl)thio]acetamide (12a)
Grey amorphous solid; Yield: 96%; M.P. 176-178oC; Mol. formula: C19H15N3O6S;
Mol. Wt: 413 gmol-1; IR (KBr, cm-1) vmax: 3067 (Ar-H stretching), 1540 (Ar C=C
stretching), 1133 (C-O stretching), 660 (C-Br stretching), 610 (C-S stretching).
1H-NMR (600 MHz, CDCl3, ppm):See Table 25
13C-NMR (150 MHz, CDCl3, ppm): 171.56 (C-1), 165.0 (C-2''), 164.20 (C-5''), 151.09
(C-3'''), 149.9 (C-4'''), 148.05 (C-4'), 146.07 (C-3'), 133.07 (C-1'), 122.79 (C-1'''), 119.0
(C-6'), 115.0 (C-6'''), 109.8 (C-5'''), 108.84 (C-2'''), 108.2 (C-5'), 108.06 (C-2'), 101.07 (C-
7'''), 100.7 (C-7'), 44.0 (C-8'), 32.2 (C-2).
3.4.2.2.N-[3,4-methylenedioxybenzyl]-2-[(5-(2-chlorophenyl)-1,3,4-oxadiazol-2-
yl)thio]acetamide (12b)
White amorphous solid; Yield: 97%; M.P.148-150oC; Mol. formula: C18H14ClN3O4S;
Mol. Wt: 403 gmol-1; IR (KBr, cm-1) vmax: 3067 (Ar-H stretching), 1540 (Ar C=C
stretching), 1133 (C-O stretching), 660 (C-Br stretching).
1H-NMR (600 MHz, CDCl3, ppm):See Table 25
13C-NMR (150 MHz, CDCl3, ppm):171.60 (C-1), 165.1 (C-2''), 164.90 (C-5''), 148.05 (C-
4'), 146.07 (C-3'), 134.74 (C-2'''), 133.07 (C-1'), 130.9 (C-4'''), 129.8 (C-5'''), 128.90 (C-
3'''), 126.1 (C-6'''), 122.79 (C-1'''), 119.0 (C-6'), 108.2 (C-5'), 108.06 (C-2'), 100.7 (C-7'),
44.0 (C-8'), 32.2 (C-2).
3.4.2.3.N-[3,4-methylenedioxybenzyl]-2-[(5-(3-chlorophenyl)-1,3,4-oxadiazol-2-
yl)thio]acetamide (12c)
Golden amorphous solid; Yield: 98%; M.P. 130-132oC; Mol. formula: C18H14ClN3O4S;
Mol. Wt: 403 gmol-1; IR (KBr, cm-1) vmax: 3067 (Ar-H stretching), 1543 (Ar C=C
stretching), 1131 (C-O stretching), 702 (C-Cl stretching), 665 (C-Br stretching), 616 (C-S
stretching).
1H-NMR (600 MHz, CDCl3, ppm):See Table 25
13C-NMR (150 MHz, CDCl3, ppm):170.82 (C-1), 165.1 (C-2''), 164.70 (C-5''), 148.05 (C-
4'), 146.07 (C-3'), 133.24 (C-3'''), 133.07 (C-1'), 130.9 (C-4'''), 129.8 (C-5'''), 128.90(C-
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2'''), 126.1 (C-6'''), 122.99 (C-1'''), 119.0 (C-6'), 108.2 (C-5'), 108.06 (C-2'), 101.7 (C-7'),
44.3 (C-8'), 32.2 (C-2).
3.4.2.4.N-[3,4-methylenedioxybenzyl]-2-[(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-
yl)thio]acetamide (12d)
Creamy white amorphous solid; Yield: 98%; M.P. 156-158oC;Mol. formula:
C18H14ClN3O4S; Mol. Wt: 403 gmol-1; IR (KBr, cm-1) vmax: 3063 (Ar-H stretching), 1540
(Ar C=C stretching), 1129 (C-O stretching), 706 (C-Cl stretching), 667 (C-Br stretching),
622 (C-S stretching).
1H-NMR (600 MHz, CDCl3, ppm):See Table 26
13C-NMR (150 MHz, CDCl3, ppm):170.62 (C-1), 165.5 (C-2''), 164.70 (C-5''), 146.07 (C-
3'), 140.05 (C-4'), 135.9 (C-4'''), 133.24 (C-3''' & C-5'''), 133.07 (C-1'), 128.90 (C-2''' &C-
6'''), 122.79 (C-1'''), 119.0 (C-6'), 108.6 (C-5'), 108.06 (C-2'), 101.9 (C-7'), 44.3 (C-8'),
32.2 (C-2).
3.4.2.5.N-[3,4-methylenedioxybenzyl]-2-[(5-(3-nitrophenyl)-1,3,4-oxadiazol-2-yl)
thio]acetamide (12e)
Golden amorphous solid; Yield: 98%; M.P. 150-152oC; Mol. formula: C18H14N4O6S;
Mol. Wt: 414 gmol-1; IR (KBr, cm-1) vmax: 3065 (Ar-H stretching), 1544 (Ar C=C
stretching), 1131 (C-O stretching), 673 (C-Br stretching).
1H-NMR (600 MHz, CDCl3, ppm):See Table 26
13C-NMR (150 MHz, CDCl3, ppm):170.62 (C-1), 165.5 (C-2''), 164.70 (C-5''), 148.24 (C-
3'''), 146.07 (C-3'), 140.05 (C-4'), 135.6 (C-6'''), 133.07 (C-1'), 131.8 (C-5'''), 125.9 (C-
4'''), 122.79 (C-1'''), 121.90 (C-2'''), 119.0 (C-6'), 108.6 (C-5'), 108.06 (C-2'), 101.9 (C-7'),
44.3 (C-8'), 32.2 (C-2).
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3.4.2.6.N-[3,4-methylenedioxybenzyl]-2-[(5-(benzyl)-1,3,4-oxadiazol-2-yl)thio]
acetamide (12f)
Light pink amorphous solid; Yield: 96%; M.P. 97-99oC; Mol. formula: C19H17N3O4S;
Mol. Wt: 383 gmol-1; IR (KBr, cm-1) vmax: 3058 (Ar-H stretching), 1539 (Ar C=C
stretching), 1129 (C-O stretching), 609 (C-S stretching).
1H-NMR (600 MHz, CDCl3, ppm):See Table 26
13C-NMR (150 MHz, CDCl3, ppm):170.62 (C-1), 167.2 (C-2''), 165.80 (C-5''), 146.07 (C-
3'), 140.05 (C-4'), 134.59 (C-1'''), 133.07 (C-1'), 128.90 (C-2'''& C-6'''), 128.24 (C-3'''&
C-5'''), 125.9 (C-4'''), 119.0 (C-6'), 108.6 (C-5'), 108.06 (C-2'), 101.8 (C-7'), 44.3 (C-8'),
32.71 (C-7'''), 32.2 (C-2).
3.4.2.7.N-[3,4-methylenedioxybenzyl]-2-[(5-(4-methylphenyl)-1,3,4-oxadiazol-2-
yl)thio]acetamide (12g)
White amorphous solid; Yield: 96%; M.P.178-180oC; Mol. formula: C19H17N3O4S; Mol.
Wt: 383 gmol-1; IR (KBr, cm-1) vmax: 3048 (Ar-H stretching), 1537 (Ar C=C stretching),
1112 (C-O stretching), 614 (C-S stretching).
1H-NMR (600 MHz, CDCl3, ppm):See Table 27
13C-NMR (150 MHz, CDCl3, ppm):170.62 (C-1), 167.2 (C-2''), 165.80 (C-5''), 146.07 (C-
3'), 140.9 (C-4'''), 140.05 (C-4'), 134.59 (C-1'''), 133.07 (C-1'), 129.6 (C-2''' &C-6'''),
128.8 (C-3'''& C-5'''), 119.0 (C-6'), 108.6 (C-5'), 108.06 (C-2'), 100.9 (C-7'), 44.3 (C-8'),
32.2 (C-2), 21.38 (C-7''').
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3.4.2.8.N-[3,4-methylenedioxybenzyl]-2-[(5-[1-(Phenylsulfonyl)piperidyl]-1,3,4-
oxadiazol-2-yl)thio]acetamide (12h)
White amorphous solid; Yield: 95%; M.P. 120oC; Mol. formula: C23H24N4O6S2;
Mol. Wt: 516 gmol-1; IR (KBr, cm-1) vmax: 3069 (Ar-H stretching), 1545 (Ar C=C
stretching), 1387 (S=O stretching), 1137 (C-O stretching), 616 (C-S stretching).
1H-NMR (600 MHz, CDCl3, ppm):See Table 28
13C-NMR (150 MHz, CDCl3, ppm):169.33 (C-1), 166.78 (C-2''), 164.47 (C-5''), 147.87
(C-3'), 147.00 (C-1''''), 136.12 (C-4'), 132.96 (C-1'), 131.44 (C-4''''), 129.17 (C-3''''& C-
5''''), 127.60 (C-2''''& C-6''''), 120.99 (C-6'), 108.29 (C-2'), 108.16 (C-5'), 101.06 (C-7'),
45.11 (C-3'''& C-5'''), 43.77 (C-8'), 35.18 (C-2), 32.48 (C-4'''), 28.27 (C-2'''& C-6''').
3.4.2.9.N-[3,4-methylenedioxybenzyl]-2-[(5-(pyridyl)-1,3,4-oxadiazol-2-yl)thio]
acetamide (12i)
White amorphous solid; Yield: 93%; M.P. 158-160oC; Mol. formula: C17H14N4O4S; Mol.
Wt: 370 gmol-1; IR (KBr, cm-1) vmax: 3061 (Ar-H stretching), 1540 (Ar C=C stretching),
1132 (C-O stretching), 613 (C-S stretching).
1H-NMR (600 MHz, CDCl3, ppm):See Table 27
13C-NMR (150 MHz, CDCl3, ppm):170.62 (C-1), 165.5 (C-2''), 164.70 (C-5''), 151.7(C-
4'''), 146.07 (C-3'), 140.05 (C-4'), 133.07 (C-1'), 130.6 (C-6'''), 127.8 (C-5'''), 124.06 (C-
1'''), 121.90 (C-2'''), 119.0 (C-6'), 108.6 (C-5'), 108.06 (C-2'), 101.9 (C-7'), 44.3 (C-8'),
32.2 (C-2).
3.4.2.10.N-[3,4-methylenedioxybenzyl]-2-[(5-(2-methyl-3,5-dinitrophenyl)-1,3,4-
oxadiazol-2-yl)thio]acetamide (12j)
Creamy white amorphous solid; Yield: 97%; M.P. 145-147oC; Mol. formula:
C19H15N5O8S; Mol. Wt: 473 gmol-1; IR (KBr, cm-1) vmax: 3054 (Ar-H stretching), 1532
(Ar C=C stretching), 1124 (C-O stretching), 651 (C-Br stretching).
1H-NMR (600 MHz, CDCl3, ppm):See Table 29
13C-NMR (150 MHz, CDCl3, ppm):171.76 (C-1), 167.20 (C-5''), 165.0 (C-2''), 148.05 (C-
4'), 146.07 (C-3'), 135.1 (C-5'''), 134.2 (C-1'''),  133.07 (C-1'), 132.8 (C-3'''), 130.82(C-
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2'''), 128.6 (C-4'''), 125.2 (C-6'''), 119.0 (C-6'), 108.2 (C-5'), 108.06 (C-2'), 100.97 (C-7'),
44.0 (C-8'), 32.2 (C-2), 15.9 (C-7''').
3.4.2.11. N-[3,4-methylenedioxybenzyl]-2-[(5-(3,4-Methylenedioxyphenyl)
ethenyl)-1,3,4-oxadiazol-2-yl)thio]acetamide (12k)
Grey amorphous solid; Yield: 90%; M.P. 175-177oC; Mol. formula: C21H17N3O6S;
Mol. Wt: 431 gmol-1; IR (KBr, cm-1) vmax: 3067 (Ar-H stretching), 1545 (Ar C=C
stretching), 1134 (C-O stretching), 663 (C-Br stretching), 611 (C-S stretching).
1H-NMR (600 MHz, CDCl3, ppm):See Table 29
13C-NMR (150 MHz, CDCl3, ppm):171.56 (C-1), 165.0 (C-2''), 164.20 (C-5''), 149.9 (C-
4'''), 148.4 (C-3'''), 148.05 (C-4'), 146.07 (C-3'), 140.19 (C-8'''), 133.07 (C-1'), 122.79 (C-
1'''), 120.5 (C-6'''), 119.0 (C-6'), 109.8 (C-5'''), 108.84 (C-2'''), 108.2 (C-5'), 108.06 (C-2'),
107.5 (C-9'''), 101.07 (C-7'''), 100.7 (C-7'), 44.0 (C-8'), 32.2 (C-2).
3.4.2.12.N-[3,4-methylenedioxybenzyl]-2-[(5-(1-naphthylmethyl)-1,3,4-oxadiazol-2-
yl)thio]acetamide (12l)
White amorphous solid; Yield: 99%; M.P. 100-102oC; Mol. formula: C23H19N3O4S; Mol.
Wt: 433 gmol-1; IR (KBr, cm-1) vmax: 3049 (Ar-H stretching), 1527 (Ar C=C stretching),
1118 (C-O stretching), 611 (C-S stretching).
1H-NMR (600 MHz, CDCl3, ppm):See Table 29
13C-NMR (150 MHz, CDCl3, ppm):169.96 (C-1), 167.3 (C-2''), 164.20 (C-5''), 148.05 (C-
4'), 148.0 (C-1'''), 146.07 (C-3'), 133.07 (C-1'), 130.8 (C-5'''), 129.9 (C-4'''), 128.9 (C-
10'''), 127.06 (C-7'''), 126.4 (C-3'''), 126.0 (C-6'''), 124.84 (C-2'''), 124.4 (C-8'''), 121.9 (C-
9'''), 119.0 (C-6'), 108.2 (C-5'), 108.06 (C-2'), 101.7 (C-7'), 44.6 (C-8'), 36.8 (C-11'''),
32.2 (C-2).
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3.4.2.13.N-[3,4-methylenedioxybenzyl]-2-[(5-(4-chlorophenoxy)methyl)-1,3,4-
oxadiazol-2-yl)thio]acetamide (12m)
White amorphous solid; Yield: 95%; M.P. 120-122oC; Mol. formula: C19H16ClN3O5S;
Mol. Wt: 433 gmol-1; IR (KBr, cm-1) vmax: 3058 (Ar-H stretching), 1537 (Ar C=C
stretching), 1124 (C-O stretching), 704 (C-Cl stretching), 668 (C-Br stretching), 613 (C-S
stretching).
1H-NMR (600 MHz, CDCl3, ppm):See Table 30
13C-NMR (150 MHz, CDCl3, ppm):166.95 (C-1), 166.32 (C-2''), 164.19 (C-5''), 147.80
(C-1'''), 146.9 (C-4'''), 132.00 (C-2''' &C-6'''), 131.49 (C-3''' & C-5'''), 129.13 (C-3'),
126.74 (C-4'), 123.16 (C-1'), 120.97 (C-5'), 108.30 (C-2'), 108.21 (C-6'), 101.01 (C-7'),
44.81 (C-8'), 35.21 (C-2).
3.4.2.14.N-[3,4-methylenedioxybenzyl]-2-[(5-phenyl)-1,3,4-oxadiazol-2-yl)thio]
acetamide (12n)
White amorphous solid; Yield: 97%; M.P. 153oC; Mol. formula: C18H15N3O4S; Mol. Wt:
369 gmol-1; IR (KBr, cm-1) vmax: 3059 (Ar-H stretching), 1541 (Ar C=C stretching), 1133
(C-O stretching), 675 (C-Br stretching), 613 (C-S stretching).
1H-NMR (600 MHz, CDCl3, ppm):See Table 30
13C-NMR (150 MHz, CDCl3, ppm):171.0 (C-1), 165.0 (C-2''), 164.08 (C-5''), 148.05 (C-
4'), 146.07 (C-3'), 133.1 (C-3''' &C-5'''), 133.07 (C-1'), 132.0 (C-2''' &C-6'''), 130.9 (C-
4'''), 130.67 (C-1'''), 119.0 (C-6'), 108.2 (C-5'), 108.06 (C-2'), 101.7 (C-7'), 44.0 (C-8'),
32.2 (C-2).
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3.4.2.15.N-[3,4-methylenedioxybenzyl]-2-[(5-(4-methoxyphenyl)-1,3,4-oxadiazol-
2-yl)thio]acetamide (12o)
White amorphous solid; Yield: 95%; M.P.153-155oC; Mol. formula: C19H17N3O5S;
Mol. Wt: 399 gmol-1; IR (KBr, cm-1) vmax: 3071 (Ar-H stretching), 1547 (Ar C=C
stretching), 1138 (C-O stretching), 667 (C-Br stretching), 616 (C-S stretching).
1H-NMR (600 MHz, CDCl3, ppm):See Table 30
13C-NMR (150 MHz, CDCl3, ppm):171.09 (C-1), 167.09 (C-5''), 165.0 (C-2''), 162.5 (C-
4'''), 148.05 (C-4'), 146.07 (C-3'), 133.07 (C-1'), 125.3 (C-1'''), 119.0 (C-6'), 116.9 (C-3'''
&C-5'''), 116.83 (C-2''' &C-6'''), 108.2 (C-5'), 108.06 (C-2'), 100.7 (C-7'), 56.5 (C-7'''),
44.0 (C-8'), 32.2 (C-2).
3.4.2.16.N-[3,4-methylenedioxybenzyl]-2-[(5-(2-methylphenyl)-1,3,4-oxadiazol-2-
yl)thio]acetamide (12p)
Yellow amorphous solid; Yield: 98%; M.P. 122-124oC; Mol. formula: C19H17N3O4S;
Mol. Wt: 383 gmol-1; IR (KBr, cm-1) vmax: 3055 (Ar-H stretching), 1534 (Ar C=C
stretching), 1124 (C-O stretching), 608 (C-S stretching).
1H-NMR (600 MHz, CDCl3, ppm):See Table 31
13C-NMR (150 MHz, CDCl3, ppm):167.04 (C-1), 166.51 (C-2''), 163.78 (C-5''), 147.86
(C-3'), 146.95 (C-4'), 138.30 (C-1'), 131.79 (C-1'''), 131.53 (C-2'''), 131.50 (C-3'''), 128.76
(C-4'''), 126.25 (C-5'''), 122.19 (C-6'''), 120.96 (C-6'), 108.26 (C-5'), 108.19 (C-2'), 101.00
(C-7'), 43.79 (C-8'), 35.17 (C-2), 22.09 (C-7''').
3.4.2.17.N-[3,4-methylenedioxybenzyl]-2-[(5-(2-nitrophenyl)-1,3,4-oxadiazol-2-
yl)thio]acetamide (12q)
Pale yellow amorphous solid; Yield: 96%; M.P. 140-142oC; Mol. formula: C18H14N4O6S;
Mol. Wt: 414 gmol-1; IR (KBr, cm-1) vmax: 3067 (Ar-H stretching), 1545 (Ar C=C
stretching), 1132 (C-O stretching), 620 (C-S stretching).
1H-NMR (600 MHz, CDCl3, ppm):See Table 31
13C-NMR (150 MHz, CDCl3, ppm):171.60 (C-1), 165.1 (C-2''), 164.90 (C-5''), 148.74 (C-
2'''), 148.05 (C-4'), 146.07 (C-3'), 133.07 (C-1'), 131.7 (C-4'''), 129.6 (C-5'''), 128.20 (C-
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3'''), 126.1 (C-6'''), 123.79 (C-1'''), 119.0 (C-6'), 108.2 (C-5'), 108.06 (C-2'), 101.8 (C-7'),
44.0 (C-8'), 32.2 (C-2).
3.4.2.18.N-[3,4-methylenedioxybenzyl]-2-[(5-(4-nitrophenyl)-1,3,4-oxadiazol-2-
yl)thio]acetamide (12r)
Pale yellow amorphous solid; Yield: 97%; M.P.109-111oC; Mol. formula: C18H14N4O6S;
Mol. Wt: 414 gmol-1; IR (KBr, cm-1) vmax: 3063 (Ar-H stretching), 1547 (Ar C=C
stretching), 1135 (C-O stretching), 615 (C-S stretching).
1H-NMR (600 MHz, CDCl3, ppm):See Table 31
13C-NMR (150MHz, CDCl3, ppm):171.09 (C-1), 167.09 (C-5''), 165.0 (C-2''), 148.8 (C-
4'''), 148.05 (C-4'), 146.07 (C-3'), 137.3 (C-1'''), 133.07 (C-1'), 127.83 (C-2''' &C-6'''),
125.9 (C-3''' &C-5'''), 119.0 (C-6'), 108.2 (C-5'), 108.06 (C-2'), 101.5 (C-7'), 44.0 (C-8'),
32.2 (C-2).
3.4.2.19. N-[3,4-methylenedioxybenzyl]-2-[(5-(2-chloro-3,5-dinitrophenyl)-1,3,4-
oxadiazol-2-yl)thio]acetamide (12s)
White amorphous solid; Yield: 93%; M.P.184-186oC; Mol. formula: C18H12ClN5O8S;
Mol. Wt: 493 gmol-1; IR (KBr, cm-1) vmax: 3069 (Ar-H stretching), 1551 (Ar C=C
stretching), 1137 (C-O stretching), 701 (C-Cl stretching), 669 (C-Br stretching), 617 (C-S
stretching).
1H-NMR (600 MHz, CDCl3, ppm):See Table 32
13C-NMR (150 MHz, CDCl3, ppm):170.76 (C-1), 167.20 (C-5''), 165.0 (C-2''), 148.05 (C-
4'), 147.8 (C-3'''), 147.1 (C-5'''), 146.07 (C-3'), 134.2 (C-1'''), 133.07 (C-1'), 132.72(C-
2'''), 128.6 (C-4'''), 125.2 (C-6'''), 120.0 (C-6'), 108.2 (C-5'), 108.16 (C-2'), 101.7 (C-7'),
44.0 (C-8'), 32.2 (C-2).
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3.4.2.20.N-[3,4-methylenedioxybenzyl]-2-[(5-(2,4-dichlorophenyl)-1,3,4-
oxadiazol-2-yl)thio]acetamide (12t)
Grey amorphous solid; Yield: 91%; M.P.160-162oC; Mol. formula: C18H13Cl2N3O4S;
Mol. Wt: 437 gmol-1; IR (KBr, cm-1) vmax: 3064 (Ar-H stretching), 1545 (Ar C=C
stretching), 1139 (C-O stretching), 668 (C-Br stretching), 613 (C-S stretching).
1H-NMR (600 MHz, CDCl3, ppm):See Table 32
13C-NMR (150 MHz, CDCl3, ppm):170.76 (C-1), 167.20 (C-5''), 165.0 (C-2''), 148.05 (C-
4'), 146.07 (C-3'), 130.8 (C-3'''), 136.69 (C-4'''), 134.72(C-2'''), 134.2 (C-1'''), 133.07 (C-
1'), 132.2 (C-6'''), 128.7 (C-5'''), 120.0 (C-6'), 108.2 (C-5'), 108.16 (C-2'), 101.7 (C-7'),
44.0 (C-8'), 32.2 (C-2).
3.5. General procedure for synthesis of N-substituted-2-
bromoacetamides (14a-t)
The various N-substituted alkyl/aryl/aralkyl amines (12.0 mmol, 13a-t) were taken in 100
mL round bottom flask already containing 15.0 mL distilled water. 5% Na2CO3 solution
was added to the reaction contents adjusting the pH 8.0 to 9.0. The reaction mixture was
shaken for 5 minutes at room temperature. 2-Bromoacetyl bromide (12.0 mmol, 10) was
gradually added to the reaction flask with vigorous shaking on ice bath till the
precipitates were appeared. Completion of the reaction was monitored by TLC time by
time. After the reaction ceased, the solid mass obtained was filtered, washed with water
and dried. The desired electrophiles, N-alkyl/aryl/aralkyl-2-bromoacetamides (14a-t)
were obtained in very good yield.
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3.6. General procedure for the synthesis of N-substituted-2-{(5-(3,4-
methylenedioxy) phenyl-1,3,4-Oxadiazol-2-yl) sulfanyl}acetamide
derivatives (15a-t)
Compound, 5-(3,4-methylenedioxyphenyl)-1,3,4-Oxadiazole-2-thiol(0.002 mol, 4a), was
taken in a round bottom flask containing DMF (10-15 mL) used as a solvent. NaH, acting
as a base, was added in a catalytic amount (0.002 mol) to the reaction flask. To activate
the reacting species, contents were put on stirring for thirty minutes. Later on, it was
made to react with equimolar quantity of presynthesized N-alkyl/aralkyl/aryl-2-
bromoacetamides (14a-t) with continuous stirring for the time almost 3-4 hours. In order
to monitor the reaction, TLC was applied with the mobile phase of ethyl acetate and n-
hexane (30:70). While doing workup, cold distilled water was added to the reaction
contents to get the desired precipitates. Pure solid precipitates (15a-t) were collected by
filtration which were washed and dried for structure elucidation and further analysis.
3.6.1.N-[2,3-dimethylphenyl]-2-[(5-(3,4-methylenedioxyphenyl)-1,3,4-oxadiazol-2-
yl)thio]acetamide (15a)
Grey amorphous solid; Yield: 96%; M.P. 176-178oC; Mol. formula: C19H17N3O4S;
Mol. Wt: 383 gmol-1; IR (KBr, cm-1) vmax: 3067 (Ar-H stretching), 1540 (Ar C=C
stretching), 1133 (C-O stretching), 660 (C-Br stretching), 610 (C-S stretching).
1H-NMR (600 MHz, CDCl3, ppm):See Table 33
13C-NMR (150 MHz, CDCl3, ppm):165.17 (C-2), 164.95 (C-5), 162.74 (C-1''), 150.48
(C-3'), 148.13 (C-4'), 137.56 (C-3'''), 137.10 (C-1'''), 135.16 (C-2'''), 131.58 (C-4'''),
127.22 (C-5'''), 125.88 (C-1'), 123.61 (C-6'''), 116.00 (C-6'), 109.86 (C-5'), 106.84 (C-2'),
102.13 (C-7'), 36.15 (C-2''), 20.10 (C-8'''), 13.90 (C-7''').
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3.6.2. N-[2,4-dimethylphenyl]-2-[(5-(3,4-methylenedioxyphenyl)-1,3,4-oxadiazol- 2-
yl)thio]acetamide (15b)
White amorphous solid; Yield: 97%; M.P. 148-150oC;Mol. formula:C19H17N3O4S;
Mol. Wt: 383 gmol-1; IR (KBr, cm-1) vmax: 3067 (Ar-H stretching), 1540 (Ar C=C
stretching), 1133 (C-O stretching), 610 (C-S stretching).
1H-NMR (600 MHz, CDCl3, ppm):See Table 33
13C-NMR (150 MHz, CDCl3, ppm):168.93 (C-1''), 166.50 (C-2), 164.25 (C-5), 152.71
(C-3'), 149.95 (C-4'), 137.56 (C-3'''), 135.10 (C-1'''), 128.16 (C-2'''), 126.58 (C-4'''),
125.20 (C-5'''), 122.88 (C-1'), 121.61 (C-6'''), 116.00 (C-6'), 109.76 (C-5'), 108.84 (C-2'),
101.01 (C-7'), 32.28 (C-2''), 19.97 (C-8'''), 14.89 (C-7''').
3.6.3.N-[2,5-dimethylphenyl]-2-[(5-(3,4-methylenedioxyphenyl)-1,3,4-oxadiazol-2-
yl)thio]acetamide (15c)
Golden amorphous solid; Yield: 98%; M.P.130-132oC; Mol. formula: C19H17N3O4S;
Mol. Wt: 383gmol-1; IR (KBr, cm-1) vmax: 3067 (Ar-H stretching), 1543 (Ar C=C
stretching), 1131 (C-O stretching), 702 (C-Cl stretching), 665 (C-Br stretching), 616 (C-S
stretching).
1H-NMR (600 MHz, CDCl3, ppm):See Table 33
13C-NMR (150 MHz, CDCl3, ppm):169.95 (C-1''), 165.20 (C-2), 164.25 (C-5), 152.71
(C-3'), 149.95 (C-4'), 137.56 (C-3'''), 136.10 (C-1'''), 128.00 (C-2'''), 127.58 (C-4'''),
125.22 (C-5'''), 123.88 (C-1'), 121.61 (C-6'''), 115.00 (C-6'), 109.86 (C-5'), 108.64 (C-2'),
101.07 (C-7'), 32.28 (C-2''), 19.97 (C-8'''), 16.79 (C-7''').
3.6.4.N-[2,6-dimethylphenyl]-2-[(5-(3,4-methylenedioxyphenyl)-1,3,4-oxadiazol- 2-
yl)thio]acetamide (15d)
Creamy white amorphous solid; Yield: 98%; M.P. 156-158oC; Mol. formula:
C19H17N3O4S; Mol. Wt: 383gmol-1; IR (KBr, cm-1) vmax: 3063 (Ar-H stretching), 1540
(Ar C=C stretching), 1129 (C-O stretching), 706 (C-Cl stretching), 667 (C-Br stretching),
622 (C-S stretching).
1H-NMR (600 MHz, CDCl3, ppm):See Table 34
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13C-NMR (150 MHz, CDCl3, ppm):169.25 (C-1''), 166.70 (C-2), 164.00 (C-5), 152.71
(C-3'), 149.25 (C-4'), 136.00 (C-1'''), 133.43 (C-2''' & C-6'''), 125.58 (C-4'''), 126.46 (C-
3''' &C-5'''), 122.18 (C-1'), 115.04 (C-6'), 109.86 (C-5'), 108.94 (C-2'), 101.02 (C-7'),
32.29 (C-2''), 19.01 (C-8'''), 14.89 (C-7''').
3.6.5.N-[3,5-dimethylphenyl]-2-[(5-(3,4-methylenedioxyphenyl)-1,3,4-oxadiazol-2-
yl)thio]acetamide (15e)
Golden amorphous solid; Yield: 98%; M.P. 150-152oC;Mol. formula: C19H17N3O4S;
Mol. Wt: 383gmol-1; IR (KBr, cm-1) vmax: 3065 (Ar-H stretching), 1544 (Ar C=C
stretching), 1131 (C-O stretching), 673 (C-Br stretching).
1H-NMR (600 MHz, CDCl3, ppm):See Table 34
13C-NMR (150 MHz, CDCl3, ppm):169.00 (C-1''), 166.70 (C-2), 164.00 (C-5), 152.71
(C-3'), 149.25 (C-4'), 136.00 (C-1'''), 124.11 (C-2''' & C-6'''), 125.58 (C-4'''), 135.46 (C-
3''' &C-5'''), 122.18 (C-1'), 115.04 (C-6'), 109.86 (C-5'), 108.94 (C-2'), 101.02 (C-7'),
32.29 (C-2''), 19.01 (C-8'''), 18.89 (C-7''').
3.6.6.N-phenyl-2-[(5-(3,4-methylenedioxyphenyl)-1,3,4-oxadiazol-2-yl)thio]
acetamide (15f)
Light pink amorphous solid; Yield: 96%; M.P. 97-99oC; Mol. formula: C17H13N3O4S;
Mol. Wt: 355 gmol-1; IR (KBr, cm-1) vmax: 3058 (Ar-H stretching), 1539 (Ar C=C
stretching), 1129 (C-O stretching), 657 (C-Br stretching).
1H-NMR (600 MHz, CDCl3, ppm):See Table 34
13C-NMR (150 MHz, CDCl3, ppm):169.74 (C-1''), 165.80 (C-2), 164.09 (C-5), 152.71
(C-3'), 149.25 (C-4'), 136.00 (C-1'''), 119.75 (C-2''' & C-6'''), 124.58 (C-4'''), 127.93 (C-
3''' &C-5'''), 122.18 (C-1'), 115.04 (C-6'), 109.86 (C-5'), 108.94 (C-2'), 101.02 (C-7'),
32.29 (C-2'').
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3.6.7.N-[2-methylphenyl]-2-[(5-(3,4-methylenedioxyphenyl)-1,3,4-oxadiazol-2-yl)
thio]acetamide (15g)
White amorphous solid; Yield: 96%; M.P. 178-180oC; Mol. formula: C18H15N3O4S; Mol.
Wt: 369 gmol-1; IR (KBr, cm-1) vmax: 3048 (Ar-H stretching), 1537 (Ar C=C stretching),
1112 (C-O stretching), 663 (C-Br stretching).
1H-NMR (600 MHz, CDCl3, ppm):See Table 35
13C-NMR (150 MHz, CDCl3, ppm):167.09 (C-1''), 166.25 (C-2), 164.15 (C-5), 153.71
(C-3'), 149.95 (C-4'), 137.66 (C-3'''), 136.80 (C-1'''), 128.16 (C-2'''), 127.68 (C-4'''),
125.22 (C-5'''), 122.88 (C-1'), 121.61 (C-6'''), 115.00 (C-6'), 109.86 (C-5'), 108.74 (C-2'),
101.02 (C-7'), 32.48 (C-2''), 14.89 (C-7''').
3.6.8.N-[4-methylphenyl]-2-[(5-(3,4-methylenedioxyphenyl)-1,3,4-oxadiazol-2-yl)
thio]acetamide (15h)
White amorphous solid; Yield: 79%; M.P. 120-122oC; Mol. formula: C18H15N3O4S; Mol.
Wt: 369 gmol-1; IR (KBr, cm-1) vmax: 3069 (Ar-H stretching), 1545 (Ar C=C stretching),
1387 (S=O stretching), 1137 (C-O stretching), 616 (C-S stretching).
1H-NMR (600 MHz, CDCl3, ppm):See Table 35
13C-NMR (150 MHz, CDCl3, ppm):169.19 (C-1''), 165.05 (C-2), 164.19 (C-5), 153.91
(C-3'), 149.85 (C-4'), 137.46 (), 136.00 (C-1'''), 128.16 (C-2''' &C-6'''), 125.22 (C-3''' &C-
5'''), 122.88 (C-1'), 121.68 (C-4'''), 115.90 (C-6'), 109.00 (C-5'), 108.00 (C-2'), 101.07 (C-
7'), 32.48 (C-2''), 15.09 (C-7''').
3.6.9.N-[3-methylpyridyl]-2-[(5-(3,4-methylenedioxyphenyl)-1,3,4-oxadiazol-2-
yl)thio]acetamide (15i)
White amorphous solid; Yield: 93%; M.P. 158-160oC; Mol. formula: C17H14N4O4S; Mol.
Wt: 370 gmol-1; IR (KBr, cm-1) vmax: 3061 (Ar-H stretching), 1540 (Ar C=C stretching),
1132 (C-O stretching), 672 (C-Br stretching), 613 (C-S stretching).
1H-NMR (600 MHz, CDCl3, ppm):See Table 35
13C-NMR (150 MHz, CDCl3, ppm):169.95 (C-1''), 165.20 (C-2), 164.25 (C-5), 152.71
(C-3'), 149.95 (C-4'), 137.56 (C-3'''), 136.10 (C-1'''), 127.58 (C-4'''), 125.22 (C-5'''),
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123.88 (C-1'), 115.00 (C-6'), 112.49 (C-2'''), 109.86 (C-5'), 108.64 (C-2'), 101.01 (C-7'),
32.39 (C-2''), 18.79 (C-7''').
3.6.10.N-[2-methylcarboxylate]-2-[(5-(3,4-methylenedioxyphenyl)-1,3,4-
oxadiazol-2-yl)thio]acetamide (15j)
white amorphous solid; Yield: 97%; M.P. 145-147oC; Mol. formula:    C19H15N3O6S;
Mol. Wt: 413 gmol-1; IR (KBr, cm-1) vmax: 3054 (Ar-H stretching), 1532 (Ar C=C
stretching), 1124 (C-O stretching), 651 (C-Br stretching), 607 (C-S stretching).
1H-NMR (600 MHz, CDCl3, ppm):See Table 36
13C-NMR (150 MHz, CDCl3, ppm):170.05 (C-1''), 169.19 (C-7'''), 166.20 (C-2), 164.25
(C-5), 152.71 (C-3'), 149.95 (C-4'), 137.56 (C-3'''), 136.10 (C-1'''), 128.16 (C-2'''), 127.58
(C-4'''), 125.22 (C-5'''), 122.88 (C-1'), 121.61 (C-6'''), 120.34 (C-6'), 115.00 (C-2'), 109.86
(C-5'), 101.07 (C-7'), 55.17 (C-8'''), 32.28 (C-2'').
3.6.11.N-[5-chloro-2-methoxyphenyl]-2-[(5-(3,4-methylenedioxyphenyl)-1,3,4-
oxadiazol-2-yl)thio]acetamide (15k)
Grey amorphous solid; Yield: 90%; M.P. 175-177oC;Mol. formula: C18H14ClN3O5S;
Mol. Wt: 419 gmol-1; IR (KBr, cm-1) vmax: 3067 (Ar-H stretching), 1545 (Ar C=C
stretching), 1134 (C-O stretching), 663 (C-Br stretching), 611 (C-S stretching).
1H-NMR (600 MHz, CDCl3, ppm):See Table 36
13C-NMR (150 MHz, CDCl3, ppm):165.90 (C-1''), 165.01 (C-2), 162.60 (C-5), 150.46
(C-3'), 148.12 (C-4'), 148.00 (C-3'''), 136.80 (C-1'''), 128.16 (C-2'''), 127.68 (C-4'''),
124.35 (C-5'''), 122.88 (C-1'), 121.61 (C-6'''), 115.00 (C-6'), 109.86 (C-5'), 108.74 (C-2'),
102.13 (C-7'), 56.12 (C-7'''), 36.43 (C-2'').
3.6.12.N-[tetrahydrofurfurylmethyl]-2-[(5-(3,4-methylenedioxyphenyl)-1,3,4-
oxadiazol-2-yl)thio]acetamide (15l)
White amorphous solid; Yield: 99%; M.P. 100-102oC; Mol. formula: C16H17N3O5S; Mol.
Wt: 363 gmol-1; IR (KBr, cm-1) vmax: 3049 (Ar-H stretching), 1527 (Ar C=C stretching),
1118 (C-O stretching), 658 (C-Br stretching), 611 (C-S stretching).
1H-NMR (600 MHz, CDCl3, ppm):See Table 36
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13C-NMR (150 MHz, CDCl3, ppm):170.25 (C-1''), 166.70 (C-2), 164.00 (C-5), 152.71
(C-3'), 149.25 (C-4'), 122.18 (C-1'), 115.04 (C-6'), 109.86 (C-5'), 108.94 (C-2'), 101.02
(C-7'), 77.01 (C-1'''), 68.29 (C-3''') 43.00 (C-6'''), 42.14 (C-5'''), 32.13 (C-2''), 25.79 (C-
4''').
3.6.13.N-[2-phenylethyl]-2-[(5-(3,4-methylenedioxyphenyl)-1,3,4-oxadiazol-2-yl)
thio]acetamide (15m)
White amorphous solid; Yield: 95%; M.P. 120-122oC; Mol. formula: C19H17N3O4S; Mol.
Wt: 383 gmol-1; IR (KBr, cm-1) vmax: 3058 (Ar-H stretching), 1537 (Ar C=C stretching),
1124 (C-O stretching), 704 (C-Cl stretching), 668 (C-Br stretching), 613 (C-S stretching).
1H-NMR (600 MHz, CDCl3, ppm):See Table 37
13C-NMR (150 MHz, CDCl3, ppm):169.03 (C-1''), 166.20 (C-2), 164.25 (C-5), 152.71
(C-3'), 149.95 (C-4'), 136.10 (C-1'''), 128.16 (C-2''' & C-6'''), 127.58 (C-4'''), 125.22 (C-
3'''&C-5'''), 122.88 (C-1'), 115.00 (C-6'), 109.86 (C-5'), 108.84 (C-2'), 101.07 (C-7'),
41.35 (C-8'''), 36.08 (C-7'''), 32.28 (C-2'').
3.6.14.N-[2-ethylphenyl]-2-[(5-(3,4-methylenedioxyphenyl)-1,3,4-oxadiazol-2-
yl)thio]acetamide (15n)
White amorphous solid; Yield: 97%; M.P. 150-152oC; Mol. formula: C19H17N3O4S; Mol.
Wt: 383 gmol-1; IR (KBr, cm-1) vmax: 3059 (Ar-H stretching), 1541 (Ar C=C stretching),
1133 (C-O stretching), 675 (C-Br stretching), 613 (C-S stretching).
1H-NMR (600 MHz, CDCl3, ppm):See Table 37
13C-NMR (150 MHz, CDCl3, ppm):165.93 (C-1''), 165.50 (C-2), 164.25 (C-5), 156.70
(C-4'''), 152.71 (C-3'), 149.95 (C-4'), 135.10 (C-1'''), 125.11 (C-2'''& C-6'''), 122.88 (C-1'),
117.61 (C-3''' &C-5'''), 116.00 (C-6'), 109.76 (C-5'), 108.84 (C-2'), 101.01 (C-7'), 59.07
(C-7'''), 32.28 (C-2''), 14.90 (C-8''').
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3.6.15.N-[4-ethylphenyl]-2-[(5-(3,4-methylenedioxyphenyl)-1,3,4-oxadiazol-2-yl)
thio]acetamide (15o)
White amorphous solid; Yield: 95%; M.P. 153-155oC; Mol. formula: C19H17N3O4S; Mol.
Wt: 383 gmol-1; IR (KBr, cm-1) vmax: 3071 (Ar-H stretching), 1547 (Ar C=C stretching),
1138 (C-O stretching), 667 (C-Br stretching), 616 (C-S stretching).
1H-NMR (600 MHz, CDCl3, ppm):See Table 37
13C-NMR (150 MHz, CDCl3, ppm):169.25 (C-1''), 166.70 (C-2), 164.00 (C-5), 152.71
(C-3'), 149.25 (C-4'), 141.38 (C-4'''), 140.56 (C-1'''), 128.46 (C-3''' &C-5'''), 123.43 (C-2'''
& C-6'''), 122.18 (C-1'), 115.04 (C-6'), 109.86 (C-5'), 108.94 (C-2'), 101.02 (C-7'), 32.29
(C-2''), 29.01 (C-7'''), 14.89 (C-8''').
3.6.16.N-[4-ethoxyphenyl]-2-[(5-(3,4-methylenedioxyphenyl)-1,3,4-oxadiazol-2-
yl)thio]acetamide (15p)
Yellow amorphous solid; Yield: 98%; M.P. 122-124oC;Mol. formula: C19H17N3O5S; Mol.
Wt: 399 gmol-1; IR (KBr, cm-1) vmax: 3055 (Ar-H stretching), 1534 (Ar C=C stretching),
1124 (C-O stretching), 654 (C-Br stretching).
1H-NMR (600 MHz, CDCl3, ppm):See Table 38
13C-NMR (150MHz, CDCl3, ppm):166.75 (C-1''), 166.70 (C-2), 164.00 (C-5), 152.71 (C-
3'), 149.25 (C-4'), 141.38 (C-4'''), 140.56 (C-1'''), 128.46 (C-3''' &C-5'''), 123.43 (C-2''' &
C-6'''), 122.18 (C-1'), 115.04 (C-6'), 109.86 (C-5'), 108.94 (C-2'), 101.02 (C-7'), 32.29 (C-
2''), 29.01 (C-8'''), 14.89 (C-7''').
3.6.17.N-[2-ethoxyphenyl]-2-[(5-(3,4-methylenedioxyphenyl)-1,3,4-oxadiazol-2-
yl)thio]acetamide (15q)
Pale yellow amorphous solid; Yield: 96%; M.P. 140-142oC; Mol. formula: C19H17N3O5S;
Mol. Wt: 399 gmol-1; IR (KBr, cm-1) vmax: 3067 (Ar-H stretching), 1545 (Ar C=C
stretching), 1132 (C-O stretching), 670 (C-Br stretching).
1H-NMR (600 MHz, CDCl3, ppm):See Table 38
13C-NMR (150 MHz, CDCl3, ppm):167.03 (C-1''), 165.20 (C-2), 164.25 (C-5), 152.71
(C-3'), 149.95 (C-4'), 137.56 (C-3'''), 127.18 (C-1'''), 145.00 (C-2'''), 127.58 (C-4'''),
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120.13 (C-5'''), 123.88 (C-1'), 121.61 (C-6'''), 115.00 (C-6'), 109.86 (C-5'), 108.64 (C-2'),
101.07 (C-7'), 62.79 (C-7'''), 32.28 (C-2''), 15.87 (C-8''').
3.6.18.N-[2-ethyl-6-methylphenyl]-2-[(5-(3,4-methylenedioxyphenyl)-1,3,4-
oxadiazol-2-yl)thio]acetamide (15r)
Pale yellow amorphous solid; Yield: 97%; M.P. 109-111oC; Mol. formula: C20H19N3O4S;
Mol. Wt: 397 gmol-1; IR (KBr, cm-1) vmax: 3063 (Ar-H stretching), 1547 (Ar C=C
stretching), 1135 (C-O stretching), 678 (C-Br stretching).
1H-NMR (600 MHz, CDCl3, ppm):See Table 38
13C-NMR (150 MHz, CDCl3, ppm):166.33 (C-1''), 166.20 (C-2), 164.25 (C-5), 152.71
(C-3'), 149.95 (C-4'), 136.16 (C-2'''), 136.10 (C-1'''), 133.16 (C-6'''), 130.54 (C-4'''),
127.00 (C-5'''), 125.22 (C-3'''), 122.88 (C-1'), 115.00 (C-6'), 109.86 (C-5'), 108.84 (C-2'),
102.07 (C-7'), 32.28 (C-2''), 26.08 (C-7'''), 19.08 (C-9'''), 11.35 (C-8''').
3.6.19.N-[2-methoxyphenyl]-2-[(5-(3,4-methylenedioxyphenyl)-1,3,4-oxadiazol-
2-yl)thio]acetamide (15s)
White amorphous solid; Yield: 93%; M.P. 184-186oC; Mol. formula: C18H15N3O5S; Mol.
Wt: 385 gmol-1; IR (KBr, cm-1) vmax: 3069 (Ar-H stretching), 1551 (Ar C=C stretching),
1137 (C-O stretching), 701 (C-Cl stretching), 669 (C-Br stretching), 617 (C-S stretching).
1H-NMR (600 MHz, CDCl3, ppm):See Table 39
13C-NMR (150 MHz, CDCl3, ppm):165.37 (C-2), 164.05 (C-5), 162.71 (C-1''), 150.48
(C-3'), 149.48 (C-4'), 136.16 (C-2'''), 136.10 (C-1'''), 133.16 (C-6'''), 130.54 (C-4'''),
127.00 (C-5'''), 122.88 (C-1'), 115.00 (C-6'), 111.27 (C-3'''), 109.86 (C-5'), 108.84 (C-2'),
102.17 (C-7'), 55.71 (C-7'''), 36.49 (C-2'').
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3.6.20.N-[4-hydroxy-2-methylphenyl]-2-[(5-(3,4-methylenedioxyphenyl)-1,3,4-
oxadiazol-2-yl)thio]acetamide (15t)
Grey amorphous solid; Yield: 91 %; M.P.: 160-162 oC; Mol. formula: C18H15N3O5S;
Mol. Wt: 385 gmol-1; IR (KBr, cm-1) vmax: 3064 (Ar-H stretching), 1545 (Ar C=C
stretching), 1139 (C-O stretching), 705 (C-Cl stretching), 668 (C-Br stretching), 613 (C-S
stretching).
1H-NMR (600 MHz, CDCl3, ppm):See Table 39
13C-NMR (150 MHz, CDCl3, ppm):166.01 (C-1''), 165.22 (C-2), 164.60 (C-5), 155.68
(C-4'''), 150.46 (C-3'), 148.12 (C-4'), 134.50 (C-1'''), 128.16 (C-2'''), 122.88 (C-1'), 121.61
(C-6'''), 116.00 (C-3'''), 115.75 (C-5'''), 115.00 (C-6'), 109.86 (C-5'), 108.74 (C-2'), 101.13
(C-7'), 34.40 (C-2''), 19.12 (C-7''').
3.7. General procedure for the synthesis of 2-Alkyl/aralkylthio-5-(3,4-
methylenedioxyphenyl)-1,3,4-Oxadiazole derivatives (17a-u):
5-(3,4-Methylenedioxyphenyl)-1,3,4-Oxadiazole-2-thiol(0.002 mol, 4a), DMF (5-10mL),
as a polar aprotic solvent and NaH (0.002 mol), as a base were taken in a round bottom
flask. The reaction mixture was put on stirring at room temperature for half an hour.
Different alkyl/aralkyl halides (16a-u) were added after the thirty minutes stirring in
equimolar ratio. The reaction contents were again put on stirring for about 3-5 hours. The
reaction progression was continuously monitored by TLC having a combination of non
polar, n-hexane and polar, ethylacetate solvents as a mobile phase in the ratio (4:1). After
the reaction completion, ice cold distilled water was added to the reaction flask which at
once gave precipitates or oily product. The precipitates were filtered while oily product
was extracted through solvent extraction method with an organic solvent like diethyl
ether or chloroform. The solid products were washed and later on dried for analytical
purposes. Different 2-Alkyl/aralkylthio-5-(3,4-methylenedioxyphenyl)-1,3,4-Oxadiazole
derivatives (17a-u) were obtained as a pure single products.
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3.7.1. 2-Methylthio-5-(3,4-methylenedioxyphenyl)-1,3,4-Oxadiazole (17a)
White amorphous solid; Yield: 81%; M.P. 90-92oC; Mol. formula: C10H8N2O3S; Mol.
Wt: 236 gmol-1; IR (KBr, cm-1) vmax: 3016 (aromatic C-H), 1615 (Ar C=C), 1579 (C=N),
1108 (C-O-C).
1H-NMR (400 MHz, CDCl3, ppm):See Table 40
EIMS m/z: 236 [M]·+, 221 [C9H5N2O3S]+, 189 [C9H5N2O3]+, 163 [C8H5NO3]·+, 147
[C8H5NO2]·+, 121 [C7H5O2]+, 15 [CH3]+.
3.7.2. 2-Ethylthio-5-(3,4-methylenedioxyphenyl)-1,3,4-Oxadiazole (17b)
Grey solid; Yield: 87%; M.P. 70-72oC; Mol. formula: C11H10N2O3S; Mol. Wt: 250 gmol-
1; IR (KBr, cm-1) vmax: 3018 (aromatic C-H), 1616 (Ar C=C), 1570 (C=N), 1110 (C-O-C).
1H-NMR (400 MHz, CDCl3, ppm):See Table 40
EIMS m/z: 250 [M]·+, 221 [C9H5N2O3S]+, 189 [C9H5N2O3]+, 163 [C8H5NO3]·+, 147
[C8H5NO2]·+, 121 [C7H5O2]+, 29 [C2H5]+.
3.7.3. 2-(Propan-1-yl)thio-5-(3,4-methylenedioxyphenyl)-1,3,4-Oxadiazole (17c)
Yellowish brown amorphous solid; Yield: 79%; M.P. 60-62oC; Mol. formula:
C12H12N2O3S; Mol. Wt: 264 gmol-1; IR (KBr, cm-1) vmax: 3018 (aromatic C-H), 1616 (Ar
C=C), 1570 (C=N), 1110 (C-O-C).
1H-NMR (400 MHz, CDCl3, ppm):See Table 40
EIMS m/z: 264 [M]·+, 221 [C9H5N2O3S]+, 189 [C9H5N2O3]+, 163 [C8H5NO3]·+, 147
[C8H5NO2]·+, 121 [C7H5O2]+, 43 [C3H7]+, 41 [C3H5]+.
3.7.4. 2-(Butan-1-yl)thio-5-(3,4-methylenedioxyphenyl)-1,3,4-Oxadiazole (17d)
Creamy white liquid; Yield: 90%; Mol. formula: C13H14N2O3S; Mol. Wt: 278 gmol-1; IR
(KBr, cm-1) vmax: 3019 (aromatic C-H), 1620 (Ar C=C), 1576 (C=N).
1H-NMR (400 MHz, CDCl3, ppm):See Table 41
EIMS m/z: 278 [M]·+, 221 [C9H5N2O3S]+, 189 [C9H5N2O3]+, 163 [C8H5NO3]·+, 147
[C8H5NO2]·+, 121 [C7H5O2]+, 57 [C4H9]+, 55 [C4H7]+, 29 [C2H5]+.
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3.7.5. 2-(Pentan-1-yl)thio-5-(3,4-methylenedioxyphenyl)-1,3,4-Oxadiazole (17e)
Creamy white amorphous solid; Yield: 88%; M.P. 105-106oC; Mol. formula:
C14H16N2O3S; Mol. Wt: 292 gmol-1; IR (KBr, cm-1) vmax: 3014 (aromatic C-H), 1616 (Ar
C=C), 1578 (C=N), 1108 (C-O-C)
1H-NMR (400 MHz, CDCl3, ppm):See Table 41
EIMS m/z: 292 [M]·+, 221 [C9H5N2O3S]+, 189 [C9H5N2O3]+, 163 [C8H5NO3]·+, 147
[C8H5NO2]·+, 121 [C7H5O2]+, 71 [C5H11]+, 69 [C5H9]+, 43 [C3H7]+.
3.7.6. 2-(2-Chloroethyl)thio-5-(3,4-methylenedioxyphenyl)-1,3,4-Oxadiazole (17f)
White amorphous solid;Yield:90%; M.P. 130-132oC; Mol. formula: C11H9N2O3SCl;
Mol. Wt: 284 gmol-1; IR (KBr, cm-1) vmax: 3285 (aromatic C-H stretching), 1630 (Ar C=C
stretching), 1576 (C=N stretching), 1109 (C-O-C stretching)
1H-NMR (400 MHz, CDCl3, ppm):See Table 41
EIMS m/z: 286 [M+2]·+, 284 [M]·+, 221 [C9H5N2O3S]+, 189 [C9H5N2O3]+, 163
[C8H5NO3]·+, 147 [C8H5NO2]·+, 121 [C7H5O2]+, 63 [C2H4Cl]+, 28 [C2H4]+.
3.7.7. 2-(2-Bromoethyl)thio-5-(3,4-methylenedioxyphenyl)-1,3,4-Oxadiazole
(17g)
Creamy white amorphous solid; Yield: 90%; M.P. 122-124oC; Mol. formula:
C11H9N2O3SBr; Mol. Wt: 329 gmol-1; IR (KBr, cm-1) vmax: 3014 (aromatic C-H
stretching), 1616 (Ar C=C str.), 1579 (C=N stretching), 1107 (C-O-C stretching)
1H-NMR (400 MHz, CDCl3, ppm):See Table 42
EIMS m/z: 331 [M+2]·+, 329 [M]·+, 221 [C9H5N2O3S]+, 189 [C9H5N2O3]+, 163
[C8H5NO3]·+, 147 [C8H5NO2]·+, 121 [C7H5O2]+, 108 [C2H4Br]+, 28 [C2H4]+.
3.7.8. 2-(Ethoxycarbonyl)methylthio-5-(3,4-methylenedioxyphenyl)-1,3,4-
Oxadiazole (17h)
White amorphous solid; Yield: 95%; M.P. 116-118oC; Mol. formula: C13H12N2O5S;
Mol. Wt: 308 gmol-1; IR (KBr, cm-1) vmax: 3020 (aromatic C-H str.), 1715 (C=O
stretching), 1617 (Ar C=C str.), 1576 (C=N stretching), 1106 (C-O-C stretching)
1H-NMR (400 MHz, CDCl3, ppm):See Table 42
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EIMS m/z: 308 [M]·+, 221 [C9H5N2O3S]+, 189 [C9H5N2O3]+, 163 [C8H5NO3]·+, 147
[C8H5NO2]·+, 121 [C7H5O2]+, 87 [C4H7O2]+, 42 [C2H2O]+.
3.7.9. 2-Benzylthio-5-(3,4-methylenedioxyphenyl)-1,3,4-Oxadiazole(17i)
White amorphous solid;Yield: 86%; M.P. 130-132oC; Mol. formula: C16H12N2O3S;
Mol. Wt: 312 gmol-1; IR (KBr, cm-1) vmax: 3285 (aromatic C-H stretching), 1630 (Ar C=C
stretching), 1588 (C=N stretching), 1109 (C-O-C stretching)
1H-NMR (400 MHz, CDCl3, ppm):See Table 42
EIMS m/z: 312 [M]·+, 221 [C9H5N2O3S]+, 189 [C9H5N2O3]+, 163 [C8H5NO3]·+, 147
[C8H5NO2]·+, 121 [C7H5O2]+, 122 [C7H6S]+, 91 [C7H7]·+, 77 [C6H5]·+, 65 [C5H5]+.
3.7.10. 2-(2-Phenylethyl)thio-5-(3,4-methylenedioxyphenyl)-1,3,4-Oxadiazole
(17j)
Golden brown gummy liquid; Yield: 92%; Mol. formula: C17H14N2O3S; Mol. Wt: 326
gmol-1;IR (KBr, cm-1) vmax: 3436 (aromatic C-H), 1633 (Ar C=C), 1592 (C=N), 1109 (C-
O-C).
1H-NMR (400 MHz, CDCl3, ppm):See Table 43
EIMS m/z: 326 [M]·+, 221 [C9H5N2O3S]+, 189 [C9H5N2O3]+, 163 [C8H5NO3]·+, 147
[C8H5NO2]·+, 136 [C8H9S]+, 121 [C7H5O2]+, 91 [C7H7]+, 77 [C6H5]·+, 65 [C5H5]·+.
3.7.11. 2-(3-Phenylpropyl)thio-5-(3,4-methylenedioxyphenyl)-1,3,4-Oxadiazole
(17k)
White amorphous solid; Yield: 90%; M.P. 73-75oC;Mol. formula: C18H16N2O3S;
Mol. Wt: 340 gmol-1; IR (KBr, cm-1) vmax: 3290 (aromatic C-H), 1630 (Ar C=C), 1587
(C=N), 1110 (C-O-C).
1H-NMR (400 MHz, CDCl3, ppm):See Table 43
EIMS m/z: 340 [M]+, 221 [C9H5N2O3S]+, 189 [C9H5N2O3]+, 163 [C8H5NO3]·+, 151
[C9H11S]+, 147 [C8H5NO2]·+, 121 [C7H5O2]+, 119 [C9H11]+, 105 [C8H9]+, 91 [C7H7]·+, 77
[C6H5]·+, 65 [C5H5]·+, 51 [C4H3]·+.
3.7.12. 2-(2-Methylbenzyl)thio-5-(3,4-methylenedioxyphenyl)-1,3,4-Oxadiazole
(17l)
White amorphous solid; Yield: 84%; M.P. 106-108 oC; Mol. formula: C17H14N2O3S
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Mol. Wt: 326 gmol-1; IR (KBr, cm-1) vmax: 3294 (aromatic C-H stretching), 1627 (Ar C=C
stretching), 1591 (C=N stretching), 1108 (C-O-C stretching).
1H-NMR (400 MHz, CDCl3, ppm):See Table 43
EIMS m/z: 326 [M]·+, 221 [C9H5N2O3S]+, 189 [C9H5N2O3]+, 163 [C8H5NO3]·+, 147
[C8H5NO2]·+, 137 [C8H9S]+, 121 [C7H5O2]+, 106 [C8H9]+, 90 [C7H6]·+, 77 [C6H5]+.
3.7.13. 2-(2-Bromobenzyl)thio-5-(3,4-methylenedioxyphenyl)-1,3,4-Oxadiazole
(17m)
White amorphous solid; Yield: 82%; M.P. 120-122oC; Mol. formula: C16H11N2O3SBr;
Mol. Wt: 391 gmol-1; IR (KBr, cm-1) vmax:3329 (aromatic C-H str.), 1633 (Ar C=C
stretching), 1580 (C=N stretching), 1108 (C-O-C stretching).
1H-NMR (400 MHz, CDCl3, ppm):See Table 44
EIMS m/z: 393 [M+2]·+, 391 [M]·+, 221 [C9H5N2O3S]+, 202 [C7H6SBr]+, 189
[C9H5N2O3]+, 171 [C7H7Br]·+, 163 [C8H5NO3]·+, 157 [C6H5Br]·+, 147 [C8H5NO2]·+, 121
[C7H5O2]+, 90 [C7H6]+, 77 [C6H5]+.
3.7.14. 2-(3-Bromobenzyl)thio-5-(3,4-methylenedioxyphenyl)-1,3,4-Oxadiazole
(17n)
White amorphous solid;Yield: 85%; M.P. 110-112oC; Mol. formula: C16H11N2O3SBr;
Mol. Wt: 391 gmol-1; IR (KBr, cm-1) vmax:3290 (aromatic C-H stretching), 1628 (Ar C=C
stretching), 1587 (C=N stretching), 1107 (C-O-C stretching).
1H-NMR (300 MHz, CDCl3, ppm):See Table 44
EIMSm/z: 393 [M+2]·+, 391 [M]·+, 221 [C9H5N2O3S]+, 202 [C7H6SBr]+, 189
[C9H5N2O3]+, 171 [C7H7Br]·+, 163 [C8H5NO3]·+, 157 [C6H5Br]·+, 147 [C8H5NO2]·+, 121
[C7H5O2]+, 90 [C7H6]+, 77 [C6H5]+, 65 [C5H5]·+.
3.7.15. 2-(4-Bromobenzyl)thio-5-(3,4-methylenedioxyphenyl)-1,3,4-Oxadiazole
(17o)
White amorphous solid;Yield: 93%;M.P. 125-127oC; Mol. formula: C16H11N2O3SBr;
Mol. Wt: 391 gmol-1; IR (KBr, cm-1) vmax: 3450 (aromatic C-H stretching), 1627 (Ar C=C
stretching), 1578 (C=N stretching), 1109 (C-O-C stretching)
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1H-NMR (400 MHz, CDCl3, ppm):See Table 44
EIMS m/z: 393 [M+2]·+, 391 [M]·+, 221 [C9H5N2O3S]+, 202 [C7H6SBr]+, 189
[C9H5N2O3]+, 171 [C7H7Br]·+, 163 [C8H5NO3]·+, 157 [C6H5Br]·+, 147 [C8H5NO2]·+, 121
[C7H5O2]+, 90 [C7H6]+, 77 [C6H5]+, 65 [C5H5]·+.
3.7.16. 2-(2-Chlorobenzyl)thio-5-(3,4-methylenedioxyphenyl)-1,3,4-Oxadiazole
(17p)
White amorphous solid; Yield: 83%; M.P. 98-100oC; Mol. formula: C16H11N2O3SCl;
Mol. Wt: 346.5 gmol-1; IR (KBr, cm-1) vmax: 3437 (aromatic C-H), 1633 (Ar C=C), 1590
(C=N), 1109 (C-O-C).
1H-NMR (400 MHz, CDCl3, ppm):See Table 45
EIMS m/z: 348 [M+2]·+, 346 [M]·+, 221 [C9H5N2O3S]+, 189 [C9H5N2O3]+, 163
[C8H5NO3]·+, 157 [C7H6ClS]+, 147 [C8H5NO2]·+, 126 [C7H7Cl]+, 121 [C7H5O2]+, 112
[C6H5Cl]·+, 90 [C7H6]·+, 76 [C6H4]+.
3.7.17. 2-(3-Chlorobenzyl)thio-5-(3,4-methylenedioxyphenyl)-1,3,4-Oxadiazole
(17q)
White amorphous solid; Yield: 85%; M.P. 109-111oC; Mol. formula: C16H11N2O3SCl;
Mol. Wt: 346.5 gmol-1; IR (KBr, cm-1) vmax: 3339 (aromatic C-H), 1632 (Ar C=C), 1590
(C=N), 1109 (C-O-C)
1H-NMR (400 MHz, CDCl3, ppm):See Table 45
EIMSm/z: 348 [M+2]·+, 346 [M]·+, 221 [C9H5N2O3S]+, 189 [C9H5N2O3]+, 163
[C8H5NO3]·+, 157 [C7H6ClS]+, 147 [C8H5NO2]·+, 126 [C7H7Cl]+, 121 [C7H5O2]+, 112
[C6H5Cl]·+, 90 [C7H6]·+, 76 [C6H4]+, 65 [C5H5]·+.
3.7.18. 2-(4-Chlorobenzyl)thio-5-(3,4-methylenedioxyphenyl)-1,3,4-Oxadiazole
(17r)
White amorphous solid; Yield: 95%; M.P. 100-102oC; Mol. formula: C16H11N2O3SCl;
Mol. Wt: 346.5 gmol-1; IR (KBr, cm-1) vmax: 3340 (aromatic C-H), 1630 (Ar C=C), 1592
(C=N), 1108 (C-O-C)
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1H-NMR (400 MHz, CDCl3, ppm):See Table 45
EIMS m/z: 348 [M+2]·+, 346 [M]·+, 221 [C9H5N2O3S]+, 189 [C9H5N2O3]+, 163
[C8H5NO3]·+, 157 [C7H6ClS]+, 147 [C8H5NO2]·+, 126 [C7H7Cl]+, 121 [C7H5O2]+, 112
[C6H5Cl]·+, 90 [C7H6]·+, 76 [C6H4]+, 65 [C5H5]·+.
3.7.19. 2-(3-Nitrobenzyl)thio-5-(3,4-methylenedioxyphenyl)-1,3,4-Oxadiazole
(17s)
White amorphous solid; Yield: 90%; .P. 112-114oC; Mol. formula: C16H11N3O5S;
Mol. Wt: 357 gmol-1; IR (KBr, cm-1) vmax: 3339 (aromatic C-H), 1635 (Ar C=C), 1595
(C=N), 1108 (C-O-C).
1H-NMR (300 MHz, CDCl3, ppm):See Table 46
EIMS m/z: 357 [M]·+, 221 [C9H5N2O3S]+, 189 [C9H5N2O3]+, 163 [C8H5NO3]·+, 147
[C8H5NO2]·+, 136 [C7H6NO2]+, 121 [C7H5O2]+, 90 [C7H6]+, 65 [C5H5]·+.
3.7.20. 2-(4-Nitrobenzyl)thio-5-(3,4-methylenedioxyphenyl)-1,3,4-Oxadiazole
(17t)
Creamy white amorphous solid; Yield: 80%; M.P.190-192oC;Mol. formula:
C16H11N3O5S; Mol. Wt: 357 gmol-1; IR (KBr, cm-1) vmax: 3338 (aromatic C-H), 1634 (Ar
C=C), 1594 (C=N), 1108 (C-O-C).
1H-NMR (400 MHz, CDCl3, ppm):See Table 46
EIMS m/z: 357 [M]·+, 221 [C9H5N2O3S]+, 189 [C9H5N2O3]+, 163 [C8H5NO3]·+, 147
[C8H5NO2]·+, 136 [C7H6NO2]+, 121 [C7H5O2]+, 90 [C7H6]+, 65 [C5H5]·+.
3.7.21. 2-(4-Flourobenzyl)thio-5-(3,4-methylenedioxyphenyl)-1,3,4-Oxadiazole
(17u)
White amorphous solid; Yield: 87 %; M.P. 120-122oC; Mol. formula: C16H11N2O3SF;
Mol. Wt: 330 gmol-1; IR (KBr, cm-1) vmax: 3244 (aromatic C-H), 1630 (Ar C=C), 1590
(C=N), 1109 (C-O-C).
1H-NMR (400 MHz, CDCl3, ppm):See Table 46
EIMS m/z: 330 [M]·+, 221 [C9H5N2O3S]+, 189 [C9H5N2O3]+, 163 [C8H5NO3]·+, 147
[C8H5NO2]·+, 141 [C7H6SF]+, 121 [C7H5O2]+, 96 [C6H5F]·+, 91 [C7H7]·+.
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3.8.General Procedure for the Synthesis of Aryl/aralkyl sulfonyl
paroxitine derivatives in aqueous media(20a-k, m-o)
Paroxetine (0.001 mol; 18) was dispersed in 100 mL RB flask containing 30 mL water.
The pH of solution was made 9-10 by 10% aqueous solution of Na2CO3 and maintained
during the whole reaction. Aryl/aralkyl sulfonyl chlorides (0.001 mol; 19a-k, m-o) were
added in the basic solution in small portions at pH of 9-10. The reaction contents were
kept on continuous stirring for 3-4 hours. The reaction progress was monitored through
TLC using n-hexane & ethyl acetate as solvent system (70:30). After reaction
completion, dilute HCl was poured slowly to adjust the pH of 2.0-3.0. The solid
precipitates were filtered, washed with distilled water and dried to yield the
corresponding compounds, 20a-k, m-o. Recrystallization was also processed for further
purification from methanol.
3.8.1. N-(benzenesulfonyl)paroxetine (20a)
White amorphous solid; Yield: 85%; M.P.: 205oC; Mol. formula: C25H24NO5FS; Mol.
Wt: 469; IR (KBr, cm-1) vmax: 3080 (Ar-H), 2920 (C-H), 1570 (Ar C=C), 1390 (S=O),
1170 (C-F).
1H-NMR (CDCl3, 300 MHZ): δ (ppm): See Table 47
13C-NMR (CDCl3, 75 MHz): 162.9 (C-1ꞌꞌꞌ), 132.8 (C-4ꞌꞌꞌ), 153.0 (C-1ꞌ), 148.0 (C-3ꞌ),
141.0 (C-4ꞌ), 138.1 (C-4ꞌꞌ), 138.0 (C-1ꞌꞌ), 132.4 (C-5ꞌꞌꞌ & 3ꞌꞌꞌ), 129.2 (C-6ꞌꞌꞌ & 2ꞌꞌꞌ), 127.7
(C-2ꞌꞌ & 6ꞌꞌ), 115.5 (C-3ꞌꞌ & 5ꞌꞌ), 107.0 (C-5ꞌ), 105.0 (C-6ꞌ), 101.1 (C-7ꞌ), 98.0 (C-2ꞌ), 68.5
(C-7), 49.4 (C-2), 46.7 (C-6), 43.0 (C-3), 41.0 (C-4), 33.2 (C-5).
EIMS m/z: 469 [M]+ (5%), 332 (9%), 236 (2%), 191 (5%), 141 (81%), 138 (67%), 137
(35%), 121 (14%), 77 (100%).
3.8.2. N-(4-toluenesulfonyl)paroxetine (20b)
Brown gummy liquid; Yield: 85%; Molecular formula: C26H26NO5FS; Molecular Wt:
483; IR (KBr, cm-1) vmax: 3075 (Ar-H), 2915 (C-H), 1579 (Ar C=C), 1393 (S=O), 1181
(C-F).
1H-NMR (CDCl3, 300 MHz): δ (ppm): See Table 47
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13C-NMR (CDCl3, 75 MHz): 163.9 (C-7ꞌꞌꞌ), 160.9 (C-1ꞌꞌꞌ), 158.7 (C-4ꞌꞌꞌ), 152.7 (C-1ꞌ),
149.1 (C-3ꞌ), 140.0 (C-4ꞌ), 138.2 (C-1ꞌꞌ), 138.0 (C-4ꞌꞌ), 132.0 (C-3ꞌꞌꞌ & 5ꞌꞌꞌ), 129.0 (C-6ꞌꞌꞌ &
2ꞌꞌꞌ), 128.0 (C-2ꞌꞌ & 6ꞌꞌ), 115.9 (C-3ꞌꞌ & 5ꞌꞌ), 101.2 (C-7ꞌ), 107.2 (C-5ꞌ), 105.6 (C-6ꞌ), 97.9
(C-2ꞌ), 68.7 (C-7), 48.7 (C-2), 45.9 (C-6), 43.0 (C-3), 41.0 (C-4), 33.3 (C-5).
EIMS m/z: 483 [M]+ (5%), 346 (8%), 250 (10%), 236 (4%), 191 (6%), 155 (80%), 138
(68%), 137 (33%), 121 (13%), 77 (100%).
3.8.3. N-(4-ter-butylbenzenesulfonyl)paroxetine (20c)
White amorphous solid; Yield: 95%; M.P.: 240 oC; Molecular formula: C29H32NO5FS;
Molecular Wt: 525; IR (KBr, cm-1) vmax: 3083 (Ar-H), 2927 (C-H), 1569 (Ar C=C), 1388
(S=O), 1167 (C-F).
1H-NMR (CDCl3, 300 MHz): δ (ppm): See Table 48
13C-NMR (CDCl3, 75MHz): 169.2 (C-7ꞌꞌꞌ), 162.7 (C-1ꞌꞌꞌ), 157.5 (C-4ꞌꞌꞌ), 152.6 (C-1ꞌ),
148.7 (C-3ꞌ), 140.2 (C-4ꞌ), 138.0 (C-1ꞌꞌ), 137.5 (C-4ꞌꞌ), 132.0 (C-3ꞌꞌꞌ & 5ꞌꞌꞌ), 129.2 (C-2ꞌꞌꞌ &
6ꞌꞌꞌ), 127.6 (C-2ꞌꞌ & 6ꞌꞌ), 115.9 (C-3ꞌꞌ & 5ꞌꞌ), 101.2 (C-7ꞌ), 106.9 (C-5ꞌ), 105.8 (C-6ꞌ), 97.0
(C-2ꞌ), 68.3 (C-7), 48.8 (C-2), 46.0 (C-6), 43.0 (C-3), 39.8 (C-4), 32.8 (C-5), 25.0 (C-8ꞌꞌꞌ,
C-9ꞌꞌꞌ & C-10ꞌꞌꞌ).
EIMS m/z: 525 [M]+ (5%), 388 (8%), 266 (24%), 240 (55%), 197 (75%), 138 (68%), 137
(34%), 135 (30%), 133 (60%), 109 (38%), 77 (99%), 56 (89%).
3.8.4. N-(2-mesitylenesulfonyl)paroxetine (20d)
Brown gummy liquid; Yield: 85%; Molecular formula: C28H30NO5FS; Molecular Wt:
511; IR (KBr, cm-1) vmax: 3089 (Ar-H), 2929 (C-H), 1578 (Ar C=C), 1395 (S=O), 1180
(C-F).
1H-NMR (CDCl3, 300 MHz): δ (ppm): See Table 48
13C-NMR (CDCl3, 75 MHz): 163.2 (C-1ꞌꞌꞌ), 161.3 (C-4ꞌꞌꞌ), 150.0 (C-1ꞌ), 147.0 (C-3ꞌ),
140.0 (C-4ꞌ), 137.6 (C-1ꞌꞌ), 137.0 (C-4ꞌꞌ), 131.6 (C-3ꞌꞌꞌ & 5ꞌꞌꞌ), 128.6 (C-2ꞌꞌꞌ & 6ꞌꞌꞌ), 126.5
(C-2ꞌꞌ & 6ꞌꞌ), 115.5 (C-3ꞌꞌ & 5ꞌꞌ), 107.0 (C-5ꞌ), 105.0 (C-6ꞌ), 101.2 (C-7ꞌ), 97.0 (C-2ꞌ), 67.9
(C-7), 49.0 (C-2), 46.0 (C-6), 43.0 (C-3), 40.0 (C-4), 35.3 (C-5), 33.7 (C-7ꞌꞌ), 33.6 (C-8ꞌꞌ),
30.9 (C-9ꞌꞌ).
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EIMS m/z: 511 [M]+ (4%), 374 (10%), 278 (5%), 194 (17%), 183 (70%), 138 (55%), 121
(15%), 119 (100%), 77 (13%).
3.8.5. N-(4-acetylbenzenesulfonyl)paroxetine (20e)
Brown liquid; Yield: 85%; Molecular formula: C27H26NO6FS; Molecular Wt: 511; IR
(KBr, cm-1) vmax: 3099 (Ar-H), 2934 (C-H), 1720 (C=O), 1593 (Ar C=C), 1400 (S=O),
1163 (C-F).
1H-NMR (CDCl3, 300 MHz): δ (ppm): See Table 49
13C-NMR (CDCl3, 75 MHz): 163.6 (C-7ꞌꞌꞌ), 162.9 (C-1ꞌꞌꞌ), 159.7 (C-4ꞌꞌꞌ), 153.0 (C-1ꞌ),
147.5 (C-3ꞌ), 141.0 (C-4ꞌ), 138.2 (C-1ꞌꞌ), 138.1 (C-4ꞌꞌ), 131.9 (C-3ꞌꞌꞌ & 5ꞌꞌꞌ), 129.2 (C-2ꞌꞌꞌ &
6ꞌꞌꞌ), 128.7 (C-2ꞌꞌ & 6ꞌꞌ), 115.6 (C-3ꞌꞌ & 5ꞌꞌ), 101.1 (C-7ꞌ), 107.4 (C-5ꞌ), 105.6 (C-6ꞌ), 97.9
(C-2ꞌ), 68.7 (C-7), 49.5 (C-2), 45.7 (C-6), 43.0 (C-3), 41.0 (C-4), 33.6 (C-8ꞌꞌꞌ), 32.7 (C-5).
EIMS m/z: 511 [M]+ (3%), 374 (10%), 278 (4%), 138 (59%), 191 (7%), 183 (52%), 121
(20%), 141 (75%), 43 (40%), 77 (100%).
3.8.6. N-(4-methoxybenzenesulfonyl)paroxetine (20f)
White amorphous solid; Yield: 90%; M.P.: 215 oC; Molecular formula: C26H26NO6FS;
Molecular Wt: 499; IR (KBr, cm-1) vmax: 3078 (Ar-H), 2920 (C-H), 1573 (Ar C=C), 1385
(S=O), 1167 (C-F).
1H-NMR (CDCl3, 300 MHz): δ (ppm): See Table 49
13C-NMR (CDCl3, 75 MHz): 162.9 (C-1ꞌꞌꞌ), 158.8 (C-4ꞌꞌꞌ), 152.5 (C-1ꞌ), 149.0 (C-3ꞌ),
140.2 (C-4ꞌ), 138.1 (C-1ꞌꞌ), 138.0 (C-4ꞌꞌ), 132.0 (C-3ꞌꞌꞌ & 5ꞌꞌꞌ), 129.8 (C-2ꞌꞌꞌ & 6ꞌꞌꞌ), 128.0
(C-2ꞌꞌ & 6ꞌꞌ), 115.9 (C-3ꞌꞌ & 5ꞌꞌ), 101.2 (C-7ꞌ), 106.9 (C-5ꞌ), 105.8 (C-6ꞌ), 96.8 (C-2ꞌ), 68.3
(C-7), 48.9 (C-2), 46.0 (C-6), 43.0 (C-3), 39.9 (C-4), 33.0 (C-7ꞌꞌꞌ), 32.8 (C-5).
EIMS m/z: 499 [M]+ (3%), 362 (12%), 241 (31%), 215 (60%), 172 (80%), 138 (65%),
137 (40%), 135 (45%), 121 (15%), 109 (25%), 77 (100%).
3.8.7. N-(4-acetamidobenzenesulfonyl)paroxetine (20g)
White amorphous solid; Yield: 75%; M.P.: 200 oC; Molecular formula: C27H27N2O6FS;
MolecularWt: 526; IR (KBr, cm-1) vmax: 3076 (Ar-H), 2914 (C-H), 1649 (C=O), 1581 (Ar
C=C), 1399 (S=O), 1189 (C-F).
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1H-NMR (CDCl3, 300 MHZ): δ (ppm): See Table 50
13C-NMR (CDCl3, 75 MHz): 164.0 (C-7ꞌꞌꞌ), 162.9 (C-1ꞌꞌꞌ), 159.5 (C-4ꞌꞌꞌ), 152.9 (C-1ꞌ),
148.0 (C-3ꞌ), 141.0 (C-4ꞌ), 138.1 (C-1ꞌꞌ), 138.0 (C-4ꞌꞌ), 131.9 (C-3ꞌꞌꞌ & 5ꞌꞌꞌ), 129.2 (C-2ꞌꞌꞌ &
6ꞌꞌꞌ), 128.7 (C-2ꞌꞌ & 6ꞌꞌ), 115.5 (C-3ꞌꞌ & 5ꞌꞌ), 107.2 (C-5ꞌ), 105.6 (C-6ꞌ), 101.2 (C-7ꞌ), 97.9
(C-2ꞌ), 68.7 (C-7), 49.5 (C-2), 45.8 (C-6), 43.0 (C-3), 41.0 (C-4), 33.3 (C-5), 30.9 (C-8ꞌꞌꞌ).
EIMS m/z: 526 [M]+ (3%), 389 (5%), 328 (4%), 138 (74%), 137 (36%), 121 (12%), 198
(100%), 176 (6%), 81 (10%), 79 (12%).
3.8.8. N-(4-bromobenzenesulfonyl)paroxetine (20h)
White amorphous solid; Yield: 90%; M.P.: 205oC; Molecular formula: C25H23NO5BrFS;
Molecular Wt: 548; IR (KBr, cm-1) vmax: 3069 (Ar-H), 2937 (C-H), 1591 (Ar C=C), 1401
(S=O), 1201 (C-F).
1H-NMR (CDCl3, 300 MHz): δ (ppm): See Table 50
13C-NMR (CDCl3, 75 MHz): 163.0 (C-1ꞌꞌꞌ), 160.5 (C-4ꞌꞌꞌ), 153.9 (C-1ꞌ), 148.0 (C-3ꞌ),
141.0 (C-4ꞌ), 138.1 (C-1ꞌꞌ), 138.0 (C-4ꞌꞌ), 132.4 (C-3ꞌꞌꞌ & 5ꞌꞌꞌ), 129.2 (C-2ꞌꞌꞌ & 6ꞌꞌꞌ), 128.7
(C-2ꞌꞌ & 6ꞌꞌ), 115.5 (C-3ꞌꞌ & 5ꞌꞌ), 101.2 (C-7ꞌ), 107.0 (C-5ꞌ), 105.0 (C-6ꞌ), 97.9 (C-2ꞌ), 68.5
(C-7), 49.5 (C-2), 46.7 (C-6), 43.0 (C-3), 41.0 (C-4), 33.3 (C-5).
EIMS m/z: 548 [M]+ (3%), 412 (3%), 328 (2%), 290 (8%), 262 (15%), 219 (26%), 155
(44%), 138 (67%), 76 (100%).
3.8.9. N-(2,3-diclorobenzenesulfonyl)paroxetine (20i)
White amorphous solid; Yield: 90%; M.P.: 215oC; Molecular formula: C25H22NO5FSCl2;
Molecular Wt: 537; IR (KBr, cm-1) vmax: 3090 (Ar-H), 2941 (C-H), 1584 (Ar C=C), 1410
(S=O), 1163 (C-F), 685 (C-Cl).
1H-NMR (CDCl3, 300 MHz): δ (ppm): See Table 51
13C-NMR (CDCl3, 75 MHz): 163.5 (C-1ꞌꞌꞌ), 159.3 (C-2ꞌꞌꞌ), 157.6 (C-3ꞌꞌꞌ), 153.0 (C-1ꞌ),
148.2 (C-3ꞌ), 140.9 (C-4ꞌ), 138.2 (C-4ꞌꞌ), 138.0 (C-1ꞌꞌ), 132.8 (C-4ꞌꞌꞌ), 132.4 (C-5ꞌꞌꞌ), 129.2
(C-6ꞌꞌꞌ), 125.6 (C-2ꞌꞌ & 6ꞌꞌ), 115.4 (C-3ꞌꞌ & 5ꞌꞌ), 101.1 (C-7ꞌ), 107.2 (C-5ꞌ), 104.9 (C-6ꞌ),
97.9 (C-2ꞌ), 68.5 (C-7), 49.5 (C-2), 46.5 (C-6), 43.0 (C-3), 41.0 (C-4), 33.1 (C-5).
EIMS m/z: 537 [M]+ (3%), 400 (10%), 280 (30%), 254 (55%), 211 (87%), 147 (95%),
138 (70%), 137 (45%), 135 (30%), 109 (38%).
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3.8.10. N-(3,4-diclorobenzenesulfonyl)paroxetine (20j)
White amorphous solid; Yield: 90%; M.P.: 215 oC; Molecular formula: C25H22NO5FSCl2;
Molecular Wt: 537; IR (KBr, cm-1) vmax: 3092 (Ar-H), 2943 (C-H), 1586 (Ar C=C), 1408
(S=O), 1165 (C-F), 689 (C-Cl).
1H-NMR (CDCl3, 300 MHz): δ (ppm): See Table 51
13C-NMR (CDCl3, 75 MHz): 163.5 (C-1ꞌꞌꞌ), 159.2 (C-4ꞌꞌꞌ), 157.5 (C-3ꞌꞌꞌ), 153.5 (C-1ꞌ),
147.8 (C-3ꞌ), 140.8 (C-4ꞌ), 138.2 (C-4ꞌꞌ), 137.6 (C-1ꞌꞌ), 133.2 (C-2ꞌꞌꞌ), 132.4 (C-5ꞌꞌꞌ), 130.1
(C-6ꞌꞌꞌ), 125.7 (C-2ꞌꞌ & 6ꞌꞌ), 115.4 (C-3ꞌꞌ & 5ꞌꞌ), 101.1 (C-7ꞌ), 107.2 (C-5ꞌ), 105.0 (C-6ꞌ),
97.8 (C-2ꞌ), 68.5 (C-7), 49.6 (C-2), 46.6 (C-6), 43.0 (C-3), 41.0 (C-4), 33.1 (C-5).
EIMS m/z: 537 [M]+ (3%), 400 (10%), 280 (30%), 254 (55%), 211 (87%), 147 (95%),
138 (70%), 137 (45%), 135 (30%), 109 (38%).
3.8.11. N-(benzylsulphonyl)paroxetine (20k)
Brown liquid; Yield: 85%; Mol. formula: C26H26NO5FS; Mol. Wt: 483; IR (KBr, cm-1)
vmax: 3096 (Ar-H), 2923 (C-H), 1577 (Ar C=C), 1391 (S=O), 1178 (C-F).
1H-NMR (CDCl3, 300 MHz): δ (ppm): See Table 52
13C-NMR (CDCl3, 75 MHz): 162.7 (C-7ꞌꞌꞌ), 162.8 (C-1ꞌꞌꞌ), 159.2 (C-4ꞌꞌꞌ), 153.0 (C-1ꞌ),
149.3 (C-3ꞌ), 140.0 (C-4ꞌ), 138.2 (C-1ꞌꞌ), 137.9 (C-4ꞌꞌ), 133.0 (C-3ꞌꞌꞌ & 5ꞌꞌꞌ), 129.0 (C-2ꞌꞌꞌ &
6ꞌꞌꞌ), 128.0 (C-2ꞌꞌ & 6ꞌꞌ), 115.9 (C-3ꞌꞌ & 5ꞌꞌ), 107.2 (C-5ꞌ), 105.6 (C-6ꞌ), 101.2 (C-7ꞌ), 97.9
(C-2ꞌ), 68.7 (C-7), 48.7 (C-2), 45.9 (C-6), 43.0 (C-3), 41.0 (C-4), 33.3 (C-5).
EIMS m/z: 483 [M]+ (3%), 346 (8%), 250.0 (4%), 138 (60%), 137 (25%), 155 (70%), 91
(40%), 77 (100%), 121 (10%), 91 (4%).
3.8.12. N-(4-chlorobenzenesulfonyl)paroxetine (20m)
White amorphous solid; Yield: 90%; M.P.: 210oC; Molecular formula: C25H23NO5ClFS;
Molecular Wt: 503; IR (KBr, cm-1) vmax: 3091 (Ar-H), 2931 (C-H), 1596 (Ar C=C), 1397
(S=O), 1185 (C-F), 693 (C-Cl).
1H-NMR (CDCl3, 300 MHz): δ (ppm): See Table 52
13C-NMR (CDCl3, 75 MHz): 163.0 (C-1ꞌꞌꞌ), 160.5 (C-4ꞌꞌꞌ), 153.9 (C-1ꞌ), 148.0 (C-3ꞌ),
141.0 (C-4ꞌ), 138.1 (C-1ꞌꞌ), 138.0 (C-4ꞌꞌ), 132.4 (C-3ꞌꞌꞌ & 5ꞌꞌꞌ), 129.2 (C-2ꞌꞌꞌ & 6ꞌꞌꞌ), 128.7
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(C-2ꞌꞌ & 6ꞌꞌ), 115.5 (C-3ꞌꞌ & 5ꞌꞌ), 101.2 (C-7ꞌ), 107.0 (C-5ꞌ), 105.0 (C-6ꞌ), 97.9 (C-2ꞌ), 68.5
(C-7), 49.5 (C-2), 46.7 (C-6), 43.0 (C-3), 41.0 (C-4), 33.3 (C-5).
EIMS m/z: 503 [M]+ (5%), 366 (15%), 245 (30%), 219 (56%), 176 (80%), 138 (70%),
137 (40%), 135 (25%), 121 (20%), 109 (37%), 77 (99%).
3.8.13. N-(naphthalene-2-ylsulfonyl)paroxetine (20n)
Brown gummy liquid; Yield: 85%; Molecular formula: C29H26NO5FS; Molecular Wt:
519; IR (KBr, cm-1) vmax: 3105 (Ar-H), 2951 (C-H), 1602 (Ar C=C), 1403 (S=O), 1211
(C-F).
1H-NMR (CDCl3, 400 MHz): δ (ppm): See Table 53
13C-NMR (CDCl3, 100 MHz): 153.9 (C-1ꞌ), 148.2 (C-3ꞌ), 141.9 (C-4ꞌ), 138.2 (C-1ꞌꞌ),
138.1 (C-4ꞌꞌ), 135.6 (C-6ꞌꞌꞌ), 135.1 (C-2ꞌꞌꞌ), 134.7 (C-10ꞌꞌꞌ), 134.4 (C-4ꞌꞌꞌ), 132.0 (C-1ꞌꞌꞌ),
131.7 (C-5ꞌꞌꞌ), 131.2 (C-9ꞌꞌꞌ), 128.7 (C-2ꞌꞌ & 6ꞌꞌ), 126.1 (C-7ꞌꞌꞌ), 125.2 (C-3ꞌꞌꞌ), 124.0 (C-8ꞌꞌꞌ),
115.8 (C-3ꞌꞌ & 5ꞌꞌ), 107.8 (C-5ꞌ), 105.6 (C-6ꞌ), 101.2 (C-7ꞌ), 97.9 (C-2ꞌ), 68.5 (C-7), 49.5
(C-2), 46.7 (C-6), 43.1 (C-3), 41.8 (C-4), 33.3 (C-5).
EIMS m/z: 519 [M]+ (6%), 382 (12%), 286 (9%), 234 (54%), 109 (40%), 191 (80%), 138
(64%), 127 (99%), 121 (14%).
3.8.14. N-(naphthalene-1-ylsulfonyl)paroxetine (20o)
Brown gummy liquid; Yield: 85%; Molecular formula:  C29H26NO5FS; Molecular Wt:
519; IR (KBr, cm-1) vmax: 3106 (Ar-H), 2950 (C-H), 1601 (Ar C=C), 1404 (S=O), 1213
(C-F).
1H-NMR (CDCl3, 300 MHz): See Table 53
13C-NMR (CDCl3, 75 MHz): 153.9 (C-1ꞌ), 148.2 (C-3ꞌ), 141.9 (C-4ꞌ), 138.2 (C-1ꞌꞌ), 138.1
(C-4ꞌꞌ), 137.1 (C-5ꞌꞌꞌ), 137.0 (C-9ꞌꞌꞌ), 136.9 (C-2ꞌꞌꞌ), 136.0 (C-7ꞌꞌꞌ), 130.4 (C-10ꞌꞌꞌ), 129.7 (C-
8ꞌꞌꞌ), 129.0 (C-4ꞌꞌꞌ), 128.7 (C-2ꞌꞌ & 6ꞌꞌ), 127.8 (C-6ꞌꞌꞌ), 125.3 (C-1ꞌꞌꞌ), 123.4 (C-3ꞌꞌꞌ), 115.8
(C-3ꞌꞌ & 5ꞌꞌ), 107.8 (C-5ꞌ), 105.6 (C-6ꞌ), 101.2 (C-7ꞌ), 97.9 (C-2ꞌ), 68.5 (C-7), 49.5 (C-2),
46.7 (C-6), 43.1 (C-3), 41.8 (C-4), 33.3 (C-5).
EIMS m/z: 519 [M]+ (6%), 382 (12%), 286 (9%), 234 (54%),109 (40%), 191 (80%), 138
(64%), 127 (100%), 121 (14%).
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3.9. Procedure for the synthesis of 2-(1,3-benzodioxol-5-
ylcarbonyl)arylsulfono hydrazide (21a-l)
1,3-Benzodioxol-5-carbohydrazide (3a; 0.005 mol) was dispersed in 20 mL distilled
water, adjusting the pH at 8-10 with sodium carbonate solution. Arylsulfonyl chlorides
(19a-l; 0.005 mol) were added gradually and the reaction mixture was stirred for 2-3
hours. After the reaction completion, concentrated HCl (0.5 mL) was poured gradually
while shaking. Precipitates of the products were obtained which were filtered, washed
and dried.
3.9.1. 2-(1,3-Benzodioxol-5-ylcarbonyl)benzenesulfonohydrazide (21a)
White amorphous solid; Yield: 92%; M.P: 210 oC; Molecular formula: C14H12N2O5S;
Molecular Wt: 320; IR (KBr, cm-1) vmax: 3256 (NH stretching), 3018 (aromatic C-H
stretching), 1733 (C=O amide stretching), 1612 (Ar C=C stretching), 1413 (S=O
stretching).
1H-NMR (CDCl3,400 MHz, δ/ppm): See Table 54
13C-NMR (CDCl3,100 MHz, δ/ppm): 170.5 (C-8), 148.7 (C-4), 146.4 (C-3), 145.8 (C-1'),
132.4 (C-4'), 127.1 (C-3' & C-5'), 125.6 (C-1), 124.8 (C-2' & C-6'), 122.6 (C-6), 109.3
(C-2), 107.4 (C-5), 101.6 (C-7).
EIMS (m/z): 320 [M]+ (1%), 149 (100%), 121 (27%), 91 (7%).
3.9.2. 2-(1,3-Benzodioxol-5-ylcarbonyl)-4-methylbenzenesulfonohydrazide (21b)
White amorphous solid; Yield: 90%; M.P: 205 oC; Molecular formula: C15H14N2O5S;
Molecular Wt: 334; IR (KBr, cm-1) vmax: 3259 (NH stretching), 3027 (aromatic C-H
stretching), 1739 (C=O amide stretching), 1617 (Ar C=C stretching), 1418 (S=O
stretching).
1H-NMR (CDCl3,400 MHz, δ/ppm): See Table 54
13C-NMR (CDCl3,100 MHz, δ/ppm): 170.7 (C-8), 148.4 (C-4), 146.6 (C-3), 145.3 (C-1'),
132.9 (C-4'), 127.8 (C-2' & C-6'), 125.2 (C-3' & C-5'), 124.6 (C-1), 122.5 (C-6), 109.1
(C-2), 107.6 (C-5), 101.2 (C-7), 20.3 (C-7').
EIMS (m/z): 334 [M]+ (2%), 156 (15%), 149 (100%), 121 (25%).
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3.9.3. 2-(1,3-Benzodioxol-5-ylcarbonyl)-4-ter-butylbenzenesulfonohydrazide (21c)
Brown amorphous solid; Yield: 96%; M.P: 260 oC; Molecular formula: C18H20N2O5S;
Molecular Wt: 376; IR (KBr, cm-1) vmax: 3272 (NH stretching), 3043 (aromatic C-H
stretching), 1733 (C=O amide stretching), 1612 (Ar C=C stretching), 1407 (S=O
stretching).
1H-NMR (CDCl3,300 MHz, δ/ppm): See Table 54
13C-NMR (CDCl3,75 MHz, δ/ppm): 170.4 (C-8), 152.8 (C-4'), 148.1 (C-4), 146.7 (C-3),
145.6 (C-1'), 126.9 (C-2' & C-6'), 125.3 (C-3' & C-5'), 124.9 (C-1), 122.4 (C-6), 109.8
(C-2), 107.2 (C-5), 101.5 (C-7), 32.3 (C-7'), 31.1 (C-8' to C-10').
EIMS (m/z): 376 [M]+ (1%), 331 (5%), 316 (2%), 198 (20%), 149 (100%), 121 (25%).
3.9.4. 2-(1,3-Benzodioxol-5-ylcarbonyl)mesitylen-2-ylsulfonohydrazide (21d)
Creamy white amorphous solid; Yield: 96%; M.P: 270 oC; Molecular formula:
C17H18N2O5S; Molecular Wt: 362; IR (KBr, cm-1) vmax: 3278 (NH stretching), 3032
(aromatic C-H stretching), 1737 (C=O amide stretching), 1607 (Ar C=C stretching), 1395
(S=O stretching).
1H-NMR (CDCl3,400 MHz, δ/ppm): See Table 55
13C-NMR (CDCl3,100 MHz, δ/ppm): 170.7 (C-8), 152.3 (C-1'), 149.7 (C-2' & C-6'),
148.2 (C-4), 146.4 (C-3), 140.1 (C-4'), 139.5 (C-3' & C-5'), 124.4 (C-1), 122.7 (C-6),
109.3 (C-2), 107.9 (C-5), 101.1 (C-7), 23.1 (C-7' & C-9'), 20.2 (C-8').
EIMS (m/z): 362 [M]+ (1%), 184 (15%), 165 (30%), 149 (100%), 121 (22%).
3.9.5. 2-(1,3-Benzodioxol-5-ylcarbonyl)-4-acetylbenzenesulfonohydrazide (21e)
Light brown amorphous solid; Yield: 97%; M.P: 200 oC; Molecular formula:
C16H14N2O6S; Molecular Wt: 362; IR (KBr, cm-1) vmax: 3265 (NH stretching), 3019
(aromatic C-H stretching), 1739 (C=O amide stretching), 1629 (Ar C=C stretching), 1417
(S=O stretching).
1H-NMR (CDCl3,400 MHz, δ/ppm): See Table 55
13C-NMR (CDCl3,100 MHz, δ/ppm): 197.3 (C-8'), 170.8 (C-8), 149.5 (C-1'), 148.2 (C-4),
146.9 (C-3), 137.3 (C-4'), 126.6 (C-2' & C-6'), 126.2 (C-3' & C-5'), 125.7 (C-1), 123.3
(C-6), 109.6 (C-2), 107.7 (C-5), 101.4 (C-7), 25.8 (C-7').
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EIMS (m/z): 362 [M]+ (1%), 184 (12%), 165 (28%), 149 (100%), 121 (28%), 119 (6%).
3.9.6. 2-(1,3-Benzodioxol-5-ylcarbonyl)-4-methoxybenzenesulfonohydrazide (21f)
White amorphous solid; Yield: 87%; M.P: 320 oC; Molecular formula: C15H14N2O6S;
Molecular Wt: 350; IR (KBr, cm-1) vmax: 3279 (NH stretching), 3023 (aromatic C-H
stretching), 1739 (C=O amide stretching), 1626 (Ar C=C stretching), 1419 (S=O
stretching).
1H-NMR (CDCl3,300 MHz, δ/ppm): See Table 55
13C-NMR (CDCl3,75 MHz, δ/ppm): 170.5 (C-8), 162.3 (C-4'), 148.7 (C-4), 146.4 (C-3),
144.1 (C-1'), 127.2 (C-2' & C-6'), 124.8 (C-1), 123.1 (C-6), 114.7 (C-3' & C-5'), 109.4
(C-2), 107.4 (C-5), 101.6 (C-7), 57.8 (C-7').
EIMS (m/z): 350 [M]+ (50%), 172 (59%), 165 (25%), 149 (100%), 121 (51%), 107 (7%),
91 (9%).
3.9.7. 2-(1,3-Benzodioxol-5-ylcarbonyl)-4-acetamidobenzenesulfonohydrazide (21g)
Creamy white amorphous solid; Yield: 95%; M.P: 250 oC; Molecular formula:
C16H15N3O6S; Molecular Wt: 377; IR (KBr, cm-1) vmax: 3267 (NH stretching), 3023
(aromatic C-H stretching), 1741 (C=O amide stretching), 1603 (Ar C=C stretching), 1409
(S=O stretching).
1H-NMR (CDCl3,400 MHz, δ/ppm): See Table 56
13C-NMR (CDCl3,100 MHz, δ/ppm): 170.4 (C-8), 167.8 (C-8'), 148.6 (C-4), 146.3 (C-3),
142.8 (C-1'), 138.2 (C-4'), 125.5 (C-1), 124.2 (C-2' & C-6'), 123.7 (C-6), 112.4 (C-3' &
C-5'), 109.4 (C-2), 107.2 (C-5), 101.8 (C-7), 23.7 (C-7').
EIMS (m/z): 377 [M]+ (1%), 149 (100%), 134 (1.2%), 121 (23%), 119 (4%), 91 (8%).
3.9.8. 2-(1,3-Benzodioxol-5-ylcarbonyl)-4-bromobenzenesulfonohydrazide (21h)
Brown liquid; Yield: 89%; Molecular formula: C14H11BrN2O5S; Molecular Wt: 398; IR
(KBr, cm-1) vmax: 3264 (NH stretching), 3046 (aromatic C-H stretching), 1730 (C=O
amide stretching), 1601 (Ar C=C stretching), 1398 (S=O stretching), 669 (C-Br
stretching).
1H-NMR (CDCl3,400 MHz, δ/ppm): See Table 56
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13C-NMR (CDCl3,100 MHz, δ/ppm): 170.3 (C-8), 148.3 (C-4), 146.7 (C-3), 146.1 (C-1'),
130.4 (C-3' & C-5'), 126.9 (C-2' & C-6'), 126.2 (C-4'), 125.5 (C-1), 123.8 (C-6), 109.7
(C-2), 107.3 (C-5), 101.5 (C-7).
EIMS (m/z): 400 [M+2]+ (2%), 398 [M]+ (2%), 222 (22%), 220 (22%), 157 (15%), 155
(15%), 149 (100%), 121 (25%), 119 (6%), 91 (7%).
3.9.9. 2-(1,3-Benzodioxol-5-ylcarbonyl)-2,3-dichlorobenzenesulfonohydrazide (21i)
Yellow amorphous solid; Yield: 98%; M.P: 355 oC; Molecular formula: C14H10Cl2N2O5S;
Molecular Wt: 388; IR (KBr, cm-1) vmax: 3286 (NH stretching), 3028 (aromatic C-H
stretching), 1743 (C=O amide stretching), 1615 (Ar C=C stretching), 1435 (S=O
stretching), 703 (C-Cl stretching).
1H-NMR (CDCl3,300 MHz, δ/ppm): See Table 56
13C-NMR (CDCl3,75 MHz, δ/ppm): 170.6 (C-8), 148.7 (C-4), 146.9 (C-3), 143.2 (C-1'),
134.1 (C-2'), 132.8 (C-4'), 131.4 (C-3'), 126.7 (C-5'), 125.4 (C-1), 124.5 (C-6'), 123.6 (C-
6), 109.9 (C-2), 107.1 (C-5), 101.6 (C-7).
EIMS (m/z): 392 [M+4]+ (0.7%), 390 [M+2]+ (1%), 388 [M]+ (2%), 213 (5%), 211 (8%),
209 (25%), 165 (25%), 149 (100%), 147 (30%), 145 (60%), 123 (2%), 119 (5%).
3.9.10. 2-(1,3-Benzodioxol-5-ylcarbonyl)-3,4-dichlorobenzenesulfonohydrazide (21j)
White amorphous solid; Yield: 98%; M.P: 400 oC; Molecular formula: C14H10Cl2N2O5S;
Molecular Wt: 388; IR (KBr, cm-1) vmax: 3275 (NH stretching), 3036 (aromatic C-H
stretching), 1741 (C=O amide stretching), 1605 (Ar C=C stretching), 1415 (S=O
stretching), 707 (C-Cl stretching).
1H-NMR (CDCl3,300 MHz, δ/ppm): See Table 57
13C-NMR (CDCl3,75 MHz, δ/ppm): 170.8 (C-8), 148.5 (C-4), 146.8 (C-3), 142.9 (C-1'),
132.2 (C-4'), 128.6 (C-5'), 127.5 (C-3'), 126.2 (C-2'), 125.6 (C-1), 124.6 (C-6'), 123.3 (C-
6), 109.7 (C-2), 107.4 (C-5), 101.9 (C-7).
EIMS (m/z): 392 [M+4]+ (0.7%), 390 [M+2]+ (1%), 388 [M]+ (2%), 213 (9%), 211
(13%), 209 (28%), 165 (30%), 149 (100%), 147 (32%), 145 (63%), 123 (2%), 119 (5%).
3.9.11. 2-(1,3-Benzodioxol-5-ylcarbonyl)benzylsulfonohydrazide (21k)
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White amorphous solid; Yield: 87%; M.P: 275 oC; Molecular formula: C15H14N2O5S;
Molecular Wt: 334; IR (KBr, cm-1) vmax: 3273 (NH stretching), 3024 (aromatic C-H
stretching), 1746 (C=O amide stretching), 1614 (Ar C=C stretching), 1411 (S=O
stretching).
1H-NMR (CDCl3,400 MHz, δ/ppm): See Table 57
13C-NMR (CDCl3,100 MHz, δ/ppm): 170.7 (C-8), 148.2 (C-4), 146.5 (C-3), 130.4 (C-2'
& C-6'), 129.1 (C-4'), 127.9 (C-1'), 127.2 (C-3' & C-5'), 125.9 (C-1), 123.6 (C-6), 109.3
(C-2), 107.8 (C-5), 101.5 (C-7), 60.1 (C-7').
EIMS (m/z): 334 [M]+ (1%), 165 (20%), 156 (18%), 154 (22%), 149 (100%), 121 (26%),
119 (6%), 91 (17%).
3.9.12. 2-(1,3-Benzodioxol-5-ylcarbonyl)-3,5-dichloro-2-hydroxybenzenesulfono
hydrazide (21l)
Light brown amorphous solid; Yield: 92%; M.P: 189 oC; Molecular formula:
C14H10Cl2N2O6S; Molecular Wt: 404; IR (KBr, cm-1) vmax: 3276 (NH stretching), 3016
(aromatic C-H stretching), 1735 (C=O amide stretching), 1608 (Ar C=C stretching), 1401
(S=O stretching), 701 (C-Cl stretching).
1H-NMR (CDCl3,400 MHz, δ/ppm): See Table 57
13C-NMR (CDCl3,100 MHz, δ/ppm): 170.4 (C-8), 148.4 (C-4), 146.7 (C-3), 143.2 (C-1'),
133.6 (C-3' & C-5'), 129.4 (C-4'), 125.5 (C-1), 124.1 (C-2' & C-6'), 123.5 (C-6), 109.4
(C-2), 107.7 (C-5), 101.8 (C-7).
EIMS (m/z): 408 [M+4]+ (0.7%), 406 [M+2]+ (1%), 404 [M]+ (2%), 226 (24%), 165
(25%), 162 (90%), 149 (100%), 119 (5%).
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3.10. Biological activity assays
3.10.1. Bacterial strains
All the synthesized compounds were tested against different bacterial strains, including
Gram-positive bacteria: B. subtilis andS. aureus and Gram-negative bacteria: S. typhi,E.
coli,K. pneumonaeand P. aeruginosa. All bacterial strains were prevailed from
Department of Clinical Medicine and Surgery, University of Agriculture, Faisalabad,
Pakistan. Purity and identification of the microorganisms were verified by the
Department of Microbiology, University of Agriculture, Faisal Abad, Pakistan. Bacterial
strains were cultured at 37 ºC in NA overnight [121].
3.10.2. Antibacterial activity
The antibacterial activity assay includes sterile 96-wells microplates. Aseptic conditions
were applied for the assay.This particular method works on the directly related bacterial
cell number to the bacterial growth (log phase of growth) and so incremented absorbance
of the broth medium [122, 123]. Five bacterial strains were used including Gram-negative
and Gram-positive bacteria after maintaining stock culture agar medium. The 200 µL of
each well was filled with 20 µg of test samples (after diluting them with appropriate
solvents) and 180 µL fresh bacterial cultures, (overnight maintained after suitable
dilution with freshly prepared nutrient broth). The initial absorbance was kept between
0.12-0.19 at 540 nm and the incubation was made at 37 oC for 16-24 hrs with lid on the
microplate. The difference in the absorbance before and after the incubation at 540 nm
was an index for bacterial growth using microplate reader. The percent inhibition was
calculated according to the formula given:
Inhibition (%) = × 100
where X = absorbance in control with bacterial culture
Y = absorbance in test sample
Results are expressed as mean of triplicate (n=3, ± SEM). Ciprofloxacin was used as
reference standard. MIC was also calculated with suitable dilutions (5-30 µg/well) and all
the results were calculated using EZ-Fitz Perrella Scientific Inc. Amherst USA software.
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3.10.3. Lipoxygenase inhibition activity
LOX activity was processed by the method [124-126]. First of all volume of 2 × 10-4 L
mixture was made including 1.5 × 10-4 L Na3PO4 buffers (0.1 M with pH of 8.0), 1 × 10-5
L target compound and 1.5 × 10-5 L LOX enzyme (6 × 10-4 units well-1). The mixture
components were then pre-read at 234 nm & pre-incubated for 10 min at 25°C. The
initiation of reaction was progressed by addition of 2.5 × 10-5 L substrate. The gradual
variation in the absorbance was recorded after six min at 234 nm using 96-well plate
reader Synergy HT, Biotek, USA. The assay was executed in three-folds. Baicalein (5 ×
10-4 M well-1) was used as positive control. The %age inhibition was calculated by the
formula given below. IC50 values were tabulated as in the last experiment.
Where Control = Enzyme activity in the absence of inhibitor
Test = Activity in the comportment of inhibitor (testing compound)
IC50 values were calculated employing EZ–Fit Enzyme Kinetics software (Perrella
Scientific Inc. Amherst, USA). IC50 values were measured with the help of graph through
dilutions to varied concentrations and were shown as median of three values for three
different measurements.
3.10.4. Urease inhibition assay
This assay wasperformedaccording to the known Berthelot assay [127]. First, a total
volume of 85 µL assay mixture containing 10 µL of phosphate buffer (pH 7.0) in each
well in the 96-well plate and followed by the addition of 10 µL of test solution and 25 µL
of enzyme solution (0.135 units). The contents were pre-incubated at 37ºC for 5 minutes.
Then, 40 µL of urea stock solution (20 mM) was added to each well and incubation
continued at 37ºC for further 10 min. After particular time, 115 µL phenol hypochlorite
reagents were added in each well (freshly prepared by mixing 45 µL phenol with 70 µL
of alkali reagent). For color development, incubation was done at 37ºC for another 10
min. Absorbance was measured at 625 nm using the 96-well plate reader (Synergy HT
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BioTek, USA). The percentage enzyme inhibition was calculated by the formula as given
below:
Inhibition (%) = 100 - (Abs of test sample / Abs of control) × 100
IC50 values (concentration at which 50% enzyme catalyzed reaction occurs) of
compounds were calculated using EZ-Fit Enzyme Kinetics Software (Perrella Scientific
Inc. Amherst, USA).
3.10.5. Statistical analysis:
The observations were recorded astriplicate and statistical analysis was done via
Microsoft Excel 2010. All the mentioned results are as mean ± SEM.
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CHAPTER-4
RESULTS & DISCUSSION
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4.0. General
In the present research work, some poly-functional compounds were synthesized
containing oxadiazole ring, benzodioxole moiety and acetamide functionality merged in
one molecule. The whole work has been splitted into nine schemes according to the
mentioned synthetic plan of work. The routes of synthesis were purely adopted as
described in the literature, however, where there was the requirement, minor
modifications were also made to get maximum yield in minimum time. Product purity
was checked through TLC on silica plates and run in different solvent systems. Further
confirmation and structure elucidation of the synthesized compounds was made through
different spectroscopic techniques i.e. IR, 1H-NMR, EIMS and 13C-NMR. Moving ahead,
antibacterial activities of the synthesized compounds were also carried out to calculate
their potential against different bacterial strains. Bacterial strains selected for this purpose
were Salmonella typhi (-), Escherichia coli (-), Klebsiella pneumonae (-), Pseudomonas
aeruginos (-), Bacillis subtilis (+) & Staphylococcus aureus (+). The whole project
remained successful.
4.1. Synthesis of 5-aryl/aralkyl-1,3,4-Oxadiazol-2-thiol (4a-x)
The synthesis of 5-aryl/aralkyl-1,3,4-Oxadiazol-2-thiols (4a-x), comprised of three steps.
In the first step, ethyl esters (2a-x) from corresponding carboxylic acids (1a-x) were
prepared in the presence of conc. sulfuric acid acting as catalyst and ethyl alcohol in
excess as solvent by vigorous and continuous refluxing for 4-5 hrs. The products were
recovered from the reaction mixture by the usual physical methods i.e. neutralization of
the reaction mixture and then solvent extraction by appropriate solvent. The solvent, after
evaporation, gave pure required products.
R OH
O
R OC2H5
O
Acid
1a-x
Ethyl ester
2a-x
I
Reagents & condition: (I) C2H5OH/H+, refluxing for 4-5 hrs
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In the second step, ethyl esters were converted into respective carbohydrazides (3a-x) by
stirring/refluxing for 2-3 hrs with hydrazine hydrate (80%) in methanol. Methanol was
distilled off to get the precipitates. The yield was made better by adding ice cold distilled
water while precipitation. Some water soluble carbohydrazides were collected after
complete distillation of methanol and washed by n-hexane.
R OC2H5
O
R NH
O
NH2
Ethyl ester
2a-x
Acid hydrazide
3a-x
I
Reagents & condition: (I) NH2NH2 (80%), refluxing for 2-3 hrs
Third step is the intermolecular cyclization of carbohydrazides 3a-x, generating
respective 5-aryl/aralkyl-1,3,4-Oxadiazol-2-thiols, 4a-x. Cyclization of 3a-x, were
completed with CS2 in a basic medium, refluxing for 6-7 hrs.
R NH
O
NH 2
R
N
O
N
SH
Acid hydrazide
3a-x
5-Substituted-1,3,4-oxadiazol-
2-thiol 4a-x
I
Reagents & condition: (I) CS2, KOH, refluxing for 6-7 hrs
The dissolved salt form of oxadiazoles were made undissolved by the addition of conc.
HCl dropwise (pH=2-3) with continuous shaking. Excellent yields were obtained in the
form of precipitates (4a-x) which were washed, dried and save for further experimental
work.
4.2. Synthesis of 5-(aryl/ aralkyl)-2-((6-chloro-3,4-methylene dioxy
benzyl)thio)-1,3,4-Oxadiazole (6a-x)
This series involved the synthesis of some pharmacologically important 5-(aryl/aralkyl)-
2-((6-chloro-3,4-methylenedioxybenzyl)thio)-1,3,4-Oxadiazoles (6a-x), by the reaction
of different presynthesised oxadiazoles (4a-x) with a comercially available electrophile,
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6-chloro-3,4-methylenedioxybenzylchloride (5). The reaction was carried out with
equimolar quantities of the two reacting entities in DMF and NaH. NaH acting as a base
abstracts hydrogen atom from sulfur atom (-SH) of oxadiazole. This sulfur, being a
nucleophile, attacks on the methylenic carbon, (-CH2Cl, electrophilic in character), of (5)
in mild applied reaction conditions and hence departure of chloride ion (Cl−) takes place.
Hydrogen gas (H2) is evolved in this reaction. The products were obtained in the form of
precipitates.
R
N
O
N
SH
+
5
6a-x
5-Substituted-1,3,4
-Oxadiazol-2-thiol
4a-x
5-Substituted-2-((6-chloro-3,4-methylene
dioxyphenyl)methylthio)-1,3,4-oxadiazole
6-chloro-3,4-methylene
dioxybenzylchloride
R
N
O
N
S
Cl O
O
Cl
Cl O
O I
Reagents & condition: (I) DMF, NaH and stir for 3-4 hrs
The products were characterized and confirmed by different spectral analysis like IR, 1H-
NMR, EI-MS and 13C-NMR. A brief overlook of the whole series is described as under
while one of the compounds is discussed in detail.
In 1H-NMR, the two methylenic protons of methylenedioxy ring falls at about δ 5.95 ppm
which indicates that the protons are highly deshielded due to the two electronegative
oxygen atoms and hence the signal appeared at highly downfield region. The
benzodioxole ring is tetrasubstituted and only two signals appear for H-2ꞌ & H-5ꞌ at about
δ (ppm) 6.84 and 7.08 respectively as singlets. The signal for methylene (-CH2) attached
to sulfur atom appeared at about δ (ppm) 4.53 (due to the deshielding effect of sulfur) as
singlet and integration of two protons. The different 5-substituted phenyl rings exhibit
their respective characteristic signals in aromatic region.
In EIMS spectra, different characteristic peaks for particular fragments appeared which
confirmed the formation of the synthesized compounds. Amongst the peaks, m/z 169, 134
and 104 correspond to the benzodioxole cation fragments of electrophile while
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oxadiazole cation fragments appeared at their respective m/z due to the different
substituted phenyl rings. The isotopic peaks for chloro or bromo groups also appeared in
spectra which further supports the data.
In 13C-NMR, quaternary carbon, methylene carbon and methyne carbon gave appropriate
signals and confirmed the synthesized compounds. The whole data of 13C-NMR of all the
compounds has been given in the experimental section. The above discussed spectral data
is the general characteristic data for all the synthesised derivatives (6a-x).
The 1H-NMR data of the compound, 5-[1-(Phenylsulfonyl)piperidyl]-2-((6-chloro-3,4-
methylenedioxybenzyl)thio)-1,3,4-Oxadiazole (6h) has been presented in table-4. The
compound contains one phenyl ring, one benzodioxole ring and one piperidine ring,
besides the oxadiazole ring. The phenyl ring is confirmed through three signals appearing
in the aromatic region. One doublet due to the proton H-2ꞌꞌꞌ and H- 6ꞌꞌꞌ appear at the same
chemical shift value, δ (ppm) 7.76. The peak gives the integration of two which indicates
that the signal of one proton overlaps the signal of the other proton due to the symmetry
of the two protons. The J value (7.6 Hz) gives the information about the envoirnment of
the two protons. Presence of sulfonyl group pushed the signal more downfield due to the
deshielding effect arises from the electron withdrawing phenomenon of sulfonyl group.
One triplet at δ (ppm) 7.54 having J = 7.6 Hz and integration of two and one more triplet
having J = 7.6 Hz and integration of one proton are due to, H-3ꞌꞌꞌ & 5ꞌꞌꞌ and H-4ꞌꞌꞌ
respectively. Their J values indicate that the phenyl ring is totally unsubstituted and all
the protons are ortho to one another. There are two more singlets in the aromatic region
indicating the presence of benzodioxole ring. The signals at δ 7.00 (s, 1H, H-2ꞌ) and at δ
6.82 (s, 1H, H-5ꞌ) show the para position of the two protons to one another. A very sharp
and highly downfield signal in the aliphatic region, at δ 5.94 (s, 2H, H-7ꞌ) having the
integration of two protons indicate the presence of methylene group (-CH2), directly
attached to two oxygen atoms and is under the high deshielding effect of electronegative
oxygen atoms thus shifting the signal towards highly downfield aliphatic region. The
compound also contains one piperidine ring which gave a characteristic splitting pattern
of five signals in the aliphatic region. The axial and equatorial protons of the ring are
Results and Discussion
Department of Chemistry, GCU Lahore Page 104
very much clear in the spectrum. The oxadiazole ring, depriving of protons, does not give
any signal in the 1H-NMR spectrum and hence confirmation is made by other spectral
analysis (13C-NMR). The attachment of benzodioxole moiety with 5-substituted
oxadiazole though methylene group, attached to the sulfur atom of the oxadiazole ring, is
confirmed by the signal at δ 4.42 (s, 2H, H-8ꞌ) having integration of two protons in
aliphatic region.The 1H-NMR spectrum is given in figure-1.
The 13C-NMR of 6h is given in the experimental section. The signals at δ/ppm 164.1 and
168.9 corresponded to the two quaternary carbon of oxadiazole ring C-2 and C-5
respectively. The signal for methylenic carbon (attached to sulfur of oxadiazole ring)
appeared at 34.7 and for methlenic carbon, C-7ꞌ (attached to two oxygen atoms), appeared
at δ/ppm 102.0 due to the deshielding effect of oxygen atoms. The four methylenic
carbon atoms of piperidine ring appeared in the form of two signals; one at at δ/ppm 45.1
integrating of two symmetrical carbon atoms C-2ꞌꞌ & C-6ꞌꞌ and at δ/ppm 28.3 integrating
for two other symmetrical carbon atoms C-3ꞌꞌ & C-5ꞌꞌ. The spectyrum of 13C-NMR is
given in figure-2.
The mass fragmentation spectrum and fragmentation pattern of 6h is given in figure-3
&figure-4 respectively in which various peaks confirmed the synthesized compound.
Molecular ion [M]+ peak is absent indicating that the molecule is highly unstable and was
readily fragmentized. The base peak appeared at m/z 169 (100%) for 6-chloro-3,4-
methylenedioxybenzyl cation. The other distinct peaks resonated at m/z 104, 147
corresponding to, epoxy benzyl radical cation and 3,4-methylenedioxyphenyl cyanide
radical cation respectively. A significant peak at m/z 83 corresponded to the piperidine
ring. Phenylsulfonyl and Phenylsulfonylpiperidyl cationic fragments appeared at m/z 141
and 224 respectively. Peak at m/z 68, referred to the oxadiazole ring with significant
abundance. Detail of 13C-NMR and EI-MS data has been given in the experimental
section (chapter-3).
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Figure-1: 1H-NMR of compound 6h
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Figure-2: 13C-NMR of compound 6h
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Figure-3: EIMS spectrum of compound 6h
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Figure-4: Mass fragmentation pattern of compound 6h
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Table-1: 1H-NMR data of compounds, 6a & 6b
1H-NMR (400 MHz, CDCl3) (ppm), Multiplicity, J (Hz)
Proton No. Compounds6a 6b
H-2' 7.08 (s, 1H) 7.11 (s, 1H)
H-5' 6.84 (s, 1H) 6.85 (s, 1H)
H-7' 5.94 (s, 2H) 5.95 (s, 2H)
H-8' 4.52 (s, 2H) 4.55 (s, 2H)
H-2'' 7.42 (d, J = 1.6, 1H) -
H-3'' - 7.91 (dd, J = 8.0, 1.6, 1H)
H-4'' - 7.45 (dt, J = 7.6, 1.2, 1H)
H-5'ꞌ 6.88 (d, J = 8.4, 1H) 7.38 (dt, J = 7.6, 1.6, 1H)
H-6'ꞌ 7.51 (dd, J = 8.0, 1.2, 1H) 7.53 (dd, J = 8.0, 1.6, 1H)
H-7'ꞌ 6.03 (s, 2H) -
N
O
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Cl O
OCl
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Table-2: 1H-NMR data of compounds, 6c & 6d
1H-NMR (400 MHz, CDCl3) (ppm), Multiplicity, J (Hz)
Proton No. Compounds6c 6d
H-2' 7.08 (s, 1H) 7.08 (s, 1H)
H-5' 6.85 (s, 1H) 6.84 (s, 1H)
H-7' 5.95 (s, 2H) 5.95 (s, 2H)
H-8' 4.53 (s, 2H) 4.53 (s, 2H)
H-2'' 7.96 (s, 1H) 7.46 (d, J = 8.8, 2H)*
H-3'' - 7.92 (d, J = 8.4, 2H)**
H-4'' 7.88 (d, J = 7.6, 1H) -
H-5'ꞌ 7.41 (t, J = 8.0, 1H) -
H-6'ꞌ 7.48(d, J = 8.0, 1H) -
* = H-2'' & H-6'ꞌ        ** = H-3'' & H-5''
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Table-3: 1H-NMR data of compounds, 6e & 6f
1H-NMR (400 MHz, CDCl3) (ppm), Multiplicity, J (Hz)
Proton No. Compounds6e 6f
H-2' 7.13 (s, 1H) 7.02 (s, 1H)
H-5' 7.02 (s, 1H) 6.97 (s, 1H)
H-7' 5.95 (s, 2H) 5.94 (s, 2H)
H-8' 4.58 (s, 2H) 4.57 (s, 2H)
H-2'' 7.99 (s, 1H) 7.32-7.24 (m, 5H)*
H-3'' - -
H-4'' 8.35 (d, J = 8.0, 1H) -
H-5'ꞌ 7.92-7.90 (m, 1H) -
H-6'ꞌ 8.17 (d, J = 7.6, 1H) -
H-7'ꞌ - 4.43 (s, 2H)
* = H-2'' to H-6'ꞌ
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Table-4: 1H-NMR data of compounds, 6g & 6h
1H-NMR (400 MHz, CDCl3) (ppm), Multiplicity, J (Hz)
Proton No. Compounds6g 6h
H-2' 7.09 (s, 1H) 7.00 (s, 1H)
H-5' 6.84 (s, 1H) 6.82 (s, 1H)
H-7' 5.94 (s, 2H) 5.94 (s, 2H)
H-8' 4.52 (s, 2H) 4.42 (s, 2H)
H-2''a & 6'' a 7.86 (d, J = 8.0, 2H)* 2.62 (dt, J = 13.2, 2.8, 2H)
H-2''e & 6'' e - 3.71 (brd.d, J = 12.0, 2H)
H-3''a & 5'' a 7.20 (d, J = 8.4, 2H)** 2.00 (dq, J = 10.4, 3.6, 2H)
H-3''e & 5'' e - 2.12 (dd, J = 13.6, 3.6, 2H)
H-4'ꞌ - 2.86-2.81 (m, 1H)
H-7'ꞌ 2.40 (s, 3H) -
H-2''' & 6''' - 7.76 (d, J = 7.6, 2H)
H-3''' & 5''' - 7.54 (t, J = 7.6, 2H)
H-4''' - 7.59 (t, J = 7.6, 1H)
* = H-2'' & H-6'ꞌ       ** = H-3'' & H-5''
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Table-5: 1H-NMR data of compounds, 6i & 6j
1H-NMR (400 MHz, CDCl3) (ppm), Multiplicity, J (Hz)
Proton No. Compounds6i 6j
H-2' 7.09 (s, 1H) 7.10 (s, 1H)
H-5' 6.85 (s, 1H) 6.85 (s, 1H)
H-7' 5.95 (s, 2H) 5.96 (s, 2H)
H-8' 4.55 (s, 2H) 4.53 (s, 2H)
H-2'' 9.20 (s, 1H) -
H-3'' - -
H-4'' 8.27 (d, J = 8.0, 1H) 7.29 (d, J = 2.4, 1H)
H-5'ꞌ 7.43 (t, J = 8.0, 1H) -
H-6'ꞌ 8.74 (d, J = 7.6, 1H) 7.14 (d, J = 2.8, 1H)
H-7'ꞌ - 2.51 (s, 3H)
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Table-6: 1H-NMR data of compounds, 6k & 6l
1H-NMR (400 MHz, CDCl3) (ppm), Multiplicity, J (Hz)
Proton No. Compounds6k 6l
H-2' 6.84 (s, 1H) 6.93 (s, 1H)
H-5' 7.06 (s, 1H) 6.77 (s, 1H)
H-7' 5.94 (s, 2H) 5.92 (s, 2H)
H-8' 4.50 (s, 2H) 4.37 (s, 2H)
H-2'' 7.02 (d, J = 1.6, 1H) 7.44-7.41 (m, 2H)*
H-3'' - -
H-4'' - 8.09 (d, J = 8.4, 1H)
H-5'ꞌ 6.81 (d, J = 8.0, 1H) 7.81 (dd, J = 7.2, 2.0, 1H)
H-6'ꞌ 6.98 (dd, J = 8.0, 1.2, 1H) 7.51 (t, J = 8.0, 1H)
H-7'ꞌ 5.99 (s, 2H) 7.54 (t, J = 7.2, 1H)
H-8'ꞌ 6.79 (d, J = 16.4, 1H) 7.86 (d, J = 8.0, 1H)
H-9'ꞌ 7.35 (d, J = 16.4, 1H) -
H-11'ꞌ - 4.58 (s, 2H)
* = H-2'' & H-3'ꞌ
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Table-7: 1H-NMR data of compounds, 6m & 6n
1H-NMR (400 MHz, CDCl3) (ppm), Multiplicity, J (Hz)
Proton No. Compounds
6m 6n
H-2' 7.06 (s, 1H) 7.09 (s, 1H)
H-5' 6.83 (s, 1H) 6.84 (s, 1H)
H-7' 5.95 (s, 2H) 5.94 (s, 2H)
H-8' 4.49 (s, 2H) 4.53 (s, 2H)
H-2'' & H-6'ꞌ 6.92 (d, J = 8.8, 2H) 7.98 (dd, J = 8.0, 1.2, 2H)
H-3'' & H-5'ꞌ 7.25 (d, J = 8.8, 2H) 7.50-7.45 (m, 3H)*
H-7'' 5.16 (s, 2H) -
*= H-3'' to H-5'ꞌ
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Table-8: 1H-NMR data of compounds, 6o & 6p
* = H-2'' & H-6'ꞌ           ** = H-3'' & H-5''
1H-NMR (400 MHz, CDCl3) (ppm), Multiplicity, J (Hz)
Proton No. Compounds
6o 6p
H-2' 7.84 (s, 1H) 7.12 (s, 1H)
H-5' 7.08 (s, 1H) 6.85 (s, 1H)
H-7' 5.94 (s, 2H) 5.95 (s, 2H)
H-8' 4.51 (s, 2H) 4.53 (s, 2H)
H-2'' 7.91 (d, J = 8.8, 2H)* -
H-3'' 6.98 (d, J = 8.8, 2H)** 7.32 (d, J = 7.6, 1H)
H-4'' - 7.40 (t, J = 7.2, 1H)
H-5'ꞌ - 7.28 (t, J = 7.6, 1H)
H-6'ꞌ - 7.84 (d, J = 7.6, 1H)
H-7'ꞌ 3.85 (s, 3H) 2.67 (s, 3H)
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Table-9: 1H-NMR data of compounds, 6q & 6r
1H-NMR (400 MHz, CDCl3) (ppm), Multiplicity, J (Hz)
Proton No. Compounds6q 6r
H-2' 7.02 (s, 1H) 7.10 (s, 1H)
H-5' 6.85 (s, 17H) 6.85 (s, 1H)
H-7' 5.96 (s, 2H) 5.97 (s, 2H)
H-8' 4.52 (s, 2H) 4.60 (s, 2H)
H-2'' - 8.17 (d, J = 8.8, 2H)*
H-3'' 8.01 (dd, J = 9.2, 1.6, 1H) 8.35 (d, J = 8.8, 2H)**
H-4'' 7.74 (dt, J = 9.2, 2.0, 1H) -
H-5'ꞌ 6.74 (t, J = 7.6, 1H) -
H-6'ꞌ 7.92 (dd, J = 8.8, 1.6, 1H) -
*=H-2'ꞌ & H-6'ꞌ                                    ** = H-3'' & H-5''
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Table-10: 1H-NMR data of compounds, 6s & 6t
1H-NMR (400 MHz, CDCl3) (ppm), Multiplicity, J (Hz)
Proton No. Compounds6s 6t
H-2' 7.12 (s, 1H) 7.10 (s, 1H)
H-5' 6.84 (s, 1H) 6.85 (s, 1H)
H-7' 5.97 (s, 2H) 5.95 (s, 2H)
H-8' 4.62 (s, 2H) 4.53 (s, 2H)
H-3'' - 7.55 (d, J = 2.0, 1H)
H-4'' 8.38 (s, 1H) -
H-5'ꞌ - 7.37 (dd, J = 8.8, 1.6, 1H)
H-6'ꞌ 8.20 (s, 1H) 7.88 (d, J = 8.8, 1H)
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Table-11: 1H-NMR data of compounds, 6u & 6v
1H-NMR (400 MHz, CDCl3) (ppm), Multiplicity, J (Hz)
Proton No. Compounds6u 6v
H-2' 7.12 (s, 1H) 7.13 (s, 1H)
H-5' 6.84 (s, 1H) 6.84 (s, 1H)
H-7' 5.94 (s, 2H) 5.96 (s, 2H)
H-8' 4.51 (s, 2H) 4.62 (s, 2H)
H-2'' & H-6'ꞌ 7.88 (d, J = 8.4, 2H) 8.28 (s, 2H)
H-3'' & H-5'ꞌ 6.91 (d, J = 8.8, 2H) -
H-4'' - 8.31 (s, 1H)
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Table-12: 1H-NMR data of compounds, 6w & 6x
* = H-3'' to H-5''
1H-NMR (CDCl3) (ppm), Multiplicity, J (Hz)
Proton No. Compounds
6w (400 MHz) 6x (500 MHz)
H-2' 7.11 (s, 1H) 7.12 (s, 1H)
H-5' 6.94 (s, 1H) 7.01 (s, 1H)
H-7' 5.95 (s, 2H) 5.94 (s, 2H)
H-8' 4.53 (s, 2H) 4.54 (s, 2H)
H-2''& H-6'ꞌ 7.53 (dd, J = 7.8, 2.1, 2H) 7.53 (d, J = 8.5, 2H)
H-3''& H-5'ꞌ 7.38-7.36 (m, 3H)* 7.19 (d, J = 8.5, 2H)
H-7'' 7.01 (d, J = 16.4, 1H) -
H-8'ꞌ 7.41 (d, J = 16.4, 1H) -
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4.3. Synthesis of 5-(aryl/aralkyl)-2-((6-bromo-3,4-methylenedioxy
benzyl) thio)-1,3,4-Oxadiazole (8a-x)
This particular series involved the synthesis of new oxadiazole derivatives, 5-
(aryl/aralkyl)-2-((6-bromo-3,4-methylene dioxybenzyl)thio)-1,3,4-Oxadiazoles (8a-x).
The reaction of commercially available electrophile (7) with all the oxadiazoles (4a-x)
(already synthesised), gave the products in high yield. The whole reaction methodology
adopted was the same as described in the previous series (6a-x). The electrophile used in
the current series (7), have bromine instead of chlorine which was in the previous
electrophile (5). The series was successfully synthesized and products were obtained in
solid state. Further, they were confirmed by different spectral analysis as 1H-NMR, IR,
13C-NMR and EIMS.
R
N
O
N
SH
+
7
8a-x
5-Substituted-1,3,4
-Oxadiazol-2-thiol
4a-x
5-Substituted-2-((6-bromo-3,4-methylene
dioxyphenyl)methylthio)-1,3,4-oxadiazole
6-bromo-3,4-methylene
dioxybenzylbromide
R
N
O
N
S
Br O
O
Br
Br O
O I
Reagents & condition: (I) DMF, NaH and stir for 3-4 hrs
All the signals exhibited by the series in 1H-NMR, and 13C-NMR spectra fall at nearly the
same range as in the previous one. The cationic fragments in EIMS spectra also match the
fragmentation pattern of the previous compounds. After the confirmation, the compounds
were put for their biological activities. One of the compounds amongst the series is
discussed in detail as follows while 1H-NMR of all the other compounds is given in
tabulated form as under.
The resonating signals of the compound, 5-benzyl-2-((6-bromo-3,4-methylene
dioxybenzyl)thio)-1,3,4-Oxadiazole (8f) in 1H-NMR spectrum are illustrated in figure-5
and the data is given in table-15. The substitution at 5- position of oxadiazole ring is
confirmed by the signals appeared at δ 7.31-7.25 as multiplet, corresponding five protons
of penyl ring. The resonating signals at δ 7.02 and at δ 6.97 as singlets and integration of
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one belongs to the proton H-2ꞌ and H-5ꞌ respectively of benzodioxole moiety. The phenyl
ring is attached to the 5th-position of oxadiazole ring through a methylene group
confirmed by the signal at δ 4.43 in aliphatic region and having integration of two. Other
important signals are expressed in the relative tables.
The 13C-NMR data of 8f is given in the experimental section. The compound contains
three methyenic carbon atoms which were confirmed by three signals at δ/ppm 31.9 for
CH2 group attached to phenyl ring, at δ/ppm 37.3 for CH2 attached to sulfur atom and at
δ/ppm 101.9 for CH2 of benzodioxole ring. The signals at δ/ppm 147.4 and 148.4
corresponded to the two quaternary carbon of oxadiazole ring C-2 and C-5 respectively.
The compound contains seven methyne carbons. The C-2ꞌ and C-5ꞌ gave signals at δ/ppm
111.0 and 112.9 respectively. The phenyl ring attached to the 5th position of oxadiazole
ring showed symmetry so it gave two signals at 128.9 and 133.5 integrating for four
methyne carbons; C-2ꞌꞌ, 3ꞌꞌ, 5ꞌꞌ and 6ꞌꞌ. The methyne carbon C-4ꞌꞌ gives signal separately at
δ/ppm 127.6. The spectrum is displayed in figure-6.
The mass fragmentation spectrum and pattern of 8f is given in figure-7 and figure-8
respectively in which molecular ion [M]+ peak at m/z 405 did not appear but we can
clearly observe a prominent peak at m/z 325 which might be after the removal of bromide
radical from the parent molecule. This peak is also called as the base peak with 100%
abundance. There were two very important and distinct peaks at m/z 213 and 215 in the
spectra for 6-bromo-3,4-methylenedioxybenzyl cation. These two peaks for a single
fragment with the difference of two mass units and almost the same relative abundance
was the indication of the presence of isotopic bromine. There were some other peaks in
the spectra following the same difference of two mass units as well as relative abundance
between them, corresponding to those cationic fragments which contain isotopic bromine.
A very common and important peak at m/z 91 indicated the presence of benzyl cation
which is readily converted into a well known rearranged cationic fragment, (tropylium)
through an intramolecular rearrangement mechanism, frequently met in fragmentation
patterns. The other detailed signals in the 13C-NMR and EI-MS spectra have been given
in the experimental section (chapter-3).
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Figure-5: 1H-NMR spectrum of compound 8f
Figure-6: 13C-NMR of compound 8f
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Figure-7: EIMS spectrum of compound 8f
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Figure-8: Mass fragmentation pattern of the synthesized compound 8f
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Table-13: 1H-NMR data of compounds, 8a & 8b
1H-NMR (CDCl3) (ppm), Multiplicity, J (Hz)
Proton No. Compounds
8a (300 MHz) 8b (500 MHz)
H-2' 7.00 (s, 1H) 7.15 (s, 1H)
H-5' 7.12 (s, 1H) 7.01 (s, 1H)
H-7' 6.03 (s, 2H) 5.95 (s, 2H)
H-8' 4.52 (s, 2H) 4.55 (s, 2H)
H-2'' 7.42 (d, J = 1.2, 1H) -
H-3'' - 7.91 (dd, J = 8.0, 1.5, 1H)
H-4'' - 7.45 (dt, J = 7.5, 1.5, 1H)
H-5'ꞌ 6.88 (d, J = 8.1, 1H) 7.38 (dt, J = 7.5, 1.0, 1H)
H-6'ꞌ 7.51 (dd, J = 8.1, 1.2, 1H) 7.53 (dd, J = 8.0, 1.0, 1H)
H-7'ꞌ 5.94 (s, 2H) -
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Table-14: 1H-NMR data of compounds, 8c & 8d
* = H-2'' & H-6'ꞌ       ** = H-3'' & H-5''
1H-NMR (CDCl3) (ppm), Multiplicity, J (Hz)
Proton No. Compounds
8c (400 MHz) 8d (500 MHz)
H-2' 7.08 (s, 1H) 7.11 (s, 1H)
H-5' 6.84 (s, 1H) 7.00 (s, 1H)
H-7' 5.95 (s, 2H) 5.94 (s, 2H)
H-8' 4.53 (s, 2H) 4.53 (s, 2H)
H-2'' 7.96 (s, 1H) 7.45 (d, J = 8.0, 2H)*
H-3'' - 7.90 (d, J = 8.0, 2H)**
H-4'' 7.88 (d, J = 7.6, 1H) -
H-5'ꞌ 7.41 (t, J = 8.0, 1H) -
H-6'ꞌ 7.48(d, J = 8.0, 1H) -
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Table-15: 1H-NMR data of compounds, 8e & 8f
1H-NMR (CDCl3) (ppm), Multiplicity, J (Hz)
Proton No. Compounds8e (400 MHz) 8f (300 MHz)
H-2' 7.13 (s, 1H) 7.02 (s, 1H)
H-5' 7.02 (s, 1H) 6.97 (s, 1H)
H-7' 5.95 (s, 2H) 5.94 (s, 2H)
H-8' 4.58 (s, 2H) 4.55 (s, 2H)
H-2'' 7.99 (s, 1H) 7.31-7.25 (m, 5 H)*
H-4'' 8.35 (d, J = 7.6, 1H) -
H-5'ꞌ 7.92 -7.90 (m, 1H) -
H-6'ꞌ 8.17 (d, J = 7.2, 1H) -
H-7'ꞌ - 4.43 (s, 2H)
*= H-2'' to H-6'ꞌ
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Table-16: 1H-NMR data of compounds, 8g & 8h
* = H-2'' & H-6'ꞌ      ** = H-3'' & H-5''
1H-NMR (CDCl3) (ppm), Multiplicity, J (Hz)
Proton No. Compounds8g (400 MHz) 8h (500 MHz)
H-2' 7.12 (s, 1H) 7.04 (s, 1H)
H-5' 7.00 (s, 1H) 6.98 (s, 1H)
H-7' 5.95 (s, 2H) 5.94 (s, 2H)
H-8' 4.54 (s, 2H) 4.43 (s, 2H)
H-2''a & 6''a 7.52 (d, J = 8.4, 2H)* 2.60 (dt, J = 12.0, 2.0, 2H)
H-2''e & 6''e - 3.70 (dd, J = 8.5, 4.0, 2H)
H-3''a & 5''a 7.20 (d, J = 8.4, 2H)** 1.98 (dq, J = 11.0, 4.0, 2H)
H-3''e & 5''e - 2.11 (dd, J = 13.5, 3.0, 2H)
H-4'ꞌ - 2.85-2.80 (m, 1H)
H-7'ꞌ 2.34 (s, 3H) -
H-2''' & 6''' - 7.75 (d, J = 7.0, 2H)
H-3''' & 5''' - 7.60 (t, J = 8.0, 2H)
H-4''' - 7.59 (t, J = 7.5, 1H)
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Table-17: 1H-NMR data of compounds, 8i & 8j
1H-NMR (400 MHz, CDCl3) (ppm), Multiplicity, J (Hz)
Proton No. Compounds8i 8j
H-2' 7.06 (s, 1H) 7.10 (s, 1H)
H-5' 6.85 (s, 1H) 6.84 (s, 1H)
H-7' 5.95 (s, 2H) 5.96 (s, 2H)
H-8' 4.55 (s, 2H) 4.53 (s, 2H)
H-2'' 9.19 (s, 1H) -
H-3'' - -
H-4'' 8.25 (d, J = 8.0, 1H) 7.28 (d, J = 2.4, 1H)
H-5'ꞌ 7.43 (t, J = 8.0, 1H) -
H-6'ꞌ 8.76 (d, J = 8.4, 1H) 7.14 (d, J = 2.8, 1H)
H-7'ꞌ - 2.51 (s, 3H)
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Table-18: 1H-NMR data of compounds, 8k & 8l
* = H-6'' & H-7'ꞌ
1H-NMR (400 MHz, CDCl3) (ppm), Multiplicity, J (Hz)
Proton No. Compounds8k 8l
H-2' 7.06 (s, 1H) 6.97 (s, 1H)
H-5' 6.84 (s, 1H) 6.94 (s, 1H)
H-7' 5.94 (s, 2H) 5.92 (s, 2H)
H-8' 4.50 (s, 2H) 4.58 (s, 2H)
H-2'' 7.02 (d, J = 1.6, 1H) 7.42 (dd, J = 8.4, 2.0,1H)
H-3'' - 7.80 (t, J = 7.2, 1H)
H-4'' - 7.87 (dd, J = 8.0, 2.0, 1H)
H-5'ꞌ 6.81 (d, J = 8.0, 1H) 7.46 (dd, J = 8.0, 2.0, 1H)
H-6'ꞌ 6.98 (dd, J = 8.0, 1.2, 1H) 7.55-7.49 (m, 2H)*
H-7'ꞌ 5.99 (s, 2H) -
H-8'ꞌ 6.79 (d, J = 16.4, 1H) 8.10 (d, J = 8.4, 1H)
H-9'ꞌ 7.35 (d, J = 16.4, 1H) -
H-11'ꞌ - 4.38 (s, 2H)
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Table-19: 1H-NMR data of compounds, 8m & 8n
1H-NMR (CDCl3) (ppm), Multiplicity, J (Hz)
Proton No. Compounds
8m (300 MHz) 8n (500 MHz)
H-2' 7.06 (s, 1H) 7.13 (s, 1H)
H-5' 6.99 (s, 1H) 7.01 (s, 1H)
H-7' 5.95 (s, 2H) 5.94 (s, 2H)
H-8' 4.49 (s, 2H) 4.54 (s, 2H)
H-2'' & H-6'ꞌ 6.93 (dd, J = 7.2, 2.1, 2H) 7.98 (dd, J = 7.5, 1.0, 2H)
H-3'' & H-5'ꞌ 7.25 (dd, J = 7.2, 2.1, 2H) 7.49-7.45 (m, 3H)*
H-7'' 5.16 (s, 2H) -
*= H-3'' to H-5'ꞌ
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Table-20: 1H-NMR data of compounds, 8o & 8p
* = H-2'' & H-6'ꞌ      ** = H-3'' & H-5''
1H-NMR (CDCl3) (ppm), Multiplicity, J (Hz)
Proton No. Compounds
8o (300 MHz) 8p (400 MHz)
H-2' 7.00 (s, 1H) 7.10 (s, 1H)
H-5' 7.12 (s, 1H) 6.85 (s, 1H)
H-7' 5.94 (s, 2H) 5.95 (s, 2H)
H-8' 4.52 (s, 2H) 4.53 (s, 2H)
H-2'' 7.92 (d, J = 8.7, 2H)* -
H-3'' 6.98 (d, J = 8.7, 2H)** 7.31 (d, J = 7.6, 1H)
H-4'' - 7.39 (t, J = 7.2, 1H)
H-5'ꞌ - 7.28 (t, J = 7.6, 1H)
H-6'ꞌ - 7.80 (d, J = 7.6, 1H)
H-7'ꞌ 3.85 (s, 3H) 3.78 (s, 3H)
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Table-21: 1H-NMR data of compounds, 8q & 8r
1H-NMR (300 MHz, CDCl3) (ppm), Multiplicity, J (Hz)
Proton No. Compounds
8q 8r
H-2' 7.11 (s, 1H) 7.12 (s, 1H)
H-5' 7.00 (s, 1H) 7.01 (s, 1H)
H-7' 5.94 (s, 2H) 5.94 (s, 2H)
H-8' 4.53 (s, 2H) 4.54 (s, 2H)
H-2'' - 7.19 (d, J = 8.1, 2H)*
H-3'' 8.01 (dd, J = 7.2, 2.4, 1H) 7.94 (d, J = 8.4, 2H)**
H-4'' 7.32 (t, J = 7.5, 1H) -
H-5'ꞌ 6.88 (t, J = 7.5, 1H) -
H-6'ꞌ 7.92 (dd, J = 7.5, 2.7, 1H) -
*= H-2'' & H-6'ꞌ      ** = H-3'' & H-5''
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Table-22: 1H-NMR data of compounds, 8s & 8t
1H-NMR (400 MHz, CDCl3) (ppm), Multiplicity, J (Hz)
Proton No. Compounds
8s 8t
H-2' 7.13 (s, 1H) 7.10 (s, 1H)
H-5' 6.85 (s, 1H) 6.85 (s, 1H)
H-7' 5.95 (s, 2H) 5.95 (s, 2H)
H-8' 4.54 (s, 2H) 4.53 (s, 2H)
H-3'' - 7.56 (d, J = 2.0, 1H)
H-4'' 8.34 (s, 1H) -
H-5'ꞌ - 7.35 (dd, J = 8.8, 1.6, 1H)
H-6'ꞌ 8.16 (s, 1H) 7.89 (d, J = 8.8, 1H)
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Table-23: 1H-NMR data of compounds, 8u & 8v
1H-NMR (400 MHz, CDCl3) (ppm), Multiplicity, J (Hz)
Proton No. Compounds8u 8v
H-2' 7.12 (s, 1H) 7.12 (s, 1H)
H-5' 6.00 (s, 1H) 6.84 (s, 1H)
H-7' 5.94 (s, 2H) 5.96 (s, 2H)
H-8' 4.54 (s, 2H) 4.62 (s, 2H)
H-2'' & H-6'ꞌ 7.88 (d, J = 8.4, 2H) 8.27 (s, 2H)
H-3'' & H-5'ꞌ 6.92 (d, J = 8.8, 2H) -
H-4'' - 8.30 (s, 1H)
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Table-24: 1H-NMR data of compounds, 8w & 8x
* = H-3'' to H-5''
1H-NMR (CDCl3) (ppm), Multiplicity, J (Hz)
Proton No. Compounds8w (300 MHz) 8x (500 MHz)
H-2' 7.11 (s, 1H) 7.12 (s, 1H)
H-5' 6.94 (s, 1H) 7.01 (s, 1H)
H-7' 5.95 (s, 2H) 5.94 (s, 2H)
H-8' 4.53 (s, 2H) 4.54 (s, 2H)
H-2'' & H-6'ꞌ 7.53 (dd, J = 7.8, 2.1, 2H) 7.53 (d, J = 8.5, 2H)
H-3'' & H-5'ꞌ 7.38-7.36 (m, 3H)* 7.19 (d, J = 8.5, 2H)
H-7'' 7.01 (d, J = 4.8, 1H) -
H-8'ꞌ 7.41 (d, J = 5.1, 1H) -
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4.4. Synthesis of N-[3,4-methylenedioxybenzyl]-2-[(5-substituted-1,3,4-
oxadiazol-2-yl)thio]acetamide (12a-t)
In this series, first of all, an electrophile, 2-bromo-N-(3, 4-methylenedioxy benzyl)
acetamide (11), was synthesized by treating 3,4-methylenedioxy benzylamine (9) with 2-
bromoacetyl bromide (10) taking equimolar quantities of both in a basic medium on
vigorous shaking. The product was obtained as precipitates which were filtered, washed
and dried for further use.
I
3,4-methylenedioxy
benzylamine 9 11
O
ON
H
Br
O
O
OH2N
2-bromo-N-[3,4-methylene
dioxybenzyl]acetamide
Br
O
Br
+
10
Bromoacetyl bromide
Reagents & condition: (I) Aqueous Na2CO3 solution, stir for ½ hr
After the formation of 2-bromo-N-(3,4-methylenedioxybenzyl)acetamide (11), it was
further utilized  to complete the series (12a-t) by treating it with different  5-substituted
oxadiazoles (4a-x) which were already synthesized. The reactions were carried out in
DMF using NaH as a base. The products were obtained in good yield as precipitates.
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+
Reagents & condition: (I) DMF, NaH and stir for 4-5 hrs.
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The purity of all the synthesized compounds was checked by TLC on silica gel and
structure elucidations were made by different spectral techniques i-e IR, 1H-NMR, 13C-
NMR, EI-MS. IR spectra represents the presence of following bands for different
functional groups; aromatic C-H stretching at around 3010-3040 cm-1, C=N stretching at
about 1600-1625 cm-1, C=C stretching ranging 1460-1480 cm-1 while C-O-C stretching
arises around 1225-1250 and 1050-1070 cm-1.
The 1H-NMR spectrum display the following splitting pattern for the synthesized
compounds in general. 3,4-methylenedioxy benzyl ring is trisubstituted; at 1', 3' and 4'
positions, so the remaining three protons, 2', 5' and 6' positions  gave the signal at δ (ppm)
6.70-6.68 in the aromatic region as a broad signal for two protons and a singlet for one
proton. The 5-substituted phenyl rings of different oxadiazoles exhibited their
characteristic resonating signals in the range of at δ (ppm) 7.51-7.42. The doublet at δ
(ppm) 4.35 in the aliphatic region having J value 5.7, due to germinal coupling and
integration of two indicated the presence of methylene group (-CH2) of sulfur which joins
the two moieties (benzodioxole moiety and oxadiazole moiety) together as one molecule.
The high downfield signal is due to the neighboring carbonyl group (-C=O) which
deshielded the two protons. The detailed description of one of the compounds in the
series is as follows.
The 1H-NMR spectrum of the compound, N-[3,4-methylenedioxybenzyl]-2-[(5-(2-
methylphenyl)-1,3,4-oxadiazol-2-yl)thio]acetamide, 12p is presented in figure-9 and its
data is given in table-31. The compound showed one doublet at δ (ppm) 7.84 (J = 7.7Hz,
1H, H-6'''), one triplet at δ (ppm) 7.42 (J = 7.3Hz, 1H, H-5'''), one doublet at δ (ppm) 7.32
(J = 7.7, 1H, H-3''') and one more triplet at δ (ppm) 7.30 (J = 7.4, 1H, H-4''') in aromatic
region indicating the presence of ortho substituted phenyl ring. There is one more signal
in aromatic region appeared at δ (ppm) 6.70 and 6.68 as a singletand a broad signal due to
three protons of  benzodioxole ring, H-2', H-5' and H-6'. The compound contains three
methylene groups and one methyl group. One methyl group gives signal in aliphatic
region at δ (ppm) 2.65 having integration of three protons. The methylene group attached
to sulfur atom appeared at δ (ppm) 4.35 (d, J = 5.7, 2H), quite downfield due to the
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electron withdrawing carbonyl group (C=O) present in the neighborhood. One more
methylene group attached to (NH) gives signal at δ (ppm) 3.91 as singlet integrating two
protons. The methylene group present in between two oxygen atoms is confirmed by a
signal in aliphatic region highly downfield at δ (ppm) 5.84 as a singlet. The oxadiazole
ring is confirmed by the 13C-NMR analysis.
In 13C-NMR analysis, the compound 12p, gives seven very clear signals for seven
methyne carbons (CH) present in the molecule in DEPT 90 region of the spectra. There
are three methylene carbons which are expressed by three signals in DEPT 135 region.
One methyl carbon is confirmed by a signal appeared at δ (ppm) 22.0. The two
quaternary carbons of oxadiazole ring are expressed by the two signals at 167.0 and 166.5
for C-2'' and C-5'' respectively. The whole spectral detail has been given in the
experimental section while the specytrum is given in figure-10.
Figure-9: 1H-NMR of compound 12p
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Figure-10: 13C-NMR of compound 12p
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Table-25: 1H-NMR data of compounds, 12a, 12b & 12c
1H-NMR (600 MHz, CDCl3)  (ppm), Multiplicity, J (Hz)
Proton No. Compounds
12a 12b 12c
H-2 4.35 (d, J = 5.7, 2H) 4.35 (d, J = 5.7, 2H) 4.35 (d, J = 5.7, 2H)
H-2' 6.70 (s, 1H) 6.70 (s, 1H) 6.70 (s, 1H)
H-5' & H-6' 6.68 (brd.s, 2H) 6.68 (brd.s, 2H) 6.68 (brd.s, 2H)
H-7' 5.84 (s, 2H) 5.84 (s, 2H) 5.84 (s, 2H)
H-8' 3.91 (s, 2H) 3.91 (s, 2H) 3.91 (s, 2H)
H-2''' 7.42 (d, J = 1.6, 1H) - 7.96 (s, 1H)
H-3''' - 7.91 (dd, J = 8.0, 1.6, 1H) -
H-4''' - 7.45 (dt, J = 7.6, 1.2, 1H) 7.88 (d, J = 7.6, 1H)
H-5''' 6.88 (d, J = 8.4, 1H) 7.38 (dt, J = 7.6, 1.6, 1H) 7.41 (t, J = 8.0, 1H)
H-6''' 7.51 (dd, J = 8.0, 1.2,1H, 7.53 (dd, J = 8.0, 1.6, 1H)
7.48 (d, J = 8.0, 1H)
H-7''' 6.03 (s, 2H) - -
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Table-26: 1H-NMR data of compounds, 12d, 12e & 12f
* = H-2ꞌꞌꞌ & H-6ꞌꞌꞌ         ** = H-3ꞌꞌꞌ & H-5ꞌꞌꞌ          *** = H-2ꞌꞌꞌ to H-6ꞌꞌꞌ
1H-NMR (600 MHz, CDCl3)  (ppm), Multiplicity, J (Hz)
Proton No. Compounds
12d 12e 12f
H-2 4.35 (d, J = 5.7, 2H) 4.35 (d, J = 5.7, 2H) 4.35 (d, J = 5.7, 2H)
H-2' 6.70 (s, 1H) 6.70 (s, 1H) 6.70 (s, 1H)
H-5' & H-6' 6.68 (brd.s, 2H) 6.68 (brd.s, 2H) 6.68 (brd.s, 2H)
H-7' 5.84 (s, 2H) 5.84 (s, 2H) 5.84 (s, 2H)
H-8' 3.91 (s, 2H) 3.91 (s, 2H) 3.91 (s, 2H)
H-2''' 7.46 (d, J = 8.8, 2H)* 7.99 (s, 1H) 7.32-7.24 (m, 5H)***
H-3''' 7.92 (d, J = 8.4, 2H)** - -
H-4''' - 8.35 (d, J = 8.0, 1H) -
H-5''' - 7.92-7.90 (m, 1H) -
H-6''' - 8.17 (d, J = 7.6, 1H) -
H-7''' - - 4.43 (s, 2H)
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Table-27: 1H-NMR data of compounds, 12g, & 12i
* = H-2ꞌꞌꞌ & H-6ꞌꞌꞌ ** = H-3ꞌꞌꞌ & H-5ꞌꞌꞌ
1H-NMR (600 MHz, CDCl3)  (ppm), Multiplicity, J (Hz)
Proton No. Compounds
12g 12i
H-2 4.34 (d, J = 5.6, 2H) 4.34 (d, J = 5.6, 2H)
H-2' 7.09 (s, 1H) 7.09 (s, 1H)
H-5' & H-6' 6.68 (brd.s, 2H) 6.67 (brd.s, 2H)
H-7' 5.84 (s, 2H) 5.84 (s, 2H)
H-8' 3.90 (s, 2H) 3.90 (s, 2H)
H-2''' 7.86 (d, J = 8.0, 2H)* 9.20 (s, 1H)
H-3''' 7.28 (d, J = 8.4, 2H)** -
H-4''' - 8.27 (d, J = 8.0, 1H)
H-5''' - 7.37 (dd, J = 8.8, 1.6, 1H)
H-6''' - 7.88 (d, J = 8.8, 1H)
H-7''' 2.40 (s, 3H) -
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Table-28: 1H-NMR data of compounds, 12h
1H-NMR (600 MHz, CDCl3)  (ppm), Multiplicity, J (Hz)
Proton No. Compounds
12h
H-2 4.34 (d, J = 5.6, 2H)
H-2' 7.09 (s, 1H)
H-5' & H-6' 6.68 (brd.s, 2H)
H-7' 5.84 (s, 2H)
H-8' 3.90 (s, 2H)
H-2'''a & H-6'''a 2.57 (dt, J = 6.8, 2.0, 2H)
H-2'''e & H-6'''e 3.70 (dt, J = 7.6, 4.0, 2H)
H-3'''a & H-5'''a 1.97 (dq, J = 14.2, 3.6, 2H)
H-3'''e & H-5'''e 2.11 (dd, J = 13.5, 2.7, 2H)
H-4''' 2.83-2.80 (m, 1H)
H-2''''  & H-6'''' 7.76 (d, J = 7.6, 2H)
H-3''''  & H-5'''' 7.54 (t, J = 7.6, 2H)
H-4'''' 7.59 (t, J = 7.6, 1H)
Results and Discussion
Department of Chemistry, GCU Lahore Page 136
12j
1
2
1'''3'''
5'''
1' 3'
5'
1''
3''
5'' 7'
N
O
N
S
O2N
8'
H
N O
O
O
CH3
NO2
7'''
12k
1
2 1' 3'
5'
1''
3''
5''
7'
N
O
N
S 8'
H
N O
O
O
1'''3'''
5'''
O
O
8'''
9'''7'''
12l
1
21'''3'''
5'''
1' 3'
5'
1''
3''
5'' 7'
N
O
N
S 8'
H
N O
O
O
7'''
9'''
11'''
Table-29: 1H-NMR data of compounds, 12j, 12k & 12l
1H-NMR (600 MHz, CDCl3)  (ppm), Multiplicity, J (Hz)
Proton No. Compounds
12j 12k 12l
H-2 4.34 (d, J = 5.6, 2H) 4.35 (d, J = 5.7, 2H) 4.35 (d, J = 5.7, 2H)
H-2' 7.09 (s, 1H) 6.70 (s, 1H) 6.70 (s, 1H)
H-5' & H-6' 6.67 (brd.s, 2H) 6.68 (brd.s, 2H) 6.68 (brd.s, 2H)
H-7' 5.84 (s, 2H) 5.84 (s, 2H) 5.84 (s, 2H)
H-8' 3.90 (s, 2H) 3.91 (s, 2H) 3.91 (s, 2H)
H-2''' - 7.02 (d, J = 1.6, 1H) 7.42 (s, 1H)
H-3''' - - 7.81 (d, J = 9.2, 1H)
H-4''' 7.29 (d, J = 2.4, 1H) - 7.43 (d, J = 6.0, 1H)
H-5''' - 6.81 (d, J = 8.0, 1H) 7.86 (d, J = 8.0, 1H)
H-6''' 7.14 (d, J = 2.8, 1H) 6.98 (dd, J = 8.0, 1.2,1H)
7.51 (t, J = 8.0, 1H)
H-7''' 2.51 (s, 3H) 5.99 (s, 2H) 7.54 (t, J = 7.2, 1H)
H-8''' - 6.79 (d, J = 16.4, 1H) 8.09 (d, J = 8.4, 1H)
H-9''' - 7.35 (d, J = 16.4, 1H) -
H-11''' - - 3.58 (s, 2H)
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Table-30: 1H-NMR data of compounds, 12m, 12n & 12o
1H-NMR (600 MHz, CDCl3)  (ppm), Multiplicity, J (Hz)
Proton No. Compounds
12m 12n 12o
H-2 4.35 (d, J = 5.7, 2H) 4.35 (d, J = 5.7, 2H) 4.34 (d, J = 5.6, 2H)
H-2' 6.70 (s, 1H) 6.70 (s, 1H) 7.09 (s, 1H)
H-5' & H-6' 6.68 (brd.s, 2H) 6.68 (brd.s, 2H) 6.67 (brd.s, 2H)
H-7' 5.84 (s, 2H) 5.84 (s, 2H) 5.84 (s, 2H)
H-8' 3.91 (s, 2H) 3.91 (s, 2H) 3.90 (s, 2H)
H-2''' & H-6''' 6.92 (d, J = 8.8, 2H) 7.98 (dd, J = 8.0, 1.2,1H) 7.91 (d, J = 8.0, 2H)
H-3''' & H-5''' 7.25 (d, J = 8.8, 2H) 7.50-7.45 (m, 3H)* 6.98 (d, J = 8.4, 2H)
H-4''' - - -
H-7''' 3.58 (s, 2H) - 2.40 (s, 3H)
H-8''' - - -
* = H-3ꞌꞌꞌ to H-5ꞌꞌꞌ
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Table-31: 1H-NMR data of compounds, 12p, 12q & 12r
1H-NMR (600 MHz, CDCl3)  (ppm), Multiplicity, J (Hz)
Proton No. Compounds
12p 12q 12r
H-2 4.35 (d, J = 5.7, 2H) 4.35 (d, J = 5.7, 2H) 4.35 (d, J = 5.7, 2H)
H-2' 6.70 (s, 1H) 6.70 (s, 1H) 6.70 (s, 1H)
H-5' & H-6' 6.68 (brd.s, 2H) 6.68 (brd.s, 2H) 6.67 (brd.s, 2H)
H-7' 5.84 (s, 2H) 5.84 (s, 2H) 5.84 (s, 2H)
H-8' 3.91 (s, 2H) 3.91 (s, 2H) 3.91 (s, 2H)
H-2''' - - 8.17 (d, J = 8.8, 2H)*
H-3''' 7.32 (d, J = 7.7, 1H) 8.01 (dd, J = 9.2, 1.6, 1H) 8.35 (d, J = 8.8, 2H)**
H-4''' 7.30 (t, J = 7.4, 1H) 7.74 (dt, J = 9.2, 2.0, 1H) -
H-5''' 7.42 (t, J = 7.3, 1H) 6.74 (t, J = 7.6, 1H) -
H-6''' 7.84 (d, J = 7.7, 1H) 7.92 (dd, J = 8.8, 1.6, 1H) -
H-7''' 2.65 (s, 3H) - -
* = H-2ꞌꞌꞌ & H-6ꞌꞌꞌ         ** = H-3ꞌꞌꞌ & H-5ꞌꞌꞌ
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Table-32: 1H-NMR data of compounds, 12s & 12t
1H-NMR (600 MHz, CDCl3) (ppm), Multiplicity, J (Hz)
Proton No. Compounds
12s 12t
H-2 4.34 (d, J = 5.6, 2H) 4.34 (d, J = 5.6, 2H)
H-2' 7.09 (s, 1H) 7.09 (s, 1H)
H-5' & H-6' 6.67 (brd.s, 2H) 6.67 (brd.s, 2H)
H-7' 5.84 (s, 2H) 5.84 (s, 2H)
H-8' 3.90 (s, 2H) 3.90 (s, 2H)
H-3''' - 7.55 (d, J = 2.0, 1H)
H-4''' 8.38 (s, 1H) -
H-5''' - 7.37 (dd, J = 8.8, 1.6, 1H)
H-6''' 8.20 (s, 1H) 7.88 (d, J = 8.8, 1H)
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4.5. Synthesis of different N-substituted-2-bromoacetamides (14a-t)
A series of different electrophiles, N-substituted-2-bromoacetamide (14a-t) were
synthesized by the reaction of equimolar mixture of N-substituted amines (13a-t) and 2-
bromoacetyl bromide (10) in a basic aqueous medium.
R1H2N
I Br
N
H
O
N-Substitued-2-bromoacetamideDifferent N-substituted amines
13a-t 14a-t
R1
Reagents & conditions: (I) 2-bromoacetyl bromide (10), H2O, 5% Na2CO3 soln, stirring for 1
hour
The products were obtained as solid precipitates which were filtered washed and dried
for further use.
4.6. Synthesis of N-substituted-2-{(5-(3,4-methylenedioxy)phenyl-1,3,4-
Oxadiazol-2-yl) sulfanyl}acetamide derivatives (15a-t)
N-Substituted-2-((5-(3,4-methylenedioxyphenyl)-1,
3,4-oxadizole-2-yl)thio)acetamide
Br
N
H
O
R1
15a-t
N-Substitued-2-bromoacetamide
14a-t
I
O
O
5-(3,4-methylenedioxyphenyl)-1
,3,4-oxadiazol-2-thiol 4a
N
O
N
SH
O
O
N
O
N
S
H
N
R1
O
Reagents & conditions: (I) DMF, NaH, stirring for 3-4 hours
The series involved the synthesis of some new biologically active compounds (15a-t) by
treating 5-(3,4-methylene dioxyphenyl)1,3,4-oxadiazol-2-thiol (4a) with different
presynthesised acetamides (14a-t). The product purity was checked by TLC on silica gel
using appropriate solvent systems. All the products were obtained in solid state as pure
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compounds. Different spectral data, including 1H-NMR, 13C-NMR, IR and EI-MS,
supports the formation of new acetamide derivatives (15a-t).
The 1H-NMR spectra showed a very clear peak at around δ/ppm 9.81 as singlet and
having integration of one. This particular peak indicates the presence of amide linkage (-
CONH) within the molecule. The other resonating signals confirmed the presence of
benzodioxole moiety as well as different substituted phenyl rings. One of the compounds
(15a), has been discussed in detail as follows while 1H-NMR data of the whole series is
represented in tabulated form in the coming pages.
The compound 15a, N-(2,3-dimethyl phenyl-2-{(5-(3,4-methylenedioxy)phenyl-1,3,4-
Oxadiazol-2-yl) sulfanyl}acetamide, gave different resonating signals in aromatic as well
as aliphatic region of the 1H-NMR spectrum given in figure-11, confirming the
synthesized compound. The data is given in table-33. The important signal at 9.80 (s, 1H)
confirmed the presence of amide linkage in the molecule. The three protons, H-2', H-5'
and H-6' of benzodioxole ring appeared at δ/ppm 7.45 (s, 1H), 7.52 (d, J = 7.3, 1H) and
7.12 (s, 1H) respectively in the aromatic region. The two methylenic protons sandwitched
between two oxygen atoms of benzodioxole moiety appear in highly downfield aliphatic
region due to the electronegative oxygen atoms. On the other hand, one phenyl ring
substituted at 2 and 3 position with two methyl groups also gives three resonating signals
in the aromatic region. The protons H-4''', H-5''' and H-6''' give signals at δ/ppm 7.01 (d, J
= 7.0, 1H), 7.04 (t, J = 7.6, 1H) and 7.11 (d, J = 7.9, 1H) respectively. One methylene
attached to sulfur and two methyl groups attached to the phenyl ring appear as three
singlets in the aliphatic region at δ/ppm 4.31 (s, 2H), 2.22 (s, 3H) and 2.04 (s, 3H)
respectively.
In 13C-NMR spectrum of the compound 15a, displayed in figure-12, the two methyl
carbons appear at δ/ppm 20.1 and 13.9 for C-7''' and C-8''' respectively. There are two
methylene carbons in the molecule represented by the signal at δ/ppm 36.1 for C-2'' and
at δ/ppm 102.1 for C-7'. The six very significant signals for all the six methyne carbons
within the molecule lie in the range δ/ppm 106.1-127.2. The two quaternary carbon atoms
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of oxadiazole ring C-2 and C-5 are shown by the two signals, at δ/ppm 165.1 and 164.9
respectively. The detailed spectral data has been given in experimental section.
Figure-11: 1H-NMR of compound 15a
Figure-12: 13C-NMR of compound 15a
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Table-33: 1H-NMR data of compounds, 15a, 15b & 15c
* = H-6' & H-6'''
1H-NMR (600 MHz, CDCl3)  (ppm), Multiplicity, J (Hz)
Proton No. Compounds
15a 15b 15c
-CON-H 9.80 (s, 1H) 9.80 (s, 1H) 9.81 (s, 1H)
H-2' 7.45 (s, 1H) 7.45 (s, 1H) 7.43 (s, 1H)
H-5' 7.52 (d, J = 7.3, 1H) 7.52 (d, J = 7.5, 1H) 7.50 (d, J = 7.6, 1H)
H-6' 7.12-7.11 (m, 2H)* 7.12 (d, J = 7.5, 1H) 7.15 (d, J =7.6, 1H)
H-7' 6.14 (s, 2H) 6.13 (s, 2H) 6.14 (s, 2H)
H-2'' 4.31 (s, 2H) 4.30 (s, 2H) 4.32 (s, 2H)
H-3''' - 7.00 (s, 1H) 7.05 (d, J = 7.6, 1H)
H-4''' 7.01 (d, J = 7.0, 1H) - 7.07 (d, J = 7.8, 1H)
H-5''' 7.04 (t, J = 7.6, 1H) 7.04 (d, J = 7.6, 1H) -
H-6''' - 7.06 (d, J = 7.6, 1H) 7.01 (d, J = 7.6, 1H)
H-7''' 2.22 (s, 3H) 2.23 (s, 3H) 2.26 (s, 3H)
H-8''' 2.04 (s, 3H) 2.04 (s, 3H) 2.04 (s, 3H)
Results and Discussion
Department of Chemistry, GCU Lahore Page 144
15d
1''' 3'''
5'''
1'3'
5'
1''
2''
7'
7'''
5
1
3
N
O
N
S
O
O
H
N
O
CH3
8'''
H3C
15e
1''' 3'''
5'''
1'3'
5'
1''
2''
7'
7'''5
1
3
N
O
N
S
O
O
H
N
O
8'''
CH3
CH3
15f
1''' 3'''
5'''
1'3'
5'
1''
2''
7'
5
1
3
N
O
N
S
O
O
H
N
O
Table-34: 1H-NMR data of compounds, 15d, 15e & 15f
*= H-3''' to H-5''' **= H-2''' & H-6''' ***= H-2''' to H-6'''
1H-NMR (600 MHz, CDCl3)  (ppm), Multiplicity, J (Hz)
Proton No. Compounds
15d 15e 15f
-CON-H 9.82 (s, 1H) 9.80 (s, 1H) 9.81 (s, 1H)
H-2' 7.45 (s, 1H) 7.45 (s, 1H) 7.43 (s, 1H)
H-5' 7.52 (d, J = 7.3, 1H) 7.52 (d, J = 7.5, 1H) 7.50 (d, J = 7.6, 1H)
H-6' 7.12 (d, J = 7.3, 1H) 7.12 (d, J = 7.5, 1H) 7.15 (d, J =7.6, 1H)
H-7' 6.14 (s, 2H) 6.14 (s, 2H) 6.14 (s, 2H)
H-2'' 4.31 (s, 2H) 4.30 (s, 2H) 4.32 (s, 2H)
H-2''' - 7.16 (s, 2H)** 7.38-7.24 (m, 5H)***
H-3''' 7.05-7.02 (m, 3H)* - -
H-4''' - 6.73 (s, 1H) -
H-5''' - - -
H-6''' - - -
H-7''' & H-8''' 2.23 (s, 6H) 2.26 (s, 6H) -
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Table-35: 1H-NMR data of compounds, 15g, 15h & 15i
*= H-2''' & H-6''' **= H-3''' & H-5'''
1H-NMR (600 MHz, CDCl3)  (ppm), Multiplicity, J (Hz)
Proton
No.
Compounds
15g 15h 15i
-CON-H 9.80 (s, 1H) 9.82 (s, 1H) 9.81 (s, 1H)
H-2' 7.46 (s, 1H) 7.52 (s, 1H) 7.43 (s, 1H)
H-5' 7.49 (d, J = 7.0, 1H) 7.50 (d, J = 7.5, 1H) 7.50 (d, J = 7.6, 1H)
H-6' 7.10 (d, J = 7.0, 1H) 7.18 (d, J = 7.6, 1H) 7.15 (d, J =7.6, 1H)
H-7' 6.14 (s, 2H) 6.14 (s, 2H) 6.13 (s, 2H)
H-2'' 4.30 (s, 2H) 4.28 (s, 2H) 4.32 (s, 2H)
H-2''' - 7.40 (d, J = 8.4, 2H)* 7.01 (d, J = 2.4, 1H)
H-3''' 7.36 (d, J = 7.6, 1H) 7.08 (d, J = 8.0, 2H)** -
H-4''' 7.16 (dt, J = 6.6, 1.0, 1H) - 7.10 (dd, J = 7.6, 2.4,1H)
H-5''' 7.22 (dt, J = 7.6, 1.2,1H) - 7.20 (d, J = 7.6, 1H)
H-6''' 8.28 (d, J = 7.6, 1H) - -
H-7''' 2.38 (s, 3H) 2.28 (s, 3H) 2.27 (s, 3H)
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Table-36: 1H-NMR data of compounds, 15j, 15k & 15l
*= H-1''' to H-4'''
1H-NMR (600 MHz, CdCl3)  (ppm), Multiplicity, J (Hz)
Proton No. Compounds
15j 15k 15l
-CON-H 9.80 (s, 1H) 9.82 (s, 1H) 9.81 (s, 1H)
H-2' 7.49 (s, 1H) 7.42 (d, J = 1.4, 1H) 7.43 (s, 1H)
H-5' 7.48 (d, J = 7.2, 1H) 7.50 (d, J =7.0, 1H) 7.52 (d, J = 7.0, 1H)
H-6' 7.19 (d, J = 7.2, 1H) 7.12 (dd, J = 8.4,2.4,1H)
7.15 (d, J = 8.4, 2.0,
1H)
H-7' 6.14 (s, 2H) 6.14 (s, 2H) 6.14 (s, 2H)
H-2'' 4.30 (s, 2H) 4.38 (s, 2H) 4.32 (s, 2H)
H-2''' - - 2.86-2.74 (m, 7H)*
H-3''' 7.99 (dd, J = 8.0,1.6,1H) 7.07 (d, J = 7.6, 1H)
-
H-4''' 7.11 (t, J = 7.6, 1H) 7.09 (dd, J = 7.6,1.6,1H)
-
H-5''' 7.53 (dt, J =7.6,1.6, 1H) - -
H-6''' 8.66 (d, J = 8.4, 1H) 8.07 (s, 1H) 2.90 (s, 2H)
H-7''' - 3.83 (s, 3H) -
H-8''' 3.83 (s, 3H) - -
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Table-37: 1H-NMR data of compounds, 15m, 15n & 15o
*= H-2''' & H-6''' **= H-3''' to H-5''' ***= H-3''' & H-5'''
1H-NMR (600 MHz, CDCl3)  (ppm), Multiplicity, J (Hz)
Proton
No.
Compounds
15m 15n 15o
-CON-H 9.81 (s, 1H) 9.82 (s, 1H) 9.81 (s, 1H)
H-2' 7.42 (s, 1H) 7.42 (d, J = 2.4, 1H) 7.40 (s, 1H)
H-5' 7.47 (d, J = 7.2, 1H) 7.50 (d, J =8.0, 2.4, 1H) 7.50 (d, J = 7.2, 1H)
H-6' 7.10 (d, J = 7.2, 1H) 7.12 (dd, J = 8.4, 2.4,1H)
7.11 (dd, J = 7.2, 2.4,
1H)
H-7' 6.14 (s, 2H) 6.14 (s, 2H) 6.14 (s, 2H)
H-2'' 4.30 (s, 2H) 4.28 (s, 2H) 4.30 (s, 2H)
H-2''' 7.96 (d, J = 8.0, 2H)* - 7.42 (d, J = 8.4, 2H)*
H-3''' 7.51-7.48 (m, 3H)** 7.30 (d, J = 7.6, 1H) 6.98 (d, J = 8.0, 2H)***
H-4''' - 7.26 (dt, J = 7.6, 1.6,1H)
-
H-5''' - 7.22 (t, J = 7.6, 1H) -
H-6''' - 8.24 (d, J = 7.6, 1H) -
H-7''' 2.76 (t, J = 6.8, 2H) 2.31 (q, J = 6.8, 2H) 2.31 (q, J = 6.8, 2H)
H-8''' 3.71 (t, J = 6.8, 2H) 1.36 (t, J = 6.8, 3H) 1.36 (t, J = 6.8, 3H)
Results and Discussion
Department of Chemistry, GCU Lahore Page 148
15p
1''' 3'''
5'''
1'3'
5'
1''
2''
7'
7'''
5
1
3
N
O
N
S
O
O
H
N
O
8'''
O
CH 3
15q
1''' 3'''
5'''
1'3'
5'
1''
2''
7'
7'''
5
1
3
N
O
N
S
O
O
H
N
O
8'''
O
CH 3
15r
1''' 3'''
5'''
1'3'
5'
1''
2''
7'
7'''
5
1
3
N
O
N
S
O
O
H
N
O
8'''
H3C
9'''
CH3
Table-38: 1H-NMR data of compounds, 15p, 15q & 15r
*= H-2''' & H-6''' **= H-3''' & H-5''' ***= H-3''' to H-5'''
1H-NMR (600 MHz, CDCl3)  (ppm), Multiplicity, J (Hz)
Proton No. Compounds
15p 15q 15r
-CON-H 9.80 (s, 1H) 9.80 (s, 1H) 9.81 (s, 1H)
H-2' 7.42 (s, 1H) 7.42 (s, 1H) 7.45 (s, 1H)
H-5' 7.48 (d, J = 7.2, 1H) 7.50 (d, J =8.4, 1H) 7.52 (d, J = 7.2, 1H)
H-6' 7.10 (d, J = 7.2, 1H) 7.10 (d, J = 8.4, 1H) 7.12 (dd, J = 7.2, 2.0,1H)
H-7' 6.14 (s, 2H) 6.14 (s, 2H) 6.14 (s, 2H)
H-2'' 4.32 (s, 2H) 4.29 (s, 2H) 4.30 (s, 2H)
H-2''' 7.46 (d, J = 8.0,2H)* -
-
H-3''' 7.51 (d, J = 8.0,2H)** 7.38 (d, J = 7.6, 1H)
7.06-7.03 (m, 3H)***
H-4''' - 7.16 (dt, J = 6.6, 1.0,1H)
-
H-5''' - 7.22 (t, J = 7.2 1H) -
H-6''' - 8.24 (d, J = 7.2, 1H) -
H-7''' 3.94 (q, J = 6.8) 3.94 (q, J = 6.8, 2H) 2.31 (q, J = 6.8, 2H)
H-8''' 1.36 (t, J = 6.8) 1.36 (t, J = 6.8, 3H) 1.30 (t, J = 6.8, 3H)
H-9''' - - 2.38 (s, 3H)
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Table-39: 1H-NMR data of compounds, 15s & 15t
1H-NMR (600 MHz, CDCl3)  (ppm), Multiplicity, J (Hz)
Proton No. Compounds
15s 15t
-CON-H 9.60 (s, 1H) 9.82 (s, 1H)
H-2' 7.43 (s, 1H) 7.42 (s, 1H)
H-5' 7.50 (d, J = 7.2, 1H) 7.56 (d, J = 8.4, 1H)
H-6' 7.09 (d, J = 7.2, 1H) 7.10 (d, J = 8.4, 1H)
H-7' 6.13 (s, 2H) 6.14 (s, 2H)
H-2'' 4.36 (s, 2H) 4.32 (s, 2H)
H-3''' 7.34 (d, J = 8.4, 2H) 7.28 (d, J = 2.4, 1H)
H-4''' 6.90 (t, J = 7.2, 1H) -
H-5''' 7.06 (br.s, 1H) 7.22 (dd, J = 7.2, 2.4, 1H)
H-6''' 7.93 (d, J = 7.2, 1H) 8.26 (d, J = 7.2, 1H)
H-7''' 3.80 (s, 3H) 2.34 (s, 3H)
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4.7. Synthesis of 2-Alkyl/aralkylthio-5-(3,4-methylenedioxyphenyl)-
1,3,4-Oxadiazole derivatives (17a-u)
This series involved the synthesis of alkylated derivatives of 5-(3,4-methylene
dioxyphenyl)1,3,4-oxadiazol-2-thiol (4a). The alkylation was made at sulfur atom of
oxadiazole. Alkylating agents used for this purpose included different aliphatic as well as
substituted aromatic halides. Slightly basic polar aprotic reaction envoirnment
(DMF/NaH) was provided to facile the reaction. An equimolar quantity of 5-(3,4-
methylene dioxyphenyl)1,3,4-oxadiazol-2-thiol (4a) was treated with equimolar
quantities of different aryl/aralkyl halides (16a-u). Pure products (17a-u) were obtained,
confirmed through TLC on silica gel and structure elucidation by different spectral
techniques comprising of IR, 1H-NMR, 13C-NMR, EI-MS.
IO
O
5-(3,4-methylenedioxyphenyl)-1
,3,4-oxadiazol-2-thiol
4a
2-Alkyl/aralkylthio-5-(3,4-methylene
dioxyphenyl)-1,3,4-Oxadiazole
17a-u
N
O
N
SH O
O
N
O
N
S
R
Reagents & conditions: (I) Different alkyl/aryl halides (16a-u), DMF, NaH, stirring for 3-5 hrs
The compound, 2-(2-Bromobenzyl)thio-5-(3,4-methylenedioxyphenyl)-1,3,4-Oxadiazole
(17m), was obtained as a single product in good yield in solid form. Its IR spectra gave
characteristic bands for functional groups I.e. at 3329 for aromatic C-H stretching, at
1633 for Ar C=C stretching, at 1580 for C=N stretching, and at 1108 for C-O-C
stretching.
The compound (17m) also expressed a clear 1H-NMR spectra. Three resonating signals,
at (δ/ppm) 7.41 (d, J = 1.6 Hz, 1H, H-2'), at 6.88 (d, J = 8.0 Hz, 1H, H-5') and at 7.58 (d,
J = 8.0 Hz, 1H, H-6') in aromatic region indicated the presence of benzodioxole ring. The
J value gives the information that proton H-2' is meta substituted while H-5' and H-6' are
ortho to each other. Other three signals at (δ/ppm) 7.62 (dd, J = 7.6, 1.6 Hz, 1H, H-3''),
7.50 (dd, J = 8.0, 1.6 Hz, 1H, H-6'') and 7.18-7.12 (m, 2H, H-4'', H-5'') corresponded to
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the brominated benzyl ring. The signal for methylenic protons surrounded by two oxygen
atoms of methylene dioxy ring (O-CH2-O) fell at high downfield chemical shift i.e. at
(δ/ppm) 6.03 (s, 2H, H-7'). One more signal is found in aliphatic region at (δ/ppm) 4.60
(s, 2H, H-7'') corresponds to one more methylene (-CH2) which served the attachment
point of two moieties (phenyl ring of aryl halide and oxadiazole ring). The whole
molecule was also supported by other spectral data as EI-MS.
EI-MS spectra of the compound (17m), presented some very important peaks. There are
two molecular ion peaks with the difference of two mass units, at m/z 393 [M+2]·+ and at
391 [M]·+ clearly indicated the presence of isotopic bromine in the molecule. Other
important peaks at m/z 147, 91 and 121 are for 3,4-methylene dioxy phenyl cation,
tropylium cation and simple methylenedioxy phenyl cation respectively. The phenyl
bromide radical cation fragment is obtained at m/z 157 which by releasing bromide
radical gives peak at 77 corresponding to benzene ring. The 1H-NMR data of the other
compounded is listed below in the tabulated form.
Figure-13: 1H-NMR spectrum of the synthesized compound 17m
17m
1'3'
5'
7'
5
1
3
N
O
N
S
O
O
7''
1''
5''
3''
Br
Results and Discussion
Department of Chemistry, GCU Lahore Page 152
Br- CN
O
N
O
O
N
O
O
O
O
O
NN
Br
C2H2
O
NN
S
Br
O
O
H2C
Br Br
O
NN
SO
O
O
O
Br C2H2CH2S
S
H2C
C7H6Br
C7H6BrS
- CNO S
- CN
m/z = 201 (7%) m/z = 156 (13%) m/z = 77 (100 %) m/z = 51 (9 %)
C9H5N2O3
[M]+ m/z = 390 C9H5N2O3S
m/z = 221 (11 %)
m/z = 169 (3 %)
m/z = 91 (8 %)
m/z = 65 (19 %)
m/z = 189 (15 %)
m/z = 163 (5 %)
m/z = 147 (24 %)
m/z = 121 (17 %)
m/z = 203 (8%) m/z = 158 (14%)
m/z = 171 (4 %)
[M +2] m/z = 392
Figure-14: Mass fragmentation pattern of the synthesized molecule 17m
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Table-40: 1H-NMR data of compounds, 17a, 17b & 17c
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1H-NMR (400 MHz, CDCl3)  (ppm), Multiplicity, J (Hz)
Proton No. Compounds
17a 17b 17c
H-2' 7.44 (s, 1H) 7.44 (s, 1H) 7.44 (d, J = 1.2, 1H)
H-5' 6.89 (d, J = 8.4, 1H) 6.89 (d, J = 8.0, 1H) 6.89 (d, J = 8.0, 1H)
H-6' 7.53 (dd, J = 8.4, 1.2 1H) 7.53 (d, J = 8.0, 1H) 7.53 (dd, J = 8.4,1.6 1H)
H-7' 6.03 (s, 2H) 6.03 (s, 2H) 6.03 (s, 2H)
H-1'' 2.74 (s, 3H) 3.30 (q, J = 7.2, 2H) 3.26 (t, J = 7.2, 2H)
H-2'' - 1.50 (t, J = 7.6, 3H) 1.89 (sex, J = 7.2, 2H)
H-3'' - - 1.07 (t, J = 7.2, 3H)
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Table-41: 1H-NMR data of compounds, 17d, 17e & 17f
*= H-3'' & H-4''
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1H-NMR (400 MHz, CDCl3)  (ppm), Multiplicity, J (Hz)
Proton No. Compounds
17d 17e 17f
H-2' 7.44 (d, J =1.6, 1H) 7.44 (d, J =1.2, 1H) 7.43 (d, J = 1.6, 1H)
H-5' 6.88 (d, J = 8.0, 1H) 6.89 (d, J = 8.0, 1H) 6.87 (d, J = 8.0, 1H)
H-6' 7.53 (dd, J = 8.4, 1.6, 1H) 7.53 (dd, J = 8.0,1.6, 1H) 7.53 (dd, J =8.0,1.6, 1H)
H-7' 6.03 (s, 2H) 6.03 (s, 2H) 6.04 (d, J = 2.4, 2H)
H-1'' 3.28 (t, J = 7.2, 2H) 3.27 (t, J = 7.2, 2H) 3.93 (t, J = 7.2, 2H)
H-2'' 1.81 (qui, J = 7.2, 2H) 1.81 (qui, J = 7.2, 2H) 3.61 (t, J = 7.2, 2H)
H-3'' 1.50 (sex, J = 7.2, 2H) 1.45-1.35 (m, 4H)* -
H-4'' 0.96 (t, J = 7.2, 3H) - -
H-5'' - 0.89 (t, J = 7.2, 3H) -
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Table-42: 1H-NMR data of compounds, 17g, 17h & 17i
*= H-2'' & H-6'' **= H-3'' to H-5''
1H-NMR (400 MHz, CDCl3)  (ppm), Multiplicity, J (Hz)
Proton No. Compounds
17g 17h 17i
H-2' 7.43 (d, J = 1.2, 1H) 7.42 (d, J =1.2, 1H) 7.44 (brd.s, 1H)
H-5' 6.89 (d, J = 8.0, 1H) 6.89 (d, J = 8.0, 1H) 6.88 (d, J = 7.2, 1H)
H-6' 7.53 (dd, J =8.0, 1.2, 1H) 7.52 (dd, J = 8.4, 1.6, 1H) 7.51 (dd, J = 7.2, 1.2, 1H)
H-7' 6.04 (s, 2H) 6.03 (s, 2H) 6.03 (s, 2H)
H-1'' 3.76 (t, J = 7.2, 2H) 4.06 (s, 2H) -
H-2'' 3.68 (t, J = 7.2, 2H) - 7.41 (d, J = 7.2, 2H)*
H-3'' - 4.26 (q, J = 7.2, 2H) 7.34-7.30 (m, 3H)**
H-4'' - 1.29 (t, J = 7.2, 3H) -
H-5'' - - -
H-6'' - - -
H-7'' - - 4.48 (s, 2H)
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Table-43: 1H-NMR data of compounds, 17j, 17k & 17l
*= H-2'' to H-6'' **= H-2'' & H-6'' ***= H-3'' to H-5'' ****= H-4'' & H-5''
1H-NMR (400 MHz, CDCl3)  (ppm), Multiplicity, J (Hz)
Proton No. Compounds
17j 17k 17l
H-2' 7.44 (d, J = 1.2, 1H) 7.42 (d, J =1.2, 1H) 7.43 (d, J = 1.6, 1H)
H-5' 6.89 (d, J = 8.0, 1H) 6.89 (d, J = 8.4, 1H) 6.89 (d, J = 8.0, 1H)
H-6' 7.52 (dd, J =8.0,1.2, 1H) 7.51 (dd, J = 8.0,1.6, 1H) 7.52 (dd, J = 8.4,1.6, 1H)
H-7' 6.04 (s, 2H) 6.03 (s, 2H) 6.03 (s, 2H)
H-2'' 7.30-7.25 (m, 5H)* 7.27 (d, J = 7.6, 2H)** -
H-3'' - 7.20-7.17 (m, 3H)*** 6.06 (d, J = 6.4, 1H)
H-4'' - - 7.19-7.12 (m, 2H)****
H-6'' - - 7.38 (d, J = 7.2, 1H)
H-7'' 3.15 (t, J = 7.2, 2H) 2.80 (t, J = 7.6, 2H) 4.52 (s, 2H)
H-8'' 3.52 (t, J = 7.2, 2H) 2.18 (qui, J = 7.2, 2H) 2.43 (s, 3H)
H-9'' 3.27 (t, J = 7.6, 2H) -
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Table-44: 1H-NMR data of compounds, 17m, 17n & 17o
*= H-4'' & H-5'' **= H-4'' & H-6'' ***= H-2'' & H-6'' ****= H-3'' & H-5''
1H-NMR (CDCl3)  (ppm), Multiplicity, J (Hz)
Proton No. Compounds
17m (400 MHz) 17n (300 MHz) 17o (400 MHz)
H-2' 7.41 (d, J = 1.6, 1H) 7.41 (brd.s, 1H) 7.40 (d, J = 1.6, 1H)
H-5' 6.88 (d, J = 8.0, 1H) 6.89 (d, J = 7.1, 1H) 6.88 (d, J = 8.0, 1H)
H-6' 7.58 (d, J = 8.0, 1H) 7.51 (dd, J = 8.1, 1.5, 1H) 7.50 (dd, J = 8.0, 1.6, 1H)
H-7' 6.03 (s, 2H) 6.06 (brd.s, 2H) 6.03 (s, 2H)
H-2'' - 7.59 (s, 1H) 7.32 (d, J = 8.4, 2H)***
H-3'' 7.62 (dd, J = 7.6, 1.6,1H) - 7.44 (d, J = 8.4, 2H)****
H-4'' 7.18-7.12 (m, 2H)* 7.39-7.37 (m, 2H)** -
H-5'' - 7.18 (t, J = 7.8, 1H) -
H-6'' 7.50 (dd, J = 8.0, 1.6, 1H) - -
H-7'' 4.60 (s, 2H) 4.43 (s, 2H) 4.42 (s, 2H)
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Table-45: 1H-NMR data of compounds, 17p, 17q & 17r
*= H-4'' & H-5'' **= H-4'' to H-6'' ***= H-2'' & H-6'' ****= H-3'' & H-5''
1H-NMR (400 MHz, CDCl3)  (ppm), Multiplicity, J (Hz)
Proton No. Compounds
17p 17q 17r
H-2' 7.37 (brd.s, 1H) 7.41 (d, J = 1.2, 1H) 7.41 (brd.s, 1H)
H-5' 6.88 (d, J = 8.4, 1H) 6.88 (d, J = 8.4, 1H) 6.88 (d, J = 8.4, 1H)
H-6' 7.50 (dd, J = 8.4, 1.6, 1H) 7.50 (dd, J = 8.0,1.6, 1H) 7.50 (dd, J = 8.0, 1.2, 1H)
H-7' 6.03 (s, 2H) 6.03 (s, 2H) 6.03 (s, 2H)
H-2'' - 7.43 (brd.s, 1H) 7.28 (d, J = 8.4, 2H)***
H-3'' 7.60 (dd, J = 7.2, 2.4,1H) - 7.39 (d, J = 8.4, 2H)****
H-4'' 7.23-7.18 (m, 2H)* 7.33-7.26 (m, 3H)** -
H-6'' 7.41 (dd, J = 7.2, 2.0, 1H) - -
H-7'' 4.59 (s, 2H) 4.43 (s, 2H) 4.43 (s, 2H)
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Table-46: 1H-NMR data of compounds, 17s, 17t & 17u
*= H-5'' & H-6'' **= H-2'' & H-6'' ***= H-3'' & H-5''
1H-NMR (CDCl3)  (ppm), Multiplicity, J (Hz)
Proton No. Compounds
17s (300 MHz) 17t (400 MHz) 17u (400 MHz)
H-2' 7.40 (d, J = 1.5, 1H) 7.39 (d, J = 1.6, 1H) 7.41 (d, J = 2.0, 1H)
H-5' 6.88 (d, J = 8.1, 1H) 6.88 (d, J = 8.0, 1H) 6.87 (d, J = 8.0, 1H)
H-6' 7.85 (d, J = 7.5, 1H) 7.49 (dd, J = 8.4, 2.0, 1H) 7.51 (dd, J = 7.2, 1.2, 1H)
H-7' 6.03 (s, 2H) 6.03 (s, 2H) 6.03 (s, 2H)
H-2'' 8.32 (s, 1H) 7.65 (d, J = 8.8, 2H)** 7.03 (t, J = 8.4, 2H)**
H-3'' - 8.18 (d, J = 8.8, 2H)*** 7.39 (t, J = 8.0, 2H)***
H-4'' 8.15 (d, J = 8.1, 1H) - -
H-5'' 7.53-7.47 (m, 2H)* - -
H-7'' 4.54 (s, 2H) 4.53 (s, 2H) 4.45 (s, 2H)
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4.8. Synthesis of sulfonamide derivatives of paroxetine (20a-k,m-o)
The presented series, sulfonamide derivatives of paroxetine (20a-k,m-o) was prepared by
the reaction of commercially available paroxetine (18) with different sulfonyl chlorides
(19a-k,m-o) in an equimolar ratio. The reaction was carried out in basic medium
(H2O/Na2CO3) giving 3-4 hrs stirring to the reaction contents. The products were
obtained in excellent yields as solid precipitates.
I
R
S
Cl
O O
+
Alkyl/Aryl substituted
sulfonyl chloride
O
O
O
H
N
F
H
H
20a-k,m-o
19a-k,m-o
18
Paroxetine
N-(alkyl/aryl substituted
sulfonyl)paroxetine
O
O
O
N
S
F
H
H
O R
O
Reagents & conditions: (I) H2O, 5% Na2CO3 soln, stirring for 3-4 hours
The products were characterized and confirmed by different spectral analysis like IR, 1H-
NMR, EI-MS and 13C-NMR. One of the compounds is discussed in detail as under while
1H-NMR data of rest of the compounds is given in the following tables.
In 1H-NMR spectrum of the compound, N-(4-bromobenzenesulfonyl)paroxetine (20h),
the resonating signals appeared at different chemical shift values corresponding to the
relative protons in the compound. The compound contains three aromatic rings, one
attached to methylenedioxy ring, second ring is para flouro substituted and is attached to
piperidine ring while the third ring is attached to sulfonyl group and it is also para bromo
substituted. The ring which is attached to sulfonyl group appeared at the most downfield
aromatic region of the spectrum. As the ring is para substituted with bromide so the
signal pattern is in the form of two broad doublets for four protons, H-2ꞌꞌꞌ & H-6ꞌꞌꞌ and H-
3ꞌꞌꞌ & H-5ꞌꞌꞌ having coupling constant value J = 8.7 Hz. The para flouro substituted ring
appeared as two multiplets for four protons, H-2ꞌꞌ & H-6ꞌꞌ and H-3ꞌꞌ & H-5ꞌꞌ. The ring
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attached to methylene dioxy ring appeared as (d, J = 8.4 Hz, for H-5'), (d, J = 2.4 Hz, for
H-2') and (dd, J = 8.4, 2.4 Hz, for H-6') at 6.59, 6.29 and 6.07 respectively. The two
methylenic protons (H-7') of methylene dioxy ring appeared at (ppm) 5.86 as singlet in
highly downfield region. The different resonating signals for eight protons of piperidine
ring appeared in aliphatic region ranging(ppm)  3.54 to 3.48. 13C-NMR and EI-MS
data of the relative compound are given in the experimental section.
Figure-15: 1H-NMR spectrum of the synthesized compound 20h
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Figure-16: 13C-NMR spectrum of the synthesized compound 20h
Figure-17: EIMS spectrum of the synthesized compound 20h
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N S
O
O
CH2O
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O
O
N S
O
O
CH 2
F
OH
O
O
O
O
O
S
O
O
O
O
-
CO
CH2
F
N
H2C
S
O
O
HC CH-
H3C
N S
O
O
m/z = 547 [M+] (5 %)
m/z = 410 (3 %)
m/z = 138 (67 %)
m/z = 137 (36 %)
m/z = 219 (27 %) m/z = 155 (44 %)
- SO2
m/z = 121 (14 %)
m/z = 109 (47 %)
m/z = 288 (7 %)
m/z = 135 (27 %) m/z = 262 (14 %)
Br
m/z = 549 [M+1] (5 %)
Br
m/z = 412 (3.2 %)
Br
m/z = 290 (8 %)
m/z = 264 (13 %)
Br
O
O
Br
m/z = 221 (26 %)
Br
m/z = 157 (43 %)
m/z = 77 (100 %)
C18H17NSO2FBr
C8H7
C18H18NSO3FBr
C9H8NSO 2Br
C7H5O3
C18H17NSO2FBr
C19H19NO3F
Br
Figure-18: Fragmentation pattern of the compound 20h
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Table-47: 1H-NMR data of compounds, 20a, 20b
O
O
O
N
S
F
H
H
O
O
20a
1'''
3'''
5'''
1'3'
5'
1''
7'
5
1
3
7
3'' 5''
O
O
O
N
S
F
H
H
O
O
CH3
20b
1'''
3'''
5'''
1'3'
5'
1''
7'
5
1
3
7
3'' 5''
7'''
1H-NMR (300 MHz, CDCl3) (ppm), Multiplicity, J (Hz)
Proton No. Compounds
20a 20b
H-2 3.63-3.54 (m, 2H) 3.59-3.53 (m, 2H)
H-3 2.40-2.30 (m, 1H) 2.32-2.27 (m, 1H)
H-4 2.57-2.44 (m, 1H) 2.27-2.22 (m, 1H)
H-5 2.21-1.86 (m, 2H) 2.93-1.82 (m, 2H)
H-6 3.46-3.34 (m, 2H) 3.39-3.34 (m, 2H)
H-7 4.14-3.93 (m, 2H) 4.11-3.90 (m, 2H)
H-2' 6.29 (d, J = 2.4, 1H) 6.29 (d, J = 2.4, 1H)
H-5' 6.61 (d, J = 8.4, 1H) 6.58 (d, J = 8.7, 1H)
H-6' 6.08 (dd, J = 8.4, 2.7, 1H) 6.06 (dd, J = 8.7, 2.4, 1H)
H-7' 5.87 (d, J = 3.6, 2H) 5.87 (s, 2H)
H-2'' & H-6'ꞌ 7.10-7.03 (m, 2H) 7.07-7.03 (m, 2H)
H-3'' & H-5'ꞌ 6.97-6.92 (m, 2H) 6.96-6.91 (m, 2H)
H-2'''& H-6'ꞌ' 7.78 (dd, J = 6.9, 1.5, 2H) 7.65 (d, J = 8.4, 2H)
H-3'''& H-5'ꞌ' 7.58 (t, J = 6.9, 2H) 7.34 (d, J = 8.4, 2H)
H-4''' 7.63-7.61 (m, 1H) -
H-7''' 2.39 (s, 3H)
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Table-48: 1H-NMR data of compounds, 20c, 20d
*= H-8''' to H-10'ꞌ' **= H-8''' & H-9'ꞌ'
O
O
O
N
S
F
H
H
O
O
C CH3
H3C
CH31'''
3'''
5'''
1'3'
5'
1''
7'
5
1
3
7
3'' 5''
7'''
8'''
9'''
10'''
20c
O
O
O
N
S
F
H
H
O
O
CH3H3C
CH3
1'''
3'''
5'''
1'3'
5'
1''
7'
5
1
3
7
3'' 5''
7'''
8'''
9'''
20d
1H-NMR (300 MHz, CDCl3) (ppm), Multiplicity, J (Hz)
Proton No. Compounds
20c 20d
H-2 3.57-3.54 (m, 2H) 3.57-3.53 (m, 2H)
H-3 2.45-2.39 (m, 1H) 2.88-2.81 (m, 1H)
H-4 2.36-2.32 (m, 1H) 1.85-1.78 (m, 1H)
H-5 1.84-1.79 (m, 2H) 1.34-0.81 (m, 2H)
H-6 3.39-3.34 (m, 2H) 3.43-3.37 (m, 2H)
H-7 4.14-3.93 (m, 2H) 3.90-3.74 (m, 2H)
H-2' 6.29 (s, 1H) 6.26 (d, J = 2.4, 1H)
H-5' 6.61 (d, J = 8.4, 1H) 6.57 (d, J = 8.7, 1H)
H-6' 6.09 (dd, J = 8.4, 2.1, 1H) 6.04 (dd, J = 8.4, 2.4, 1H)
H-7' 5.86 (s, 2H) 5.82 (s, 2H)
H-2'' & H-6'ꞌ 7.04-7.02 (m, 2H) 7.13-7.08 (m, 2H)
H-3'' & H-5'ꞌ 6.96-6.91 (m, 2H) 6.97-6.92 (m, 2H)
H-2'''& H-6'ꞌ' 7.71 (d, J = 7.5, 2H) -
H-3'''& H-5'ꞌ' 7.54 (d, J = 7.8, 2H) 6.95 (s, 2H)
H-7''' - 2.29 (s, 3H)
H-8''' 1.34 (s, 9H)* 2.64 (s, 6H)**
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Table-49: 1H-NMR data of compounds, 20e, 20f
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O
O
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H
H
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CH3
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20e
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O
O
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H
H
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CH3
1'''
3'''
5'''
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5'
1''
7'
5
1
3
7
3'' 5''
7'''
20f
1H-NMR (300 MHz, CDCl3) (ppm), Multiplicity, J (Hz)
Proton No. Compounds
20e 20f
H-2 3.72-3.63 (m, 2H) 3.57-3.54 (m, 2H)
H-3 2.63-2.20 (m, 1H) 2.34-2.30 (m, 1H)
H-4 1.89-1.56 (m, 1H) 2.26-2.20 (m, 1H)
H-5 1.23-0.81 (m, 2H) 1.93-1.87 (m, 2H)
H-6 3.60-3.37 (m, 2H) 3.39-3.34 (m, 2H)
H-7 4.19-3.95 (m, 2H) 4.09-3.92 (m, 2H)
H-2' 6.28 (d, J = 2.4, 1H) 6.29 (d, J = 2.1, 1H)
H-5' 6.58 (d, J = 8.4, 1H) 6.61 (d, J = 8.4, 1H)
H-6' 6.08 (dd, J = 8.4, 2.4, 1H) 6.09 (dd, J = 8.4, 2.4, 1H)
H-7' 5.86 (d, J = 3.3, 2H) 5.85 (s, 2H)
H-2'' & H-6'ꞌ 7.12-7.03 (m, 2H) 7.08-7.03 (m, 2H)
H-3'' & H-5'ꞌ 6.98-6.88 (m, 2H) 6.98-6.91 (m, 2H)
H-2'''& H-6'ꞌ' 8.08 (d, J = 8.4, 2H) 7.70 (d, J = 8.4, 2H)
H-3'''& H-5'ꞌ' 7.87 (d, J = 8.4, 2H) 7.36 (d, J = 8.4, 2H)
H-7''' - 2.41 (s, 3H)
H-8''' 2.63 (s, 3H) -
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Table-50: 1H-NMR data of compounds, 20g, 20h
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O
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20h
1H-NMR (300 MHz, CDCl3) (ppm), Multiplicity, J (Hz)
Proton No. Compounds
20g 20h
H-2 3.63-3.54 (m, 2H) 3.63-3.54 (m, 2H)
H-3 2.39-2.29 (m, 1H) 2.39-2.29 (m, 1H)
H-4 2.55-2.43 (m, 1H) 2.55-2.43 (m, 1H)
H-5 2.08-1.88 (m, 2H) 2.08-1.88 (m, 2H)
H-6 3.48-3.34 (m, 2H) 3.48-3.00 (m, 2H)
H-7 4.10-3.90 (m, 2H) 4.10-3.90 (m, 2H)
H-2' 6.29 (d, J = 1.5, 1H) 6.29 (d, J = 2.4, 1H)
H-5' 6.58 (d, J = 8.4, 1H) 6.59 (d, J = 8.4, 1H)
H-6' 6.09 (dd, J = 8.4,1.5, 1H) 6.07 (dd, J = 8.4, 2.4, 1H)
H-7' 5.86 (d, J = 3.6, 2H) 5.86 (s, 2H)
H-2'' & H-6'ꞌ 7.14-7.04 (m, 2H) 7.08-7.04 (m, 2H)
H-3'' & H-5'ꞌ 7.00-6.92 (m, 2H) 6.97-6.92 (m, 2H)
H-2'''& H-6'ꞌ' 7.69 (d, J =8.4, 2H) 7.69 (d, J = 8.7, 2H)
H-3'''& H-5'ꞌ' 7.73 (d, J = 8.4, 2H) 7.62 (d, J = 8.7, 2H)
H-8''' 2.63 (s, 3H) -
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Table-51: 1H-NMR data of compounds, 20i, 20j
*= H-5'''& H-6'ꞌ'
O
O
O
N
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F
H
H
O
O
Cl
Cl
1'''
3'''
5'''
1'3'
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1''
7'
5
1
3
7
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20i
O
O
O
N
S
F
H
H
O
O
Cl
Cl
1'''
3'''
5'''
1'3'
5'
1''
7'
5
1
3
7
3'' 5''
20j
1H-NMR (300 MHz, CDCl3) (ppm), Multiplicity, J (Hz)
Proton No. Compounds
20i 20j
H-2 3.58-3.60 (m, 2H) 3.59-3.55 (m, 2H)
H-3 2.96-2.85 (m, 1H) 2.50-2.42 (m, 1H)
H-4 2.70-2.61 (m, 1H) 2.39-2.35 (m, 1H)
H-5 1.87-1.79 (m, 2H) 2.95-1.88 (m, 2H)
H-6 3.43-3.38 (m, 2H) 3.41-3.36 (m, 2H)
H-7 4.12-3.99 (m, 2H) 4.11-3.92 (m, 2H)
H-2' 6.30 (d, J = 2.4, 1H) 6.31 (d, J = 2.4, 1H)
H-5' 6.61 (d, J = 8.4, 1H) 6.61 (d, J = 8.4, 1H)
H-6' 6.10 (dd, J = 8.1, 2.1, 1H) 6.10 (dd, J = 8.4, 2.1, 1H)
H-7' 5.86 (s, 2H) 5.86 (s, 2H)
H-2'' & H-6'ꞌ 7.13-7.08 (m, 2H) 7.09-7.05 (m, 2H)
H-3'' & H-5'ꞌ 6.98-6.93 (m, 2H) 6.98-6.92 (m, 2H)
H-2''' - 7.87 (s, 1H)
H-4''' 7.68 (dd, J = 6.9, 2.4, 1H) -
H-5'ꞌ' 7.36 (t, J = 8.1, 1H) 7.61 (brd.s, 2H)*
H-6'ꞌ' 8.06 (dd, J = 6.9, 2.3, 1H) -
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Table-52: 1H-NMR data of compounds, 20k, 20m
O
O
O
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1''' 3'''
5'''
1'3'
5'
1''
7'
5
1
3
7
3'' 5''
20k
7'''
O
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O
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3'''
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1''
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5
1
3
7
3'' 5''
20m
1H-NMR (300 MHz, CDCl3) (ppm), Multiplicity, J (Hz)
Proton No. Compounds
20k 20m
H-2 3.72-3.53 (m, 2H) 3.58-3.54 (m, 2H)
H-3 2.64-2.27 (m, 1H) 2.37-2.30 (m, 1H)
H-4 1.98-1.83 (m, 1H) 2.51-2.42 (m, 1H)
H-5 1.83-0.83 (m, 2H) 1.94-1.85 (m, 2H)
H-6 3.44-3.36 (m, 2H) 3.40-3.34 (m, 2H)
H-7 4.25-4.00 (m, 2H) 4.11-3.90 (m, 2H)
H-2' 6.27 (d, J = 2.4, 1H) 6.30 (d, J = 2.4, 1H)
H-5' 6.57 (d, J = 8.4, 1H) 6.61 (d, J = 8.4, 1H)
H-6' 6.05 (dd, J = 8.4, 2.4, 1H) 6.09 (dd, J = 8.1, 2.4, 1H)
H-7' 5.85 (d, J = 3.3, 2H) 5.88 (s, 2H)
H-2'' & H-6'ꞌ 7.10-7.08 (m, 2H) 7.08-7.04 (m, 2H)
H-3'' & H-5'ꞌ 6.96-6.89 (m, 2H) 6.97-6.92 (m, 2H)
H-2'''& H-6'ꞌ' 7.97 (d, J = 8.4, 2H) 7.73 (d, J = 8.4, 2H)
H-3'''& H-5'ꞌ' 7.68-7.58 (m, 2H) 7.53 (d, J = 8.4, 2H)
H-4''' 7.79-7.76 (m, 1H) -
H-7''' 4.89 (br.s, 2H) -
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Table-53: 1H-NMR data of compounds, 20n, 20o
*= H-3''' & H-8''' **= H-6''' & H-7'''
1H-NMR (CDCl3) (ppm), Multiplicity, J (Hz)
Proton No. Compounds
20n (400 MHz) 20o (300 MHz)
H-2 3.54-3.50 (m, 2H) 3.54-3.50 (m, 2H)
H-3 2.69-2.63 (m, 1H) 2.69-2.63 (m, 1H)
H-4 1.83-1.59 (m, 1H) 1.83-1.59 (m, 1H)
H-5 1.28-0.81 (m, 2H) 1.28-0.81 (m, 2H)
H-6 3.37-3.32 (m, 2H) 3.37-3.32 (m, 2H)
H-7 4.21-4.01 (m, 2H) 4.21-4.01 (m, 2H)
H-2' 6.28 (d, J = 2.4, 1H) 6.24 (d, J = 2.4, 1H)
H-5' 6.57 (d, J = 8.4, 1H) 6.56 (d, J = 8.4, 1H)
H-6' 6.07 (dd, J = 8.4, 2.8, 1H) 6.03 (dd, J = 8.4, 2.4, 1H)
H-7' 5.86 (s, 2H) 5.86 (s, 2H)
H-2'' & H-6'ꞌ 7.04 (d, J = 8.4, 2H) 7.02-6.99 (m, 2H)
H-3'' & H-5'ꞌ 6.95 (d, J = 8.8, 2H) 6.95-6.88 (m, 2H)
H-1'ꞌ' 8.36 (s, 1H) -
H-2'ꞌ' - 8.26 (dd, J = 7.2, 1.0, 1H)
H-3''' 7.99-8.21 (m, 2H)* 7.57-7.49 (m, 1H)
H-4''' 7.93 (d, J = 8.0, 1H) 8.07 (d, J = 8.1, 1H)
H-5'ꞌ' 7.77 (dd, J = 8.8, 1.6, 1H) 7.94 (d, J = 7.8, 1H)
H-6''' 7.67-7.61 (m, 2H)** 7.65-7.58 (m, 1H)
H-7'ꞌ' - 7.70-7.66 (m, 1H)
H-8'ꞌ' - 8.76 (d, J = 8.7, 1H)
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4.9. Synthesis of 3,4-methylenedioxyphenyl sulfonohydrazide derivatives
(21a-l)
This novel series, (21a-l) was synthesized by the reaction of equimolar quantities of
already synthesized 3,4-methylenedioxybenzohydrazide (3a) with different sulfonyl
chlorides (19a-l). The result is the formation of different 3,4-methylene dioxyphenyl
sulfonohydrazides (21a-l) in the form of solid precipitates. The reaction was carried out
providing basic conditions.
I
3a
3,4-methylenedioxy
benzohydrazide
19a-l
21a-l
3,4-methylenedioxyphenyl
sulfonohydrazide
O
O
N
H
NH2
O
R
S
Cl
O O
O
O
N
H
S
H
N R
O
O O
Reagents & conditions: (I) H2O, 5% Na2CO3 soln.stirring for 1 hour.
The products were characterized and confirmed by different spectral analysis like IR, 1H-
NMR, EI-MS and 13C-NMR. 1H-NMR of one of the compounds is discussed in detail as
follows while rest of the series is described in the given tables.
The compound, 2-(3,4 methylenedioxy-5-ylcarbonyl)-4-acetamidobenzene sulfono
hydrazide (21g), expressed its resonating signals at different chemical shift values in the
1H-NMR spectrum. The compound contains two aromatic rings. One ring that is attached
to sulfonyl group is also substituted with acetamide group at para position, confirmed by
a broad doublet at δ/ppm 7.73 (J = 8.8 Hz) for two protons H-2ꞌ & 6ꞌ. The two protons H-
3ꞌ & 5ꞌ also give a broad doublet at δ/ppm 7.58 (J = 8.8 Hz). The second aromatic ring
that is attached to methylenedioxy ring contains only three protons which appeared as
resonating signals at δ/ppm 7.17 (dd, J = 8.4, 1.6 Hz) for one proton H-6, at δ/ppm 7.03
(d, J = 1.6 Hz) for one proton H-2 and at δ/ppm 6.72 (d, J = 8.0 Hz) for one proton H-5.
The two methylenic protons, H-7, of methylene dioxy ring surrounded by two oxygen
atoms appeared at δ/ppm 5.93 as singlet. One methyl group of acetamide appeared at
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δ/ppm 2.05 as singlet having integration of three protons. The data of 13C-NMR and that
of EIMS has been given in experimental section (chapter -3).
Figure-19: 1H-NMR spectrum of the synthesized compound 21g
Figure-20: 13C-NMR spectrum of the synthesized compound 21g
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Figure-21: EIMS spectrum of the synthesized compound 21g
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Figure-22: Fragmentation pattern of the synthesized compound 21g
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Table-54: 1H-NMR data of compounds, 21a, 21b, 21c
*= H-8' to H-10'
1H-NMR (CDCl3)  (ppm), Multiplicity, J (Hz)
Proton No. Compounds
21a (400 MHz) 21b (400 MHz) 21c (300 MHz)
H-2 7.04 (d, J = 1.2, 1H) 7.06 (d, J = 1.6, 1H) 7.04 (d, J = 1.5, 1H)
H-5 6.80 (d, J = 8.0, 1H) 6.81 (d, J = 8.4, 1H) 6.80 (d, J = 7.2, 1H)
H-6 7.19 (dd, J = 8.4, 1.6,1H)
7.19 (dd, J = 8.4, 1.6,
1H)
7.16 (dd, J = 7.2, 1.5,
1H)
H-7 6.01 (s, 2H) 6.01 (s, 2H) 6.03 (s, 2H)
H-2' & H-6ꞌ 7.92 (d, J = 7.6, 2H) 7.79 (d, J = 8.0, 2H) 7.82 (d, J = 7.2, 2H)
H-3' & H-5ꞌ 7.47 (t, J = 7.2, 2H) 7.42 (d, J = 7.6, 2H) 7.45 (d, J = 7.2, 2H)
H-4' 7.58 (t, J = 7.6, 1H) - -
H-7' - 2.35 (s, 3H)
H-8' - - 1.35 (s, 9H)*
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Table-55: 1H-NMR data of compounds, 21d, 21e, 21f
*= H-7' & H-9'
1H-NMR (CDCl3)  (ppm), Multiplicity, J (Hz)
Proton No. Compounds
21d (400 MHz) 21e (400 MHz) 21f (300 MHz)
H-2 7.06 (s, 1H) 8.08 (d, J = 3.6, 1H) 7.07 (d, J = 1.5, 1H)
H-5 6.79 (d, J = 8.0,1H) 6.75 (d, J = 8.4, 1H)
6.80 (d, J = 8.1, 1H)
H-6 7.17 (d, J = 7.6,1H) 7.37 (dd, J = 8.4, 1.6, 1H)
7.21 (dd, J = 9.3, 1.2, 1H)
H-7 6.00 (s, 2H) 5.99 (s, 2H) 6.01 (s, 2H)
H-2' & H-6ꞌ - 7.89 (d, J = 9.6, 2H) 7.84 (d, J = 8.7, 2H)
H-3' & H-5ꞌ 6.89 (s, 2H) 7.57 (d, J = 8.0, 2H) 6.90 (d, J = 9.0, 2H)
H-7' 2.71 (s, 6H)* - 3.80 (s, 3H)
H-8' 2.23 (s, 3H) 2.60 (s, 3H) -
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Table-56: 1H-NMR data of compounds, 21g, 21h, 21i
*= H-2ꞌ & H-6ꞌ **= H-3ꞌ & H-5ꞌ
1H-NMR (CDCl3)  (ppm), Multiplicity, J (Hz)
Proton
No.
Compounds
21g (400 MHz) 21h (400 MHz) 21i (300 MHz)
H-2 7.03 (d, J = 1.6,1H) 7.07 (d, J = 1.2, 1H) 7.06 (d, J = 2.4, 1H)
H-5 6.72 (d, J = 8.0, 1H) 6.82 (d, J = 8.0, 1H) 6.79 (d, J = 8.1, 1H)
H-6 7.17 (dd, J = 8.4, 1.6,1H)
7.20 (dd, J = 8.4, 1.6,
1H)
7.18 (dd, J = 7.5, 2.1,
1H)
H-7 5.93 (s, 2H) 6.02 (s, 2H) 5.99 (s, 2H)
H-2' 7.73 (d, J = 8.8, 2H)* 7.77 (d, J = 8.4, 2H)* -
H-3' 7.58 (d, J = 8.8, 2H)** 7.59 (d, J = 8.8, 2H)** -
H-4' - - 7.66 (d, J = 7.5, 1H)
H-5ꞌ - - 7.81 (d, J = 7.5, 1H)
H-6ꞌ - - 7.97 (d, J = 7.8, 1H)
H-8' 2.05 (s, 3H) - -
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Table-57: 1H-NMR data of compounds, 21j, 21k, 21l
*= H-2' to H-6'
1H-NMR (CDCl3)  (ppm), Multiplicity, J (Hz)
Proton No. Compounds
21j (300 MHz) 21k (400 MHz) 21l (400 MHz)
H-2 7.06 (d, J = 2.4, 1H) 7.08 (d, J = 2.4, 1H) 7.05 (d, J = 1.6, 1H)
H-5 6.83 (d, J = 8.1, 1H) 6.86 (d, J = 8.0, 1H) 6.73 (d, J = 8.0, 1H)
H-6 7.19 (dd, J = 7.8, 2.1,1H)
7.32 (dd, J = 8.0, 1.6,
1H)
7.17 (dd, J = 8.4, 1.6,
1H)
H-7 6.03 (s, 2H) 6.05 (s, 2H,) 5.95 (s, 2H)
H-2' 7.98 (s, 1H) 7.47-7.35 (m, 5H)* -
H-4' - - 7.41 (d, J = 2.8, 1H)
H-5ꞌ 7.53 (d, J = 8.4, 1H) - -
H-6ꞌ 7.73 (d, J = 7.5, 1H) - 7.57 (d, J = 2.8, 1H)
H-7' - 4.37 (s, 2H) -
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4.10. Biological activity of synthesized compounds
4.11. Antibacterial and enzyme inhibition activity of 5-(aryl/aralkyl)-2-
((6-chloro-3,4-methylenedioxybenzyl)thio)-1,3,4-Oxadiazole (6a-x)
All the synthesized compounds (6a-x), were screened for antibacterial and enzyme
inhibition activities. The compounds were proved to be good to moderate inhibitors
against gram positive (+) and gram negative (-) bacteria. The compound 5-(Pyridin-3-yl)-
2-((6-chloro-3,4-methylenedioxybenzyl)thio)-1,3,4-Oxadiazole 6i showed overall
maximum activity against E.coli (-), and B. subtilis (+) among the compounds. The
compound remained at the top with %age inhibition value, 76.17±5.00 for E.coli, and
70.12±3.65 for B. subtilis (+), compared to the reference standard, ciprofloxacin with the
%age inhibition value 92.02±1.97. The maximum %age inhibition value shown by the
compound (6i) is probably due to the presence of a heteroaromatic ring, pyridine within
the molecule. Second highest active compound is 6a, shown by the %age inhibition
value, 71.44±2.40 against S. typhi (-) relative to the reference standard value, 90.76±0.79.
This compound is again a heteroaromatic and contains 3,4-methylene dioxy ring within
the molecule. The other compounds, 6x and 6m showed better activities against, P.
aeroginosa & S. aureus. Both of these compounds are para substituted with
electronegative amino (NH2) and chloro (Cl) groups respectively. The compounds, 6n,
6s, 6k and 6h exhibited the least activities against the bacterial strains used. The
compounds were also checked for their MIC analysis. The MIC values also support 6a, 6i
and 6r to be the better antibacterial activators. Among them, 6r is the most active one
against P. aeroginosa with the MIC value, 9.25±2.70 compared to the reference standard
value, 8.14±1.32. The compound is considered to be the most active due to the presence
of a strong para substituted electron withdrawing group (NO2) present in the molecule.
The compounds 6a, 6i, 6d and 6f expressed better activities against S. typhi (-), E. coli (-
), B. subtilis (+) & S. aureus (+) with the MIC values 12.65±4.50, 10.66±4.54,
11.78±3.00 and 10.61±2.76 with the reference MIC values , 8.33±1.21, 8.94±1.87 ,
9.04±2.01 and 8.98±1.44 respectively. The compounds, 6b, 6p, 6q, 6r and 6s did not
show appreciable MIC values. All the other compounds fall in moderate to low activity
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range within the series. The results of the %age inhibition and MIC analysis is given in
the figure- 23 & 24 respectively.
As for as enzyme inhibition assay is concerned, the results of the under discussion series
are highly disappointing. LOX enzyme was chosen for this purpose. Only one of the
compounds, 6o showed the maximum enzyme inhibition activity with the IC50 (µM)
66.7±1.24 relative to the reference standard, baicalein with IC50 (µM) 22.41±1.3. This
high inhibition potential might be due to the presence of an electron donating para
methoxyphenyl group substituted at five position of oxadiazole ring. The second most
active LOX inhibitor is 6w which gives the IC50 (µM), 101.24±1.42. All the other
compounds did not show any appreciable activity against LOX enzyme. The results are
given in the graphical representation in figure-25.
Figure-23: Antibacterial activity (%inhibition) of the compounds 6a-6x
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Figure-24: Antibacterial activity (MIC) of the compounds, 6a-6x
Figure-25: Enzyme inhibition activity (lipoxygenase, IC50) of the compounds, 6a-x
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4.12. Antibacterial and enzyme inhibition activity of 5-(aryl/aralkyl)-2-
((6-bromo-3,4-methylenedioxybenzyl)thio)-1,3,4-Oxadiazole (8a-x)
The compounds, (8a-x), after the synthesis and confirmation, were screened for their
biological activities including, antibacterial activity and enzyme inhibition assay. All the
%inhibition results are represented in fig-26. The compound, 8x expressed the highest
%age inhibition value 79.19 ± 1.10 against E. coli (-) relative to the reference standard,
ciprofloxacin with %age inhibition value 90.44±1.23. This high activity is attributed to
the para aminophenyl (NH2), a strong electro donating group, substituted at five position
of oxadiazole ring. The other compounds, 8c, 8a, 8u and 8r are proved to be good
inhibitors against different bacterial strains; S. typhi (-), P. aeroginosa (-), B. subtilis (+)
& S. aureus (+) with the %age inhibition values, 75.82±1.00, 65.88±1.79, 58.63±1.13,
68.45±5.00 against the reference standard with %age inhibition values, 91.19±2.10,
92.00±2.76, 89.98±2.07, 92.21±1.59 respectively. The compound which showed the least
activity is 8h with the %age inhibition value, 24.35±2.59 against S. typhi (-). The
compound, 8i against E. coli (-), 8l, against both P. aeroginosa (-) and S. aureus (+)
while the compound 8o, against B. subtilis (+) are the least active in the series with %age
inhibition values, 37.81±1.19, 28.42±5.00, 24.96±1.96 and 34.60±4.60 respectively. Rest
of the compounds exhibited moderate activities. The minimum inhibitory concentrations
of the compounds were also calculated.  The results are expressed in fig-27. The
compound, 8x showed the best result regarding MIC value which is 10.48±1.76 relative
to the reference MIC value, 8.02±2.17 against E. coli (-), gram negative bacteria and
11.73±2.47 relative to the reference MIC value, 9.23±1.87 against S. aureus (+),gram
positive bacteria. This enhanced activity of the compound is considered to be due to the
presence of amino group at para position of the phenyl ring substituted at five position of
oxadiazole ring. The compounds 8k, 8f and 8e also showed considerable results against
S. typhi (-), P. aeroginosa (-), B. subtilis (+) with the MIC values, 11.70±1.76,
11.80±1.31 and 12.65±1.43 compared to the reference MIC values 9.42±1.09, 8.11±1.32
and 8.88±2.00. The compounds 8p, 8n, 8o, 8t and 8s proved to be the least active
compounds in the series clear from their MIC values which are, 18.50±1.56, 18.78±3.43,
18.72±1.67, 19.15±3.50, and 19.04±1.85 relative to their reference standard values which
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has been mentioned above against S. typhi (-), E. coli (-), P. aeroginosa (-), B. subtilis,
and S. aureus.
The whole series was also tested for its LOX enzymatic inhibition potential. The
compound, 8l is the most active compound within the series with its IC50 value,
91.93±0.61 compared to the reference standard used, baicalein with IC50 value,
22.41±1.3. 1-Naphthyl group attached at five position of oxadiazole ring might be
responsible for this good inhibition potential. The compound 8m remained as the second
best inhibitor having IC50 value 108.8±0.56. Rest of the series did not show remarkable
inhibitory potential at all. The results are given in figure-28.
Figure-26: Antibacterial activity (%inhibition) of the compounds 8a-x
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Figure-27: Antibacterial activity (MIC) of the compounds 8a-x
Figure-28: Enzyme Inhibition activity (lipoxygenase, IC50) of the compounds 8a-x
-
2.00
4.00
6.00
8.00
10.00
12.00
14.00
16.00
18.00
20.00
8a 8b 8c 8d 8e
MI
C (
µg
/ m
L)
S. typhi (-) E. coli (-)
0
50
100
150
200
250
300
350
8a 8b 8c 8d 8e
IC 5
0(µ
M)
Co
nc
./w
ell
 (0
.5 
mM
)
8e 8f 8g 8h 8i 8j 8k 8l 8m 8n 8o 8p 8q 8
r 8s 8t 8u
Compound
Antibacterial activity
P. aeroginosa (-) B. subtilis (+) S. aureus (+)
8e 8f 8g 8h 8i 8j 8k 8l 8m 8n 8o 8p 8q 8
r 8t 8u
Compound
Enzyme inhibition activity
8u 8v 8w 8x
Cip
rof
lox
aci
n
8v 8w 8x
Ba
ica
l…
Results and Discussion
Department of Chemistry, GCU Lahore Page 184
4.13. Antibacterial activity of N-[3,4-methylenedioxybenzyl]-2-[(5-
substituted-1,3,4-oxadiazol-2-yl)thio]acetamide (12a-t)
The under discussion series (12a-x), was screened for antibacterial activity against
various gram positive bacteria, B. subtilis, S. aureus and gram negative bacteria, S. typhi,
E.coli, P. aeruginosa. The compounds exhibited moderate activities against these
bacteria. The detailed results are shown in graphical representation in figure-29. The
compound, N-[3,4-methylenedioxybenzyl]-2-[(5-(4-chlorophenoxy)methyl)-1,3,4-
Oxadiazol-2-yl)thio]acetamide 12m revealed the maximum activity against P.
aeruginosa with the %age inhibition value 76.45±0.70 relative to the reference standard,
ciprofloxacine with the %age inhibition value 93.45±0.42. The compound contains para
chlorophenoxy group at five position of oxadiazole ring which is an electron donating
group. Other compounds, 12j, 12g, 12o and 12n showed maximum activities against S.
typhi, E.coli, B. subtilis and S. aureus having %age inhibition values, 64.83±0.83,
57.75±0.05, 67.00±0.12 and 53.75±0.29 respectively comparing the reference standard
values, 92.91±0.95, 92.14±0.12, 90.98±0.16 and 91.00±0.24 respectively. 12l, 12e, 12r,
12q and 12o are those compounds which exhibit the lowest %age inhibition in the series
against S. typhi, E.coli, B. subtilis, S. aureus and P. aeruginosa and among them 12o is
the weakest of all with %age inhibition value 9.80±1.55.
The minimum inhibitory concentrations MIC, of all the synthesised compounds were also
calculated and it was found that the compound, 12e is the most active one against S. typhi
with the MIC value 13.00±0.69 relative to the reference standard value 7.83±0.78. The
compound, 12g is active only against S. aureus with the MIC value 18.61±0.96 relative to
the reference standard value 7.09±0.54. This compound is totally inactive against rest of
the bacterial strains. The compounds, 12q, 12f and 12n are the most active against E.coli,
B.subtilis and P. aeruginosa while the least activities are shown by the compounds, 12s
against both S. typhi and E. coli, 12b against B. subtilis and 12t against P. aeruginosa.
Only very few compounds in the series are found to be active regarding MIC values.
Majority of the compounds are totally inactive and show nil MIC values in which12a,
12c, 12d, 12j, and 12r are the most prominent. The results are displayed in figure-30.
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Figure-29: Antibacterial Activity (%inhibition) of the compounds, 12a-t
Figure-30: Antibacterial Activity (MIC) of the compounds, 12a-t
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4.14. Antibacterial activity of N-substituted-2-{(5-(3,4-methylene
dioxy)phenyl-1,3,4-Oxadiazol-2-yl)sulfanyl}acetamide derivatives (15a-
x)
The results of antibacterial activities are expressed as %inhibition and minimum
inhibitory concentration in figure-31 and figure-32 respectively. On taking an overlook
on the %age inhibition results, it becomes clear that all the compounds are moderate
activators against the bacterial strains under investigation. The compounds which seem as
highly active within the series are 15r, 15a, 15m and 15b among which N-[2,3-
dimethylphenyl]-2-[(5-(3,4-methylenedioxyphenyl)-1,3,4-oxadiazol-2-yl)thio]acetamide
15a is the most active one with %age inhibition value 68.75±0.68 against E.coli relative
to the reference value 92.79±0.83. The compound contains two methyl groups, ortho to
one another substituted at phenyl ring which is attached to nitrogen atom and might be
responsible for this high activity. The compound 15m is best activator both for B. subtilis
with %age inhibition value, 60.69±0.51 relative to standard value 93.90±1.11 and for P.
aeruginosa with %age inhibition value, 66.22±0.60 relative to the standard value
91.05±0.15. The compound 15r showed maximum %age inhibition i-e 64.75±0.17
against S. typhi relative to the reference standard value i-e 92.95±1.56. Similarly, the
compound 15b is active against S. aureus. The %age inhibition for this compound is
56.25±0.63 compared to the reference value 92.84±0.37. Among the weak inhibitors, the
compound 15p is the least active inhibitor against S. aureus with %age inhibition value
6.25±1.15. The compound 15i showed minimum inhibition against P. aeruginosa having
%age inhibition 14.00±0.90 relative to the reference value 91.05±0.15. There is a
compound in the series which showed the least inhibitory activity for three under analysis
bacterial strains but with different inhibitory values. That compound is 15h. The
compound expressed the least inhibitory potential against S. typhi, E. coli and B. subtilis
with %age inhibitory values 25.25±1.25, 20.69±0.85 and 14.00±2.50 respectively
compared to the following reference standard values sequentially as
92.95±1.5692.79±0.8393.90 ±1.11. All the other compounds showed good to moderate
activities in the series.
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Figure-31: Antibacterial Activity (%inhibition) of the compounds, 15a-t
Figure-32: Antibacterial Activity (MIC) of the compounds, 15a-t
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4.15. Antibacterial and enzyme inhibition activity of 2-
Alkyl/aralkylthio-5-(3,4-methylenedioxyphenyl)-1,3,4-Oxadiazole
derivatives (17a-u)
This particular series, (17a-u) was analysed for antibacterial activities and enzyme
inhibition activity. In the antibacterial assay, bacterial strains used were S. Typhi, E. coli,
K. pneumonae and P. aeroginosa (gram negative), B. subtilis, S. aerus (gram positive).
The series presented remarkable results given in fig-33 as % inhibition. All the
compounds proved to be very good inhibitors against the used strains. Surprisingly, the
compound, 2-(2-Phenylethyl)thio-5-(3,4-methylenedioxyphenyl)-1,3,4-Oxadiazole 17j,
showed maximum activity against all the bacterial strains under analysis. Its %age
inhibition values are 80.50±2.64, 88.11±0.33, 87.20±1.65, 83.86±1.75, 84.25±0.58 and
87.46±0.69 relative to the reference standard, ciprofloxacine whose inhibitory values are
90.85±1.53, 92.04±1.07, 91.83±2.77, 89.59±2.00, 89.25±1.92 and 88.15±1.23 against the
bacterial strains S. typhi, E. coli, K. pneumonae and P. aeroginosa, B. subtilis, S. aerus
respectively. This excellent activity might be due to the thio substituted phenyl ethyl
group at two position of oxadiazole ring. The minimum activities shown by the
compounds, 17r, 17q, 17b, 17r, 17t and 17u are 14.64±3.79, 9.70±3.40, 7.25±3.99,
22.00±3.14, 38.35±2.17 and 24.62±3.62 against the under investigation bacterial strains;
S. typhi, E. coli, K. pneumonae and P. aeroginosa, B. subtilis, S. aerus respectively. All
the other compounds showed quite good activities. The minimum inhibitory
concentrations (MIC) of all the compounds were also calculated in which the best result
was given by the compound, 17j with MIC values, 8.27±1.60, 8.70±1.4, 19.06±2.65,
8.53±1.05, 8.87±3.40 and 8.75±3.85. All the values are very close to the reference MIC
values which are 8.04±2.00, 8.24±2.76, 8.37±1.63, 8.00±1.72, 8.41±0.99 and 8.19±0.95
respectively. The compounds, 17r, 17t and 17u are those compounds which are
completely inactive against any bacterial strain. Compounds showing weak MIC results
are 17o against S. typhi, 17n against E.coli, 17d against K. pneumonae, 17m against P.
aeroginosa, 17f against B. subtilis and 17l against S. aerus. The MIC results are given in
figure-34.
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The under discussion series was also screened for enzyme inhibition potential and the
enzymes used for this purpose are urease and lipoxygenase. Few compounds in the series
were found to be active in urease inhibition assay. Compounds, 17g, 17l, 17n, 17o and
17p are the only active compounds with IC50 values, 68.2±0.91, 46.2±0.85, 30.1±0.65,
68.5±1.4 and 313.49 respectively against the reference standard, thiourea with IC50 value
21.28±0.11. Among the compounds, 17n which is meta bromobenzyl substituted
compound and is considered as the most active compound whose activity results are very
close to the referance standard value. The rest of the compounds are totally inactive. The
whole results are presented in figure-35.
The present series was also screened against lipoxygenase enzyme. The compounds did
not show promising activities in this assay. The compounds 17a, 17i, 17j, 17n, 17o and
17p expressed high IC50 values showing that they are not good inhibitors against
lipoxygenase enzyme. Their IC50 values range from 298.67±0.21 to 417.5±0.53 relative
to the baicalein, reference standard, with the value 22.4±1.3. The rest of the compounds
did not show a bit activity at all.  LOX activity results are given in figure-36.
Figure-33: Antibacterial Activity (%inhibition) of the compounds, 17a-u
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Figure-34: Antibacterial Activity (MIC) of the compounds, 17a-u
Figure-35: Enzyme inhibition activity (Urease, IC50) of the compounds, 17a-u
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Figure-36: Enzyme inhibition activity (LOX, IC50) of the compounds, 17a-u
-
50.00
100.00
150.00
200.00
250.00
300.00
350.00
400.00
450.00
17
a
17
b 17
c
17
d
IC 5
0(µ
M)
 co
nc
/w
ell
 (0
.5m
M)
17
d
17
e 17
f
17
g
17
h 17
i
17
j
17
k 17
l
17
m 17
n
17
o
17
p
17
q 17
r
Compound
Enzyme inhibition activity
17
s
17
t
17
u
Ba
ica
lei
n
Results and Discussion
Department of Chemistry, GCU Lahore Page 192
4.16. Enzyme inhibition activity of N-Aralkyl/Aryl Sulfonated
Derivatives of Paroxetine (20a-k,m-o)
Enzyme inhibition assay was carried out to measure the inhibition potential of the
synthesized compounds (20a-k, m-o). Lipoxygenase enzyme was used in the assay and
baicalein as reference standard. The compounds exhibited moderate inhibition clear from
their %age inhibition values expressed as graphs in figure-37. The excellent inhibition
was shown by the compound N-(4-chlorobenzenesulfonyl) paroxetine (20m) with %age
inhibition value 98.01±0.01 compared with the reference standard value 93.79±1.27 and
the least was shown by the compound, N-(benzenesulfonyl) paroxetine (20a) with %age
inhibition value 16.57±0.6. The highest inhibition of the compound, (20m) might be
attributed to the para chlorophenyl ring attached to sulfonyl group. The rest of the
compounds show inhibition values in between the two extreme values. IC50 values were
also calculated for the series. Only six compounds, 20b, 20i, 20k, 20m, 20n and 20o in
the series showed high IC50 values among which the least (128.9±0.03) was shown by the
compound, N-(benzylsulphonyl) paroxetine (20k) compared with the reference value
22.41±1.3.  The compounds 20i and 20o are the least active within the series. The results
are shown in figure-38.
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Figure-37: Enzyme inhibition activity (lipoxygenase, %) of the compounds,
20a-k, m-o
Figure-38: Enzyme inhibition activity (lipoxygenase, IC50) of the compounds,
20a-k,m-o
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4.17. Enzyme inhibition activity of 3,4-methylenedioxyphenyl
sulfonohydrazide derivatives (21a-l)
This series (21a-l) was analyzed for antibacterial activity. The results are shown as %
inhibition in figure-39. All the compounds showed overall good activity against all
bacterial strains used for the assay including gram (+) and gram (-) bacteria. It was found
that all the compounds were quite active against E. coli. The results are very close to the
reference standard value. Amongst the compounds, 2-(1,3-Benzodioxol-5-ylcarbonyl)-
3,5-dichloro-2-hydroxybenzenesulfonohydrazide (21l), was found to be the most active
against all bacterial strains. Its % inhibition values are 70.35±3.06, 87.38±1.75,
89.33±1.42, 72.60±2.20 and 85.35±1.65 compared with reference values; 91.19±2.10,
90.44±1.23, 92.00±2.76, 89.98±2.07 and 92.21±1.59 against S. typhi (-), E. coli (-), P.
aeroginosa (-), B. subtilis (+) and S. aureus (+) respectively. 3,5-dichloro-2-
hydroxybenzene substituent was considered to be responsible for this high activity of the
mentioned compound. Overall the synthesized compounds showed least activity against
P. aeroginosa. The minimum inhibitory concentration (MIC) values were also calculated
for the compounds under discussion (21a-l). The results are given in figure-40. All the
compounds showed good inhibitory concentrations however the compound, 2-(1,3-
Benzodioxol-5-ylcarbonyl)-4-acetamidobenzenesulfonohydrazide (21g) did not show any
inhibition against any bacterial strain as clear from its MIC value. According to the MIC
results, the compound, 2-(1,3-benzodioxol-5-ylcarbonyl)-3,5-dichloro-2-hydroxybenzene
sulfonohydrazide (21l), was found to be the most active against all bacterial strains. The
compound showed its MIC values very close to the reference standard MIC value I.e.
13.89±2.00, 11.98±1.39, 11.58±3.25, 17.02±2.08 and 13.83±4.07 compared with the
reference values, 9.42±1.09, 8.02±2.17, 8.11±1.32, 8.88±2.00 and 9.23±1.87 against S.
typhi (-), E. coli (-), P. aeroginosa (-), B. subtilis (+) and S. aureus (+) respectively.
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Figure-39: Antibacterial activity (%inhibition) of the compounds, 21a-l
Figure-40: Antibacterial activity (MIC) of the compounds, 21a-l
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4.18. Conclusion
The whole research work remained successful in synthetic point of view. Total 135
compounds, under nine schemes, were synthesized including different S-substituted
oxadiazoles, N-substituted acetamides, different sulfonamides and many other
derivatives. The beauty of the presented work lies in the fact that the synthesized
compounds grasp various functionalities together in one skeleton i.e. oxadiazole ring,
benzodioxol moiety, acetamide group and sulfonamide functionality. According to the
objective of the work, special emphasis was given on synthesizing multifunctional
compounds. Moreover these were checked for their activity behavior regarding
antibacterial and enzyme inhibition studies. The task was successfully completed under
simple, facile and environment benign conditions. Special care was taken to avoid the
excessive use of hazardous chemicals but where there was compulsory, they were
handled with great care under complete safety. Although the schemes were run according
to the already established methods, available in the literature, but some of the substrates
created little hurdles while putting them on reaction or while doing their work up. It
became quite difficult to work with paroxetine in both during the reaction as well as in
the work up. While doing alkylations at sulfur of oxadiazole, many long chain halides did
not precipitate at once but after some stay by keeping them in ice cold conditions.
Similarly great precaution was taken in case of bromoacetyl bromides as they cause
allergy. After synthesis, the compounds were analyzed for biological studies.
The antibacterial results showed good results in some series and weak in few. In the
series (6a-x), overall the compounds are active but among them the compound 5-
(pyridin-3-yl)-2-((6-chloro-3,4-methylenedioxybenzyl)thio)-1,3,4-Oxadiazole (6i)
showed highest activity. Might this activity be due to the presence of pyridine ring which
is a heteroaromatic ring. Nitrogen atom within the ring, perhaps uses its lone pair of
electrons to build some type of interaction with the bacterial cell wall, trying to damage
them. The series (8a-x) also showed overall good result for antibacterial activities.
Among the compounds, 5-(4-aminophenyl)-2-((6-bromo-3,4-
methylenedioxyphenyl)methylthio)-1,3,4-Oxadiazole (8x) was proved to be the best
antibacterial agent and might be due to the  para-amino substituted phenyl ring. It was
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thought that the electron donating nature of amino group might alter the energy level of
the compound and hence creating some type of interactions between the compound and
the bacterial cell wall, destroying them to some or greater extent. N-[3,4-
methylenedioxybenzyl]-2-[(5-(4-chlorophenoxy)methyl)-1,3,4-Oxadiazol-2-yl) thio]
acetamide (12m) in the series (12a-t), is the highest antibacterial agent and the ring
contains chloro phenoxy group which is again an electron donating group. The drift of
electrons within the system might enhance special features which help in killing the
bacteria. In the series (15a-t), the compound N-[2,3-dimethylphenyl]-2-[(5-(3,4-
methylenedioxyphenyl)-1,3,4-oxadiazol-2-yl)thio]acetamide 15a, in the series (17a-u)
the compound 2-(2-Phenylethyl)thio-5-(3,4-methylenedioxyphenyl)-1,3,4-Oxadiazole
(17j) and in series (21a-l) the compound, 2-(1,3-Benzodioxol-5-ylcarbonyl)-3,5-dichloro-
2-hydroxybenzenesulfonohydrazide (21l) showed maximum activities due to the presence
of two electron donating methyl groups on benzene ring, one phenyl ethyl ring and three
electron donating groups, one hydroxyl and two chloro, on benzene ring respectively.
The series (17a-u) revealed surprising results in the respect that the compound 2-(2-
Phenylethyl)thio-5-(3,4-methylenedioxyphenyl)-1,3,4-Oxadiazole 17j showed excellent
activity against all bacterial strains used. Moreover the results are very much close to the
referance standard values. Enzyme inhibition assay results of all the synthesized
compounds (6a-x, 8a-x, 12a-t, 15a-t, 17a-u, 20a-k, m-o and 21a-l) are not mentionable
as majority of the compounds did not show any activity and only a few exhibited very
low activities.
It was concluded that the presence of different moieties together in one molecule affected
the overall pharmacological potential of the synthesized compounds and that they might
play some effective role in advance medicinal research as well as they might be
considered as effective novel drug candidates in local pharmaceutical industries as
proved through their biological activity analysis. The synthesized compounds can be
carried for further research in future to make life saving drugs. By taking the most active
compounds and by applying different substitutions on them, may flourish the future
results. It was also concluded that little alterations within a molecule can produce
astonishing results. The chlorinated, methylated, aminated and nitrated compounds as
well as heteroaromatic rings can play a revolutionary role in future research.
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